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AllSI"RACT
Low density lipoprote in (LOL) particles appear very promising for deliverin g
anticancer drugs specifically to tumor or macrophage cells by exploiting the LD L or the
scavenger receptor pathway . I have chosen doxorubicin [Dox ) to investigate the feas ibility
of this approach in ceecer chemotherapy. Dox could be directly incorporated into LOL
parti cles . A lipophilic cho lestery l ester [e E] analogue., cholesteryl iopanoate [Cl] was
proposed as a radiotracer to study the in. vivo fate ofLDL. CI was radioiodina ted wi th In l
by a pivalic acid exchange reaction and the radiochemical purity was detennined by HPLC
in conjunction with y-coun ting and was found to be more than 95% pure.
A Dew reverse phase HPLC procedure with UV detection was developed for the
quantitation of CI. The regression line, and intra- and interday variations for a set of
standards were determined andwere found to be statistically valid. Theminimwn detection
range was less than 10 og for the compound.. The % recovery from LOL was found to be
more than 95%. Plasmaprotei.n biDdingofDox wasstudiedex·vivo. Dox was found to be
more than 30% lipoprotein bound. The plasma distribution of Oox was refashioned by
preincubating plasma with oleic acid. With oleic acid,. Dox association with lipoproteins
increased from less than 30% to approximately 70%.
Mainly the contact method or the direct addition method was adapted to incorporate
dru gs into LOL particles. Tbe loadin g techniques were optimized in terms of incubation
time, temperature , and stoichio metry of LDlAirug conjuga tes. A four to six bour protocol
and 37 0 incubation temperature were chosen with a drug to protein ratios more than 1. The
effect of various wetting agents, such as Tween 20, 40, 60 and 80 , Span 60 , Trito n-X. and
Celite 545, and ethanol was investigated for LOL-Oox conjugate s in the contact method.
Tween 20 was chosen for its favorable loading efficiency (more than 5·fold compared to the
dry film method) . Liposomal Dox was prepared by an extrusi on technique with 24% loadin g
efficiency. The liposomal Dox preparation was found to be the most suitable (45 molecules
of Do x/L OL particle) compared to other methods such as the dry filmmethod, the contact
method with Tween 20, and the direct addition method.
All these incorporation methods were found to be suitable for generating LOL-drug
conj uga tes without disrupting the native integri ty ofLDL parti cles when characterized by
sodium dod ecyl sulphat e-po lyacrylamide gel electrophoresis [SOS-PA GE] . electro n
microscopy [EMJ. and differential scanning calorimetry [DSC] .
An insect lipid transfer catal yst [LTP] was studiedand found to enhance drug loadin g
into LOL particl es by at least 2 to S-fold, dependin g on the drug molecule s and the
incubation conditi ons. The LDL-drug conjuga tes generated by this transfer parti cle were
characterized by SDS-PAGE and EM and found to be similar to native LDL. The site of
drug location in LOL was studied by DSC and UV-visible scanning . The drug was found to
be locat ed both in the core and the outer monolayer of LOL for Oox. 1his kind of
enhancement was not observ ed with human cholesterol est er transfer protein [CETP ].
Oox interferen ce in bicinchoninic acid [BCA] prot ein assa y method was examined
and it was found that Oox interfered [33-fold more sensitive compared to protein] with the
prot ein assay method . A solution to overcome this interference wasalso suggested using the
iii
Bradford method.
To target macrophages [M4IJ. native LDL was modified by acetylation [acetylated
LOI.,. AcLDL] and Oox was loaded in AcLDL and physico-chemically characterized by
80S-PAGE and EM. The loading efficiency ofAcLDL -Oox conjugates was comparable to
that ofLDL-Dox conju gates.
Different formulations of Dox were evaluated in cell culture studies using a human
tumor cervical cell line. Hef.a, and a mouse M4I cell line. 1774.AI. LDL-Dox conjugates
were found to be greater than IS-fold more cytotoxic than the corresponding free drug Dox
using the [3-[4.5-dimethylthiazoyl-2-yIJ-2.5-dipheny l-tetrazolium bromide], [MTT] assay
in Hela cells. When the cytotoxicity of AcLDL-Dox conjugates was examined in 1774.A1
cells. a more than 7-fold increase in cytotoxic effects was observed in comparison to its free
drug counterpart, Dox.
Key Words: drug targeting; low density lipoprotein ; cytotoxic agents ; doxornbicin; insect
lipid transfer protein; drug loading ; liposome; electrophoresis; electron
microscopy; differential scanning calorimetry; lTV-visible sanning; acetylated
LDL; macrophages; cytotoxicity; HeLa cells ; 1774.AI cells; MIT assay ; drug
interference; HPLC; cholesteryl iopanoate; cholesnyl ester transfer protein.
protein assay
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CHAPTER 1:
GENERAL INTRODUcnON
1.1. C urre n t status of cancer chemo therapy
The developmen t ofteclmiques to selectively deliver cytotoxic agents to cancer cells,
without concurrent adverse effects in healthy cells, is one of the fascinating areas ofresearcb
in cancer chemotherapy. This interest is specifically centered towards optimizing the
delivery of cytotoxic agent's, which possess an intrinsic ability to discriminate cance r cell s
from normal cells [Duncan, 1992]. Unfortunately, the administration of curr ent cytotoxic
agent's almost invariably causes dose-dependent systemic toxicities due to their non-selecti ve
biodistribution, often warranting discontinuation of treatment, and thus failure to allow
successful eradication of cancer cells (Keize r et ai., 1985]. Moreover , maintaining low level
exposure of tumor cells to a cytotoxic drug may also induce resistance , so continu ed
expo sure must be viewed with cautio n [Duncan, 1992). Theoretically, total eradication of
cancer cells could be accomplished by total surgical removal of the tum or or complete
destruction of all cancer cells by chemo- and/or radiotherapy. Current treatment regimens
do not meet such a challenge and new approache s to solve this predicament are warran ted.
The therapeutic efficacy ofcurrent cancer treatment is often complicated by several
factors [e.g., existence of subpo pulations of neop lastic cells within a tumo r which
considerably differ in their mo rphology, immunogenecity, rat e of growth, capaci ty to
metastasize, and response to chemotherapeutic agents] [Calabrashi et ai., 1980]. In addition,
the total blood flow . rate of perfusion. and vesse l penetrability may vary within different
regions of the same tumor tissue [Woodruff, 1983. Peste and Kirsh. 1983; Fidler and Hart.
1982; Dexter et 01.• 1978]. Because of these differences. an increase in dose may be needed
to reach the cytotoxic concentration within cancerous tissues . In solid tumors. the
permeability of the cytotoxic agents is often too low to be effective when administered at
usual therapeutic concentrations [Brouwers, 1996; Hori et al., 1993]. This necessitates
administration of maximum to lerable dose which in turn increases the dose dependent
toxicity. Differen t parenteral routes have been anempted to increase the concentration of
cytotoxic agents into the target areas e.g., intra-arterial to cancer tissues [Bufill et ai.. 1996].
intrathecal in brain metastases. and intraperitonium in peritoneum carcinoma Limited
success was achieved in these parenteral approaches [Buc hwald et al.• 1980; Chen and
Gross, 1980; Eckman et al .• 1974].
Desp ite extensive efforts in experimental pharmacology and theoretical
considerations, the overall success in routine cancer therapy has been nominal [Daemen et
al.• 1988; Blacklock et ai., 1986; Levin.1986] . Chemotherapy. as well as radiotherapy. has
been disappointing because ofacute side effects and co mplications [Chiuten et al.• 1986;
Collin et a1.. 1985] . These difficulties have urged the need for developing "spec ialized
systems" whic h may allow selective delivery of one or more chemotherapeutic agents to
cancer ce lls as this would prevent effects on the physio logy of the nonnal cells. To mee t
these requirements, numerous targeted drug delivery systems have been proposedover recent
decades [Naeff, 19%; Torchilin and Trnbetskoy , 1995; Al lenet al., 1995, Gabizon, 1995;
Fidler and Kleinerman, 1994; Allen, 1994; Jones, 1994; Jalil., 1990; Pozansky and Juliano,
1984; Tomlinson, 1986 to 1991] .
1.2. Ta rgeted drug de livery
Theoreti cally, targeted drug deli very systems can improve the outcome of
chemotherapy due to the following proc esses [fable 1.1]: [ I] by allowing a maximum
Table 1.1. Ra tion ale for drug ta rgeting·
Exclusive delivery to specifi c compartme nts.
Access to previously inaccessib le sites [e.g., intracellular
infections] .
Protectio n ofbod y from unwanted deposition which would lead
to untoward reactions, metabolism , etc.
Controlled rate and modality of delivery to phannacological
receptor.
Reduction in the amount of active princi ple employed
· [After Tomlinson, 1987J
frac tion of the delivered drug molecules to react exclusivel y with cancer cells, with out
havin g any harmful effect on normal cells; and [2J by allowing preferential distri bution of
drug to cancer cells. The first process can beclassified as absolute drug targetin g. In the
second process , complete eradication ofcancer cells is not pos sibl e witho ut some degree of
destruction to normal ce lls; thi s proc ess therefore falls in the category of partial drug
targeting.
Dru g may be delivered by [1] carri er-dependent, and/or [2] carri er-independen t
routes. In the former case, after localization in the targ et tissue , the dru g carrier is taken up
by the target cells and the drug is released intracellularly in a controlled manner. In the latter
case,the drug is released from the carrier extracellular ly and hence the drug action inside the
target cells is not influenced by the abili ty [or inability] of the carri er to betaken up by thes e
cell s. From this discussion, it is clear that carrier-dependent targ eted delivery may allo w
utilization of drugs which are activ e intraeellularly. but are normally discarded due to their
poor intrac ellular uptake. In such situati ons, appropriate selection of a drug carrier may
allow grea ter influx of drug to the intracellular components and hence increase the overall
efficacy of drug delivery . Although the concept of a magic bul let pionee red by Ehrli ch
[1956] may still be an unrealized dream in the-context ofspeci.fic delivery of cytotoxic agen ts
to tumor ce lls, a number of carri er syste ms have been proposed over the years to achieve
partial or complete drug targetin g. For examp le, first order targeting whereb y the carri er
tak es the drug to a particular organ; second order targeting whereby the carri er is directed
towards a particular diseased part of an organ; and third order targeting where the carrier
takes the drug molecule into the cell by whatever mechani sm that may be hypoth esized.
Significant advances have been made with the identification of many delivery
systems that achieve very effective organ/ compartmental [first order] dru g targetin g.
Liposomes, particulate systems. andmacromolecular carric:n have been deve loped which can
deposit a large pera:ntage ofan intra venous [IV] dose into the liver or lung [Gabizon., 19951
One potentialadvantage ofliposomes as drug carric:n is that they arc easy to load with drugs.,
both lipi d- and water-so lub le [Crommelin el al ... 1995]. Early in vitro experiments with
liposomes were encouraging. but when drug-containing liposomes were administered to
animals, the liposomes were recognized as non-self and hence rap idly removed from the
circulation by the reticuloendotheli al system [RES] [poste, 1983; Woodl e, 1995; Allen el ai.,
199 5]. A maj or prob lem with lipo som es as dru g carriers for treatment is the lac k. of a
homing device to direct lipo somes to tumor ce lls [Crommelin et al., 1995J.
lmmunoliposo mes were proposed to increase the tar getin g potential of liposomes . So far,
ve ry little success bas been achieved in vivo [M ori and Huan g, 1995] . A more frequently
enco untered limitation ofliposomal delivery systems is tbeir relatively low stability, both i71
vitro and in vivo [NaetI. 1996 ; Peste, 1985 and 1983 ; Allen and Cleland, 1980). Stability
problems and variable delivery to the nnnor have been identified as major limitations of
liposomal formulations of cytotoxic drugs [Ianknegt, 1996 ; Codde el aJ...1993]. In short.,
this approach holds promiseofregional delivery ofcytotoxic drugs for treatment of primary
or secondary disease. but clinical success bas not been achieved..
To achieve tumor-specific [second order] targeting it is necessaryto identify uni que
features of tumo r ce ll b iology tha t will conce ntrat e dru g[s] within the tum or . From the
stan dpo int of selectivity . antibod ies are very attrac tive as dru g carri ers. Mo st approac hes
hav e sought to produc e monoclonal anti bodies that will interac t preferenti ally with tumor cell
surface antigens [Magerstadt, 1990]. Although tumor cells do express tumo r enhanced, or
specific-antigens, true tumor-specific antigens probably do not exist [Daemen et al., 1995J.
Another problem is the existing circulating antigens that could bind and neutralize the
antibodies before they reac h the tumor site. Also, the coupling of drug mo lecules to
antibodies may interfere with antigen recognition and/o r with the activity ofthe drug. Other
poten tial limitations are: limited tumor access of these relatively large macromolecules;
tumor ce ll heterogeneity; and the hum an antimousc: antibody response experienced in
patients (Duncan, 1992]. Ev en when using antibodies of the high est affinity and spec ificity
a relatively small fractio n ofadministered dose is delivered to the tumo r in vivo [possi bly less
than 0. 1% dose administered in man] (Gupta, 1990], but it is encouraging that this relative ly
small localization can theoretically be put to good use,exemplified by the antibody-directed
enzyme prodrug approach [Springer et al.. 1991]. Immunoliposcmes, the artificial
combination of liposomes and antibodies. have drawn great attention recently [Moti and
Huan g, 1995]. Most of these imm uno liposomes deliver drugs to the vicinity of the cells but
fail to internalize the agents into cells. This reduces the efficacy of anticancer drugs that act
intracellularly at the DNA level and must enter the cells by endocytic mechanisms. Repeated
injections cf immuno liposornes were ineffective in prolonging the survival of tumo r bearing
animals {Mori and Huan g, 1995]. A spectrum of other cell surface receptors have been
proposed as candidates for tumo r selective targeting and exam ples of those exp lored
experimentally are listed in Table 1.2.
There are many factors to consider when designing systems to target cell surface
receptors: the bomogeneity ofreceptor expression withic a tumor, the Dumber ofreceprors
available per cell and their ligand affinity; the possilbility o f up. and downregulation
following exposure to the targeting ligand; and DOt leas the cellular fate of the receptor
ligand complex.. In particular IcDowlcdgeof the number tOf receptors expressed at any time
is crucial as receptor saturation wou.Idobviously decrease efficiency oftatgcting [expressed
asa percentage of tile dose administered] ifthe dose givesa per bolus was increased wi thout
prior consi deration oflhis poin t Considering all these pearameters, law-dens ity lipoprotein
(LOL] recepto rs seem to be the most realistic approach which will be discussed in detai l
elsewhere in this text.
1.3. C ri teria ofa d fll g ca rTier
My primary goal is to propose a targetingcarricr fel r cytotoxic drugs . Theoretically,
a good drug carrier for in vivo use should meet the foUo\l'tt'ingcriteria;
I. the drug carrier conjugate must be stable. both dUlring storage and in vivo .
2. the carrier sbould be biocompatible and biodegtadalble, and the drug carrier conjugate
must not produce unacceptable levels of toxicity tOr immunological reactions.
3. the carrier should be suitable for targeting .
4. the drug carrier conjugate must allow release of tlbe drug at the target site.
s. the carrier must not cause unspecific uptake by nontarget ce lls.
6. for large scale clinical use , the carrier system muest bepharm aceutically acce ptable
in regard to formul ation homogeneity, cost of mamufacture, ease of handling and
Figure 1.1. Schematic model or low den sity IipoproceiD [LDLI. The surface of the
LOL particle contains the polar-bead groups of the phospholipids . The
apolipopro teins as wen as cholesterol are intercalated between the polar-head
groups of the phospholipids. The oeuttal lipids, eholesteryl esters and
trig lyeerides, are localized in the core of the LOL particle. CHOL.
cholesterol, FA, fatty acid. [After Brewer, 1994]
[Modified afte r Duncan, 1992J
Tab le 1.2. T umor ma rk en as taf1!l:ets for second orde r d n ll' d eliverv ·
Type I Comments
R"entnr iny olved in r on Uitu tiy e bjor hemjra l patbways
LDL Selective deli very of cytotoxic agents to tumor cell s is poss ible after
reee pton appropriate up- and downregulation schemes discussed througho ut the
1""-
Transferrin Thesurface density of transferrin receptors has been correlated with the
receptors degree ofmal ignancy and proposed as a tumor se lective target
[Trowbri dge and Domingo , 1981]. Howeve r, the broad cellular
distri bution oftbis receptor has prevented frui tful use for drug delivery .
Growtb- Many tumors have been reported to overexpress receptors for growth
facton factors such as epidermal growth factor [EGF] (King et al., 1990] and
recept ors fibroblast growth facto r [FGFJ [Robinson, 1991]. The EGF receptor is
overexp ressed in 20-30 % of breast cancers.
Mel an ocyte Melanocytes and malignant melanom a have a rece ptor which recognize s
stim ulating the peptide hormone MSH. Binding ofMSH increases the levels of
hormo ne intracellular cAMP and stimulates tyrosinase activity, in the (1I.1SH]
(MSH] course of melanin production. Because ofthe relative selectivity this
recepto r has been used as a target for MSH-toxin constructs, antibody
conjugates and other ligands [Ghan em er al., 1988].
Cellul ar ad besionfrecom jtiop syste ms
Several aspects of cellular recognition and adhesion have been proposed
as targets for chemo therapy , including laminin and fibronectin
receptors .
.
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Figure 1.2. Schematic represeDtatiollloflbe LDL rt«ptor, ' glycoprotein embeded in
the plasma m~brane of most body cells. lbe DNA' s nucleotide sequence
1nS detamincd and sites of attaebmeDtof sugar chains to nitroj:al aDd
oX)'gcualOmS-re identified.. Additiooally, [1] m clCVCD. amiDoacidregion
enriched in arginine and lysine rmdues as an LOLreceptor bindin& site and
[2]potentiaJ.lipid biDdingregions which contain proline-enricbcdbeta.wets
[Knon et al ...1985] were reported. (After Brown and Goldstein,.1994).
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administration. Lipoproteins meet most of the above requirements for a satisfactory drug
carrier. Thi s issue will be discussed later.
1.4. Cholesterol.a d " Deer
Before justifYin g lDL as acanier in cancer chemotherapy brief background studies
regarding cholesterol metabo lism and cancer are preseated In the 1930" Muller noted tha t
a low plasma cholestero l level was frequen tly associated wi th leukemia [Muller, 1939].
Epidemiological studi es done in recent decades have demonstrated a correlation between
plasma cholesterol levels and risk of cardiovascular disease. In some of thesestudi es,
concomitant analysis oCcancer incidence bas shown an unexpected conelation between low
plasma cholesterol levels and cancer (Sherwin el al ., 1987; Feinleib, 1983]. Two hypo theses
have been proposed to explain thi s observation: [I ] bypocbolcstcrolemia is envisaged as a
risk factor for the development of malignancy. and (2) hypocbolesterolemia is conceived as
a metabolic consequence of an existing c:ancer. With regard to the first hypothesis , it is
possible that individuals maintaining a low blood cholesterol level excrete increased amounts
ef'biliary stero ls and that bacterial metabolism of these sterols in the gut could result in an
increased prod uction of carciooa:cnic sterols (Reddy , 1981]. 1be second hypothesis is
supported by studies demonstrating thal the lowest cbolesterollevds were found in subjects
who presented clinically cverecancer the Sl:IOneSI [within 2 yean ] after blood sampling [Rose
and Shipley, 1980; Cam bien et al., L980]. The cl inical studies discussed above show that
plasma cbo lesterol levels in new ly diagn osed cancer patients are
12
Flpre 1.3. Stept in the LDL path ...ay ill viPo. HMO CoA reductase denotes 3-
hydroxy-3-methyl&1uwyl CoA reductase, and ACAT denotes acyl CoA:
cholestero l aqltransfcn.sc.. [AfterBrown aDdGoldstein, 1986].
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related to tumor burden It is now abundantly clear that it is cancer that brings abo ut a
reductio n in cholesterol , and not low cholesterol that causes cancer [Kritz et al.; 1996] . The
reduced cho lestero l often observed in cancer patients is the result of uptake ofLDL by the
tum or and not the cause ofthe cance r [Kritz eta!. , 1996; Lackner etaI.• 1989].
1.5. Fate ofLDL in the body
Structurally , LDL consists of an apolar core, co mposed mainly of cholesteryl esters
[eEl and to a lesser extent, triacylglyerol [fAG], surro unded by a monolayer of
phospholipid[s] [PLJ in which cholesterol and apoproteln 8-100 [apo B) are embeded
[Figure 1.1 and Table 1.3]. LOLs are formed durin g the metabolism of very low density
lipoproteins [VLDL]. LDL is slow ly cleared from the circulation via specific LDL Capo B,
andIor E] receptors [Figure 12J that internet with the apopro tein (Brown et aI., 1986J, Afte r
binding to the recep tor, LOL is internalized and degraded in the lysosomal compartment
[Figure 1.3J. The released unesterified cholesterol can be usedfor membrane or steroid
synthesis. Alternate ly. it can be re-esterified for storag e inside the cell by acyl Co-
A:cholesterol acyl transferase [ACAT], an enzyme stimulated by available cholestero l inside
the cell High cholesterol content can suppress the transcriptio n of the gene for 3-hydroxy-3-
me thylg lutaryl Co-A [HM O-Co A] reductase, a key enzyme for de novo cho lesterol
biosyn thesis. High cholestero l content inside the cell downregulates LOL receptor
biosynthesis, and thus the additional uptake of LOL is inhibited [Sudhof et al., 1985] [Figure
1.4]. The expression ofLOL receptors on the surface of a cell is carefully regula ted by the
14
cholest erol status ofthe cell [Goldstein and Brown, 1990] .
Ta ble 1.3. Physiochemica l p roperti es a nd com position olbuma a LDL*
Densi ty
Size
1.019-1.063 glmL
20-25 nm
Phospholipids {PL]
Chol ester ol
Cholesteryl esters [e El
Tria cylgl ycerol s rrAG]
18-24%
6-8%
45-50%
4-8%
800 molecul es
500 molecules
1500 molecules
500 molecules
Protein, apo B 18-22%
*(Aft er De Smidr and Van Berkel, 1990]
1.5.1. Catabolism ofLDL
I molecule
Innorma1 humans, the plasma halflife ofLDL is 3-4 days (Spady, 199 1]. The rate
of LDL uptak e in hamst er. rat, and rabbit, when expressed per gram of tissue, is the highest
in the endocrine organs , liver, small intestine, and spleen. Somewhat lower rate s of uptake
are observed in the kidney, lung, colon. heart, and stomach. Importantly, extremely low rates
of LO L uptake are found in the majo r tissue compartments of the body such as skel etal
muscle, adipose tissu e. skin and brain. Information concerning rates ofLDL uptake in the
vario us organs in humans is not available. However , circulating LDt levels were found to
fal l SO% in a patient with a genetic defect in the LDL receptor pathway who received a
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normal liver transplant, suggesting that the liver also accounts for the majority of LDL
turnover in humans [Bilheimer et al., 1984]. In fact.this organ accounts for the clearance
ofat least 40010 of the circulating LDL. Both the parenchymal liver cells and the Kupffer
cells. are involved in the uptake ofLDL [Van Beckel et al., 1990].
1.5.2. Regu lati on of LDL rec eptor activity in malignan t eens
Cancer cells show an increased uptake ofLDL Thi s increased uptake is caused by
an elevated LDL receptor expressed on the cellular surface. The evidence is z-fotd:
measurements ofLDL uptake by tumor cells and depletion ofLDL in the blood of cancer
patients resulting from high uptake by the tumo r [vide infra] [Firestone, 1994]. However,
it is not clear why LDL recepto r activity is elevated in cancer cells. One poss ibility is that
proliferating cells have an increased cho lestero l demand fur mem brane synthesis [Gal er al..
1981; Kruth eral. , 1979]. Alternatively cancer cells may lose more cholesterol from ce ll
membranes than do normal cells because of an accelerated membrane turnover. Finally a
defect in the regulation of the LDL receptor in cancer cells could be another exp lanation for
the elevated recepto r activity [Vito ls, 1991 ; Ho etal. , 1978].
The first report regarding cancer and LDL demonstrated that human acute mye loid
leukemi a [AML] cells take up 3- to l oo- fold more LDL than nonnal cells [Ho et al., 1978].
Human AML cells take up 4- to 25-fol d more LOL than normal whi te blood cells [Vitols et
ai. , 1984J. It was observed later that the high in vitro uptake of AML correlates with high in
vivo uptak e [Vita ls et al., 1990]. Human monocyti c [FAB -M5 J and mye1omonocytic
16
Fipn 1.4. Receptor mediated endocytosis of LDL-drvC coajucates. CirculatiDg
cytotoxk drua: I~ LOL is taken into • ceU by • receptor mediated
efIdocytosis. 0Dccinlernalized. LOL rdea:sc lOne dNa: inside the cell where
the drug exerts its cytotoxic action suchas iDten::al.tiODwith DNA. [After
Vitols,l990].
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[FAB-M4] leukemias and chronic myeloid leukemia in blast crisis [but Dot acute
lym phoblasti c leukemi a] take up much more LDL than nonna! mononuclear cells , peripheral
granulocytes, or nucleated bon e marrow cells [Vitols et al., 1984].
Some solid tumorsare also avid for LDL Epidermoidcervical cancer EC-50 absorbs
IS-fold more LDL than fetal adrenal tissue [which has exceptionally high uptake] and 50-
fold more than nonnal gynecologic tissue. Endometrial adenocarcinoma AC- 258 absorbs
IO-fold more than normal cells [Gal et al., 1981a]. EC-SO and four other gyneco logic
cancers have greater LOL uptake than normal cervical tissues [Gal et 01., 198 1b]. Gastric
carcinoma and parotid adenoma exceed every normal cell type in term of LOL receptor
numbers [Rudlin g et al., 199Oa]. Many brain tumors bind 2- to J-fold more LDL than
normal brain.especial ly medulloblastoma, oligodendroglioma, and malignant meningioma
[Ru dling et ai., 1990b}. In most of a group of nine patients, lung tumor tissues' uptake
exceeded that of'tbe neighboring normal lung by 1.5- to 43-fold [Vitols et al., 1992]. Other
tumors have been reported to have high LDL uptake; such as, glioma V-2S1MG [Vitols et
al.; 1985], G2hepatoma [Hep G2] [Dashtie tai., 1984;Havekes et el. , 1983], squamous lung
tumor [Kerr et al., 1988], and choriocarcino ma (Simpsons et al., 1979]. Most human tumors
have not yet been surveyed, so it is reasonab le to suppose tha t many more will be found to
have exceptionally high LDL requirements.
Th e most sinister aspec t of cancer is its tendency to spread, or metastasize.
throughout the body. This is most often the cause of death. even after resection of the
primary tumor, because metastasized tumor cell s are not onl y difficult to find but also
II
Flpre 1.5. IDftUCD" fir dJcuI)' rat•• LDL reaptor npll.kta laliver aadtu....
..... Wbcn...... opodIIdW, _ .... ond lUIytcicb are__ond
processed ifttheinlesline10 become chy&omicrons (eM). Afterhydrolysisof
TAG onthecapil1&ry cndothdiaJ ceDI, eM areCOO¥el'ted to remnanu wbidl
arescIcctMIy ""crnaJiud by IMr cells. Thelibcntol _ .... ond lUIy
acids willdownregu1ate 1DL receptorsynthesisiDtheMher ceIb. Tumor
cells.... noc beWbn<el bydio<o<y'"(Idl ). Alu< 0;, __alqJl
degreeofl\lJl'lOf' specificity canbe expected whenC.')'totOD: LDLit injected
in thcblood.saeam( ria!tJ : " lDL~'.O c:IJyIomicrons; ucbylomicroa
remnam recept~ ~ chy\omia"oa rcrM&nU"OLDL. (AfterVIII Bertd"
oJ., 1990).
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difficult to kill with standard chemotherapy. Therefore. particularly noteworthy is the small
but growing body of evidence that tumor cells that are either exceptionally metastatic
[Schroederet 01.,1984; Cambien et 01., 1980], aggressive [Mulle r et 01., 1989; Rudling et
aI ., 1986; Peterson et ai. , 1985], or undifferentiated [Zyada et al:.• 1990; Ponec et al., 1985;
1984] are also exceptionally high in their LOL requirements. lfthis is borne out in future
studi es, LDL based therapy will be even more valuab le than it presently appears .
Some tumors, howev er, do not intemalize great amounts ofLDL, e-z., AML [Vital s
et aI., 1984], chronic lymphocytic leukemia (e LL] [Juliusson and Vitals , 1988], several
colon adenocarcinomas (Fabricant and Broitonan, 1990], Lewi s rat renal carcinoma
[Clayman et al., 1986], cervical cancer EC- 168 [Gal et 01.• 1982). epithelioid carcinoma A-
431 {Anderson et al., 1981] , and guinea pig leukemic lymphocytes [Saint-Marie et al., 1986].
The latter three have ampl e LDL recepto rs, but internalization is deficient Thus, it is
important to show not only binding but also internalizati on ofLDL before concluding that
a given cell type is ripe for LDL targeting.
It is noteworthy to mention that some noncancerous pathogens have also been found
to have high LDL requirements and therefore are candidates for LDL based therapy [Bakker ,
1995; Coppens et al., 1993, 1992. 1988; Bennet and Caulfield. 1991; Chaudhuri, 1989
Peterson and Aldere te. 1984]. This non-neoplastic potential of LDL therapy will not be
discussed here.
~
Cholesterol
~
A) Normal
4-liver
a) ane Acid
Supplemented
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Fip " 1.6. RatiOD.1e for the ase of. bile . dd l upplemrDb ill tile dowarecu!atioD
ofLDL""ptoraptakelll.liYff. (Afta'Brown aDdGoIdsteiD. 1916].
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1.5.3. Up- and dOwn regulati ODoCLDL receptors in cance r patients
It is not possible to obtain an absolute tumor specificity since normal cells also
express LDL receptors. The organs most likely to suffer from the cytotoxic effects ofLDL-
dru g conjugates are those with a high LDL uptake , such as the liver becaus e of its size and
LOL receptor content, and the adrenaj s whose uptak e per gram is particularly high. The
protection of the liver and adrenal s is neverthel ess desirabl e. The extent of liver toxici ty is
hard to predict since many drugs are degraded to less toxic metabolites in the liver. Although
a LDL-drug conjugate may accumulate to large amounts in the liver, it is possible that the
organ may metabolize and excrete the drug without suffering heavy damage [Vitols , 1991J.
As indicated by animal studies, it may be possible to circumven t adrenal and liver
toxicity by pretreatment with steroids {Hynds et al., 1984] and bile acids [Dolec ek et aI.,
1996; Angelin etal. , 1983] (Figure 1.S]. Down regulation in the uptake ofLDL by liver can
be achieved by feeding saturated fats [Spady and Dietschy, 1985], cholesterol with
hydrogenated coconut oil [Spady and Dietsch y, 1985] , and fasting [Shimano et ai., 1988],
which is said to downregulatc LOL receptors on health y but not tumor cell s [de Smi dt and
Van Berkel , 1990J [Figures 1.5 and 1.6]. Two new strategies were proposed by Firestone
[1994 J. The first strategy would be delivering chole sterol as acetylated LDL [AcLOL].
methylated LOL [MeLDL] , or oxidized LDL [OxLDLJ to the liver through the scavenger
receptor pathway. Cholesterol liberated from this pathway enters the meta bolically active
pool [Fox and Dicorletc , 1986J and thus presumably functions normally in downregulating
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LDL receptor expression. Therefore. the liver which is rich in scavenger (pitas et al., 1985]
and normal LD L receptors. might be down-regulated by cholesterol load ed AcL DL, MeL DL,
or OxLDL which would not downregula te LDL receptor expression on tumor cells
[Firestone, 1994J. Sinusoidal epithelial cells of the spleen , bone marrow, and ovaries also
take up AcLDL [pitas et al. , 1985] and might be down-regulated at the same time. The
secon d strategy is related to using angiotensin Il, Angiotensin ITincreases the uptake and
receptor number of LOL in the adrenal gland [Leitersdorf er al. , 1985]. Therefore,
angiotensin converting enzyme inhi bitors (ACED. whic h prevent angiotensin ITformation,
might then reduce LOL uptake by the adrenaIs.
Increasing the activity ofLDL·mediated endocytosis in tumo r cells would also be
beneficial, provided normal cells were not concomitantly upregulated. LOL receptor activity
is indeed stimulated in normal cells by 3-hydroxy-3-methylglutaryl Co-A (HMG CoAJ-
reductase inhibitors [Shaw et a/,. 1990; BilheimeretaL, 1983; Kovanen et ai. , 1981], or bile
acid sequestrants [Reihner et al., 1990; Bilheimer et aI., 1983; Kovanen et aI. , 1981l.
verapamil [Filipavicetal.• 1986]. cachectin, and some growth factors [Horada et al.• 1990l.
tissue growth factor [[GFl-a [Nicholson and Hajjar, 1992]. tissue necrosis factor [Cl-lNF].
and IL-l [Hamanaka,1992}. Compactin is repo rted to upregu1ate LOL receptors on Hep-G2
cells with little effect on normal human Iibrob lasts [Cohen et al .• 1984]. Oncostatin M
potently upregulates LOL uptake by Hep 0 2 cells. more than normal cells [Grove et al.•
1991}. It is difficult to verify without clinical studies whether upregulation of tumor LOL
receptor activity by the abov e methods would or would not be therapeutically beneficial.
23
1.6. EvaluatioD of LDL lU dru g carrien
Effective anticancer therapy requiresa tumor specifi c carrier . LDL was proposed as
a targeting vehicl e in 1981-82 [Counsell and Pohland, 1982; Gal etal., 1981 ] and bas been
reviewedseveral times since then [Van Berkel, 1993 ; Vitals., 1991; Peterson et al ., 1991 ; de
Smidt and Van Berkel, 1990 ; Catapano, 1987]. The advantages c f using LDL particles as
drug carri ers are :
I . they are endogenous and can avoid such typ ical carrier problems as immunological
reaction and rapid plasma clearance due 10 uptake by RES; they have relatively a long
balflife in plasma and tissue fluids [in human t lJ2is 2-4 days] ;
2. their intracellular uptake [>70%] via recepto r mediated endocytosis enabl es the
release of the incorporated drug in spec ific tissues;
3. the lipoprotein parti cle is totall y biodegradable ;
4. their small particle size allows penetration from the vascular to the extra vascular
compartment; and
5. they provid e a biocompatible vehicle for lipophili c drugs, which is of special
importance if the drug is pro ne to decomposition .
Although the LDL possesses favorable properties concerning loading factors,
immunogenicity, toxicity, and applica bility to diseas e processes, there are certain
disadvantages associated in using lipoproteins or LDL as drug carriers, for example,
1. their comp lex nature and
2. their potential to produce cyto toxicity to normal cells through defective targ eting .
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1.6.1. LDL particles as carrien or cytotone agents
The po tential of LDL as carriers for cyto toxic agents compared to other available
carriers curre ntly in deve lopment will be eval uated in this section Growing in terest in the
use of drug de livery in cancer chemotherapy bas been in part due to the limited progress in
the successful development of effective new drug entities. but is also due to the realizatio n
th at new approac hes must be adopted ifwe are to achieve an improvement in therapeutic
activity [Conn ors, 1989J. As pointed out earlier many different systems have been exp lored
: low molecular weight prodrugs (Walke r et al., 1989J, macro molecular carriers ,
immunoconjugates (Baldwin et at.• 1990]. natural [Sezaki et 01.• 1989] and synthetic
polymers [Krinick et 01., 1991], vesicular or particul ate systems, liposomes, (Rahman et 01.,
1980], nanoparti des [Couvier et 01. 199OJ, microparticles for regional therapy [Kerr and
Keye, 1991], polymeric implants [Word et al.• 19891, and use of devices such as infusion
pumps [Blackshear, 1989].
Seve ral of these technologies have been tested clinicall y [infusion pumps are in
routine use], but it is certainly true that many [including immunoco njugates and liposomes]
have, as yet, failed to realize their promise clinically. Liposomes are attractive drug carriers
because they are easy to load with drugs of different physicochemical properties. Antibodies
have another attractive property since they specifically interact with the antigen. Ideally one
should tl)' to combine the attractive features of these two carrier syste ms. At least some of
the problems encountered with liposomes and antibodies as drug carriers could be avoided
using LOL as a natura1liposome that is taken up into cells by a specific receptor-mediated
2S
Figure 1.7. S ites of iDeorpor'll tioa ofdrv p aDd otber.dive (aDd iDaaivel moieties
on to or int o LDLI : [IJ surface attachment; £2} penetration into the PL-
cho lesterol monolay er, (3] solubilizatio n at the C'E-mooolaycr interface ; or
[4] solubilizatiOll. in the tipid interior of the pctidc. (After f10rence aDd
Halbert, 1991).
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endocytosis. Since several malignant cell types express more LDL receptors than normal
cells. selective uptake and cytotoxicity is possible as discuss ed ear lier. In fact, one human
trial ofLDL-vincristine conjugates in Europe warrants further investigation of this approach
in cancer chemotherapy [Breeze et 01. 1994; Filipowska et al., 1992].
1.6.2. Soueees of LDL for large sca le use as targeted carrien in can cer chemothe rapy
An advantage associated with LDL mediated canc er chemotherapy is the easy
availability of lipoproteins clinically in addition to commercial source[ s]. There are mainly
two sources of human LDLs , [a] LDL iso lated direc tly from the patie nt [yamamoto et 01.,
1992 ; Franceschini et of ., 1991, Schulti s et al ., 1990; Behm et 0/.• 1989; Saal et af., 1986;
Parke r et 01., 1986; Wieland and Seide l, 1983; Goldstein and Brown. 1977] and [b] LDL
isolated from plasma of other individuals [Edelst ein and Scanu., 1986; Schumaker and
Puppione, 1986]. The use of plasmapheresis for the isolation ofLDL and the preparation of
LDL-drug conjugates from the patients' own LDL has also been proposed [Lundberg and
Suominen, 1984].
1.7. In(;orporatioD of bio logi(;a lly ac tive molecules into lip oproteins
The nature of cytotoxic drug assoc iation with lipoproteins is a complex phenomenon
This topic is the main focus of this section There are at least four po tential sites for
interaction, excluding covalent interactions [Figure l. 7], whic h have analogs in the sites of
uptake into or on to lipopro tein system[s]:
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I. Adsorption onto the surface either to the protein moiety or to PL head groups.
2. Incorporation into the PL monolayer.
3. Incorpo ration into the interface betweenthe lipid core and the PL monolayer .
4. Incorpo ration into the lipid core.
Adsorption may be mediated by hydrophobic or electrostatic interactions. The
princip le hydrophobic interaction will be with the apoprotein., whereas electrostatic
interactions may occur between the PL charged groups and opposite ly charged solutes [Chen
et aI., 1987; Davis and IUum, 1986; Willmott et al.; 1985J as the result of partitioning
between the largely aqueous external phase and the particle. the ultimate destination (i.e.,
depth of penetration] oftbe solute will be dete rmined by its polarity. Amp hiphilic so lutes
are likely to be sited in the PL monolayer or in the lipid interio r, provided they are miscib le
with the CE-TAG core. Lipophilic molecules will partition into the lipid core, while
lipophilic, po lar mo lecules will straddle the core and the PL regio n.
The surface attachment of drug molecules has certain disadvantages in the case of
LOL, the LDL particles generally show a greater tendency to aggregate . possibly because of
the loss of surface charge, Any ionic drug neutralizes the surface charge ifbonded covalently
with apo B protein. Themost serious problem is the potential interference with the receptor
specificity of the system if drugs are bound to the apopro tein [MahI ey et 01.• 1977].
1.7.1. Effect of dru g location iDLDL
The apo lar core of the lipoprotein provides an ideal domain for highly lipophilic
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drugs. Drugs that are stored in the core of a lipoprotein carrier are protected from the
environment during transport. This will prolong their plasm a halflife and stab ility if the
drug is readil y degrade d in plasma. Funhermore, a drug th:at is loca ted inside the lipid
moiety of a lipoprotein carrier will not disturb the recognition, of the apop rotein presen t on
the surface ofthe particle.
Drugs, for exam ple, ampbiphilic compounds, may not be incorporated into the apolar
core, but into the more amphipbilic PL shell In this case, the compoun d is not shielded from
the environmen t during transport and it may also affect the specific uptak e of the carrie r by
the recepto r dependent pathway .
1.7.2. Design iDg ofdrup to incorporate int o LD L parti cl es
An improvement oftbe Iipophilicity ofa drug increases the possibility of enhancing
its ability to penetrate membranes and reach its site of action. This can be done by choosing
molecules with high octaacl/water partition coefficients (P] or those molecules with distinct
lipophilic and hydrophilic regions [i.e, amphi pathic). Some highly lipophilic drugs [e.g. •
porphyrin co ntaining compounds, diphenylhydantoin. reserpine, and estradiol] incorporate
spontaneous ly into lipoproteins [Yoo et ai.; 1986; lwanik et al.• 1984; Yanovic h et al., 1984;
Ramsen and Shireman, 1981J, Howeve r. most oftbe drugs tHlat are curre ntly used for the
treatme nt ofdiseases are too hydrophilic for spontaneous incor-pora tion. For incorporation,
these dru gs have to be rendered more lipophilic by the coupling of lipophilic groups. A
water soluble drug can be rendered amphipathic by covalen t llinkage via acyl ester. amide.
2.
or phosphate ester to bio logically compatible lipo philic functional gro ups such as fany acid,
cho lesterol, diacy lglyceride (VAG), or PL.
Several studies suggest tha t ifa compound is provided with certain groups that render
it com patib le with LDL's PL coat or lipophilic core, this will facilitate more drug
incorporati on in LDL. Oleyl. retinyl, and cholesteryl were proposed as suitab le groups for
this purpose [Marsh, 1974]. Howeve r, this suggestion was proven nul l and void as
compounds with thesegroups did not show higher incorporation efficiency. La ter. Shawet
al., [1989 ] incorporated a variety of compounds with dissimilar structures that had lipophilic
characters. Any lipophilic drug is considered suitable to load into LDL and there is no strict
structural requirement cons idered to optimize drug loading efficiency [Barel et al., 1986;
Candide et aI., 1986; Reyftmann et al., 1984; Counsell et 01., 1982].
To de live r a drug that will be pharmacologically active by the LDL media ted
pathway. the following conditions have to be met.
(I) The drug needs to possess a high affinity for the lipid moiety of the
lipoprotein carrie r, either of its own., or afte r the attachment ofhydrophohic
resi dues.
[2J The [deri vatized] drug should remain firmly associated with the carrier
durin g transpo rt in the circulation.
[3J Ifpresent, thehydrophohic anc hor attached to the drug needs to be removed
in the lysosomes.
[4J The parc ntdrug should be released fiom.the LDL carrier in the lysoso mes hut
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should not be deactivated.
It is equally important that the released drug is able to pass the lysosomal membrane
and become available in the cytoplasm. Also , the MW of drugs should not be too high. since
lysosomal membrane permeability may then become a problem..
1.7.3. Limitations in loading drugs into LDL particles
1.7.3 .1. Restoration of apo B protein integrity: When using synthetic or semisynthetic
colloidal drug carriers. modifications can be made to the system to optimize carrying
capacity, biodegradability, and perhaps targeting potential It is unlikely that such
approaches can be made with LDL particles, since the equilibrium state ofth e particle will
be perturbed.
In the native particle the apo B is so arranged that approximatel y halfofthe molecule
is exposed to the aqueous environment and the remainde r resides in the lipid coat Any
disruption to thi s "coat ". particularly through interaction with amphipathic molecules, might
well alter the conformation and th e binding capacity of the apoprotein to the LDL receptor.
The effects of additives such as drug molecules on the function of the particle is to some
extent dependent on changes in the relationship between the apoprotein and the particl e, and
they may be vital to the success of targeting.
31
1.7.3.1. Pa rtitioning of drugs both into core aa d surface mODolayer. The lipoproteins
in solution represent a discretecollo idal lipid phase possib ly in the fonn ofa mlcroemulsion
Lipid soluble materials should readily partitio n into the core of the lipoprotein particl e.
Indeed , it appears that a range of lipid-soluble materials bas this ability to partition into
lipoprotei n particles ; simple partitioning does oat seem to have been utilized to any great
extent to transfer drugs into lipoproteins except for LDL Daunomycin (DNM) has been
bound to LDL through the incubation ofLDL with glass beadscoated wi th the drug [Iwanik
et 01., 1984]. The drug was found to be present both in the internal core of the particle and
on the surface [Iwanik er at., 1984). Studies of the selectivity of anthracyclines for
negatively charged PL membranes [Burke et 01.• 1988J were consistent with a mode of
binding involving both hydrophobic and electrostatic interactions, in agreement with the
findings of Henry et 01., [1985 J. Theelectrostatic interacti ons involve the amino group of
the sugar mo iety and the ionizedphosphate groups of the PL, hydrop hobi c interactions with
the tetracycl ine ring and the hydrocarbon interior of the bilaye r.
Molecules that are taken up into the monolayer also have the possibility of altering
the distribution of the particle by [a] altering the surface charg e or [b] adding new receptors
[0 the surface, This technique has been used for the synth esis of Tris -Gal- Cbo l, which
interacts with galactose receptors [Kempen et al. , 1984]. In the lipo prot ein pathway, it is
known tha t exchan ge of surface constituents [apopro teins and PL] takes place among
lipoprotein species [fall and Small, 1980). Material may move from the original lipo prot ein
in which it was incorporated to another. Additionally, the apoprotein in the surface layer
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may be affected by exchanges in the mono layer composition. which would undoubtedly alter
the physicochemical properties of this layer [Scbroeder, 1979J and might diminish any
targeting specificity that the lipoprotein possesses.
1.8. Inc orp oration methods
On e of the fundamental problems in util izing LOL-mediated targeting is the
dev elopment of a satisfactory drug incorporation method Generally, the drug incorporation
method int o LDL must meet tw o basi c requirements:
[1] formation of a stabl e, nonleaking LDL-dru g conj ugate and
[2] retain the natural integrity of the apo B protein .
The second requirement restric ts the experim ental conditions [pH, die lectri c
constants, tempe rature , use of metal ions, expos ure to air , vortexing, etc .] [Fon g. et 01.,
1985J. Even small changes in parameters such as pH and dielectric constan ts may alter the
three dimensionalstructure of apo B in such a way that LOL will lose its receptorrecognition
properties. Four main methods for the incorporation of drugs into LDL can be distinguished.
1.8.1. R econstitution m ethods
Th e delip idation group of incorporation methods invol ves a more rigorous handling
of'the lipoprotein. LOL can be freeze dried in a starch {Sch outen et al., 1988, Glas s et al.,
1985 ; Soltys et al., 1982J or sucro se [Forester et al., 1983J "frame " and subseque ntly
extracted with organic solvents, followed by reconstituti on with the dru g [Lundbe rg, 1987].
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Other delipidation methods utilize detergents [Rifici et al., 1984] or enzymes [Fidg e. et al.,
1985] to prepare solubl e apo B-PL conjugates that can be reconstituted with the particular
drug [Masquelier et al., 1986; Krieger et al .• 1979]. The delipidation methods are not very
efficient and LOL particles with only limited amounts of incorporated drug result. Recovery
ofapo B was usually less than 40"10and the reconstituted LDL-drug conjugates were larger
than native LOL and passed through 0.8 ~ filters but not 0.45 J.Ul1 filters [Shaw et al.,
1987] . Moreover, the method is very tedious and the physiological behavior of the
reconstituted LDL needs to be monitored extensively, because modification can occureasily.
1.8.1.1. Solvent extraction: lbis method was first reported by Krieger et a1. [1978).
The procedure includes lyophilization and heptan e extraction ofLDL. mixing the resulting
apo B PL preparation with drug and extracted LDL neutral lipids . and finally solubilization
of reconstituted LDL-drug conjugates by addition of buffer followed by purification by
centrifugation and filtration The conjugate remained stable during dialysis, density gradient
centrifugation., and gel filtration. The reconstituted LDL retained its Il-mobility on agarose
gel electrophoresis and its ability to be precipitated by both an antibody to nativ e LDL and
by heparin manganese. The Krieger method has been used to incorporate a variety of
hydrophobic compounds into the core ofLDL. including dioleyl methotrexate (Krieger er al.,
1979], 25-hydroxy-<:holesteryl oleate (Krieger et aI., 1978J. cholesteryl nitrogen mustard
[phenesterineJ [Firestone et al .; 1984J. and pyrene coupled to a derivative of cholesteryl
oleate [Mosley et al., 1981].
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A major limitation of this method is that the LDL-drug conjugate was more rapidly
removed from plasma after IV injection than native LDL [Masquilier etaI., 1986]. This was
overcome by using sucrose instead of starch and a plasma disappearance rate equal to that
of native LDL was obtained [Masquilier et al.; 1986}. However, the amount of Ann
incorporated in LDL was lower with this modified Krieger method [100 moleculesILDL
particle] than with the original one [400 molecuIeslLDL particle]. The recovery of drug in
the final preparation in this modified method was low [Shaw et al.• 1987; Lundberg , 1987].
1.8.1.2. Detergent solubilization: Detergents [e.g., sodium deoxycholate] can be
used forthe delipidation and solubilization of the water inso luble apo B from LDL [Atkinson
and Small, 1986]. The apo B.-detergent conjugate was then isolated by gel filtration and used
for reassembly of LDL with a ncutrallipid [or drug] microemulsion Such a method has
been applied to the incorporation of eholesteryl oleate [Lundberg and Suminen, 1984] and
a cytotoxic steroid mustard carbamate [Lundberg, 1987] into the core afthe reconstituted
LDL particle. Detergent solubilization methods are rather tedious for routine LDL-drug
conjugation The conjugates prepared by this method are less than satisfactory since upon
aging at 4"C the turbidity ofthe preparations slowly increased . Complete detergent removal
was not successful. The method was not considered useful since the stability of the LDL-
drug conjugates was poor and the removal of detergent was not complete . However, by these
procedures an optically clear preparation of reassembled LDL was obtained, which was
stable as determined by density gradient ultracentrifugation and gel filtration. The LDL
3S
particles had a mean diamete r of 22 nm and exhib ited B-migration during agarose
electro phoresis. In vivo, a considerable portio n of a reconstituted LDL preparation was
cleared rapidly from the plasma [in mice ], indicating uptak e by theRES [De Smi dt and Van
Berkel, 199OJ.
1.8.1.3. Enzym atic digestion: EnzymaticdelipidationofLDL [Lundberg, 1987] was
proposed as a more gentle method Th e CE core was hydrolyzed with stero l ester hydrolase
[Ee 3.l.1 .13] in the presence of egg yolk phosphotidy lcholine [EYPC] vesi cles and albumin
in order to bind the reactio n prod ucts , free cholestero l and free fatty acid. In vitro results
were encouraging in terms ofstability and cytotoxicity. However, DO in vivo studies have
been perfonned.
1.8.2. T ra nsfer/Co nta ct melh ods
The essential step in the contact method is physicoch emi cal transfer of drug
mo lecules from a solid surface into LDL particles [e.g.• the wall ofa glass tube , glass beads
or small siliceous earth crystals such as Celite 545] (Sen et al., 1985). The procedures
invo lve evaporation to dryness of the drug in organic solvent as a thin film on the support
and then incubation with a lipoprotein preparation in the presence of the necessary
preservatives such as antioxidants, antimicro bial agents, dark room. and inert gas. Afte r
compl eted incubation [usually at 37 "C] the lipoprotein-drug conjugate can be purified by
Sephadex G-1ZQ-15 column chromatography [Iwanik et 01.,19 84] or by centrifugation [3000
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rpm for 10 min] ifCelite 545 is employed [Seki et aI., 1985}. For sterilization and removal
of aggregated com plexes a 0.20 IJIll filter can be used .
This method is increasingly used to incorporate drug s [Shaw et al., 1981; Seki et al.,
1985]. The su ccessful partitio ning ofa number of different structured drugs into LOL or
modified LDL has been reported [Shaw et al., 1987]. They include hexad ecylmethotrexate
[55 moleculesILDL], AD 32 [100 moieculesILDL1, muramyltripeptidephospbati dyl
ethanolamine [14 0 molecules!AcLDLJ, arabinofuranosyl cyto sine-5'-[n-hexadecylpbosphate
[90 molecules /LDL], and DNM [6 moleculesILDLl However, contact methods apparently
can only be used for drugs that exhibit the right physicochemical charac teristic s for
partitionin g into the LOt .
This method is technically simple and rapid. The nati ve integrity of the LOL
mol ecules and stabili ty of the drug is restored The biological behavior of the conj ugates
see m to be acceptable both in vitro [Iwanik et al. , 1984J and in vivo [Seki et aI., 1985J. The
dry film method meets the requirements for simplicity and rapidity that must be plac ed on
any practically use ful method.
1.8.3. Miscellaneous transfe r
Hynd s et al. [1985] performed a simple exchang e between LDL and a drug-lip id
microemuls ion Up to 30 % of the chlorambucil used was recovered in LDL by this method
When the inhibition of protein synthe sis was tested on human glioma cells in culture, the
conjugat e was found to be more effective than chlorambucil itself. A similar technique was
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used to incorporate 9-methoxy-elliptic in into LDt (Via et 01., 1982]. The drug was
incorpo rated into a dimethy lphosphotidyl choline, cholestery l oleate stabilized
micrcemuls ion, and the tarter fused with human LDL The LDL-drug conjugate was more
effective than the free drug to kill L1210 and P388 leukemic cells in vitro.
1.8.4. Direct/Aqu eous ad dition
This is the simplest of the incorporation methods. Conjugation of drug and
lipop rotein was accomplished sim ply by addition of an aqueous solutio n of the dru g to the
lipoprotein preparati on, fullowed by iso lation of the conjuga te by dialysis. gel filtration and
ultrafil trati on. Such measures gave incorporation of 15-4 50 molecules of aclacinomycin A
per LDt particle [Rudling et ai., 1983J, 3-5 Dox per high density lipoprotein [HOt] [Shaw
et ai, 1987], and approxima tely 130 photo frin ITper LOt [Candi de et al., 1986]. Th.is
method can only be used on a limited extent number of drugs since a delicate balance
between lipophil icity and water solubility is required. Unfortunately. the rapid and easy
incorporation ofdrugs into the lipoprotein is usuall y accompanied by a high rate of leaka ge
of the drug from the carrier (Rudlin g, et al . 1983]. In addition, drugs conjugated with
lipop rotein by aqueous addition will undergo a fast transfer to other lipoproteins and cells
[Van Berkel. 1990]
1.8.5. Fa cilit at ed traDsfe r
This is a relatively unexploited method. The exchange of strongly lipophi lic lipids,
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like TAG and CBs, from lipoproteins to cultured cells in plasma freemedium is extremely
slow [Ekman and Lundberg. 1987]. However, the addition of transfer mediators like
solvents {Fielding and Feildin g, 199 1; Fielding eta/., 1979] or lipid transfer proteins (Tall ,
1986) can appreciably increase the transfer rate. A corresponding approach may be
applicable also to lipophilic dru gs and LOL particl es.
D imethylsulfoxide [DMSO] , bas been used for the incorporation of labeled CEs into
lipoproteins and has also been tested for incorporation of AD 32 into LOL, but with inferior
results compared to that obtained by the modified Krieger method. Use of the cho lestery l
ester transfer protein [CETP] presen t in plasma (Tall, 1986. Blomho ff et a/., 1984] has been
unsuccessful in transferring two drug molecule s, dioleoyl fluoxouridine and dioleoy l
meth otrexate. from dry film into LDL particles in one study [De Smidt and Van Berkel,
1990bj. However. the method bas been used to label acetylated LDL with rt4C]
cholestery lcleare 49 and to incorporate rHJ chol estery loleyl ether into lactosy lated LDL
[Bijsterbosch and Van Berkel . 1990]. The method has proven to be successful for
endogenous molecules like cbo lesteryl oleate. Far less experi ence has been gained with the
incorporation of foreign molecules like drugs. The structural requirements of various
compounds to serve as a substrate for the transfer prote ins have to be defined more explicitl y
in order to comment on the potential wider application of this metho d.
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1.9. Statement o(reunaeh prob lems
Anticancerdtugs could, more discriminatingly, be delivered to neop lastic tissues by
means of LDLs.. However, two major obstacles to this strategy have been identified. The
first imperfection is the Jow eflicic:ocy ofdrug loading into the core ofLDL particles without
disrupting its innate integrity; and the second is the possi ble exchange or transfer of load ed
drug (s] among lipopro tein subspecies in plasma According to the existing loadin g
techniq ues, only 5-100 drug mo lecules with MW s less than 300 can be acco mmoda ted into
an LDL particle in its endogenous Conn. Drug molecul es, ifattached to the surface ofLDL
parti cles simply due to hydrophobic interacti ons , may be disp laced spontaneous ly by the
excess amount ofPL in b iological membranes and lipoproteins in the extracellular fluids.
In addition. drug [s] may und erg o exchange and transfer among lipoprotein subspecies by
lipi d transfer protein [s] even if drugs bave very hydro phob ic properti es [Morton. 1990 ;
Wasan. 1990-96]. All these factors will contribute to decrease the drug concentration at
nmor site(s]. Moreo ver , merely giving a higher dose of a LDL-drug conjugate with a low
drug concentration cannot be practical atlcilling tumon due to saturationof tbc LOL recepto r
pathway as mentiooed earlier. Tbeeefoee,loading large quantiti es of hydrophobi c drugs into
the oily core ofLDL is imperative to achie ve a thentpeutica11y effective concentration and
targeting effect To acco mplish this. the explo itation of biochemical approach[es] are
required to esta blish an effective anticancer drug targeting system.
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1.10. Rationale or tb en stu dies
1.10.1. Selection of drug candidates
Do x, wi th a broad spectrum of antitumor activity, continues to be of major
importance in cancer treatment [Neidle, 1992 ; Arcamone, 1980; Arcamone er al., 1974;
1975} and tends to be the standardagainstwhich new drugs are judged [Neidle, 1992]. It is
of value. either alone or in combination, in the treatmentoflymphatic leukemia. lymphomas,
breast cancer , genitourinary tumors , epidermoid carcinomas, and soft tissue carc inomas.
Unfo rtuna tely. many of the low growth fracti on carcinomas common in older pati ents [lung,
breast. colerecta1, and bladder tumors, for examp le] are poorly respons ive to this agent Dox
produces a range of dose dependent toxic reactions such as, cardiotoxicity ,
mye losuppression, and gastrointestinal toxicity . These dose dependent side-effects are
related to widespread biodistribution of this drug in the non-tumorous tissu es in additio n to
tumo r tiss ues. The most commo nly used formulation is Dcx-Hfl l, even though Iiposomal
fonnulations are currently in clinical use [Janknegt, 1996]. I speculat e if Dcx assoc iation
with lipop roteins coul d be increased, it would decrease its distri bution to plasma albumin
resulting in decrease cardiotoxicity and increase cytotoxicity .
Po!yiodinated cho!esteryl iopanoatc [Cl] has been proposed as a nonhydro lyzable CE
analogue and as a radiotraeer for if! vivo studies regarding LDL uptake. When drug and CI
are incorpora ted together into LDL particles. if! vivo uptake of LDL-drug conjugates in
different tissues could be detennin ed by quantification of CI inside the tissues. Unlik e
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naturally occurring CBs , this compound is not a substrate for CE hydro lase and can therefore
be trapped intraeellularly. This will help to determine total CI uptake from CI loaded LDL.
Since an insect lipid transfer particle [LTP ] coul d load a large amo unt of CE into LDL, I
speculate that a substantial amount of CI could be incorporated into LOt for the
development of an in vivo tracer for LOt uptake studies. It can be developed into a
diagnostic agent for early detection of tumors. In conc lusion, I propose to use Dox and CI
in my studies to incorporate into LDL partic les.
1.10.2. Development of analytic al methods
I have radiolabelled Cl. Radiochemical methods such as gamma counting are
available for its quantification. High performance liquid chromatography [HPLC] method
is differen t from radiochemical methods in respect to its potential to quantitate the integrity,
stability or purity of a drug . I developed a reverse phase HPLC methods for the
quantification of'Cl. Furthermore, I propose that a colorimetric method fo r Dox could be
developed by the addition elf" wing bicinchoninic acid (BCA] protein assay kit The
enhancement could mak e the colorimetric method comparable to th e spectrofluorometric
method. If successful, this DeW method is expected to be technically simple and cost -
effective.
1.10.3. Dru g as sociation to lipoproteins
There is increasing evid ence that lipoproteins may be importan t in the binding of very
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lipophilic and/or basic compounds (Danoo and Chen.,1979J. The interactio n of lipophilic
compo unds with plasma lipoproteins basbeenshown to influence the pharmacokinetics and
organ distrib ution of a num ber oflipophilic compounds. It has been dem onstrated that the
interactio n of several com pounds, incl uding amphotericin B [Am p B] [Wasan et al., 1990-
1996; Wasan and Lopez-Bcrestein, 1993b] with plasma lipop roteins modifies their
pharmacokinetics . tissue distribution. and pharmaco logical activity. Wasan et al., (l994a-c]
have demonstrated that Amp B initially associat es with the HDL fraction upon incubation
in plasma. Moreover, cydosporin A enters the hydrophobic core regions of lipoproteins
where it may be distri buted according to its high octanol /water partition coefficient [log P>
2.8] [Yang and Elmquist. 1996; Lemaire and Tillement, 1982; Tillcment et al.• 1978J.
Studi es have shown that anthracyclines are bound to human plasma protein to an
extent of 50· 85% [Eksborg et a/., 1982]. The binding of lipoproteins and differen t
anthracycline analogs could be ascribed to physicochemical determinants of lipophilicity
[Chassany et al., 1996; 1994J. In conclusion, the binding of certain classes of drugs to
lipoproteins indicates that lipophilic compounds can be incorporat ed in lipoproteins ,
especially LDL particles. To test the preference ofDo x for LDL, I propose to study ex-vivo
plasma distribution ofDox.
1.10.4. Ph ysicoch emical factors a nd drug loading
I explained ear lier that lipophilic compounds readily parti tion into the core of the
lipoprotein particle. However, simple partitioning does not seem to produce a significant
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driving force to facilitate transfer of the drugs into LDL Contact methods apparently can
only be used for a limited amount of drugs that exhibit the right physicochemical
characteristics for partitioning into the LDL Hynds et ai. [1984] perfo rmed a sim ple
exchange between LDL and a drug-lipid micr oem ulsion. A similar technique was used by
Samadi-Babo li eraI.[l990; 1989J. In this technique, drug was incorporated into a stabilized
microemulsion, and the latter was fused with LDL. Based on these findings, I hypothesized
that drug molecules ifsuspended with the aid of a suitable wetting agent or incorporated in
the liposome would be more readily incorporated into the LDL when compared to the dry
film method. Liposomal formulation of drugs was used to further investigate LDL -drug
interactions and their effect in drug loadin g. Several factors affecting drug loading into LDL
particles. such as, temperature, incubation time, stoichiometry ofLDL-drug conjugates, were
optimized to determine favorable loading condition [s].
1.10 .5. Physicoch emical characterization ofLDL-drug conjugates
The success of LD L-mediated approach coul d be ascertained from findings of
advanced biochemical and biophysical techniques, such as, sodium dodecy l sulphate-
polyacrylamide gel electrophoresis (8DS-PAGE], electron microscopy [EMJ, and differential
scanning calorimetry [DSC]. In vitro characterization is imperative to have ins ight into the
in vivo behavior ofLDL-drug conjugates. I. therefore , propose to characterize the LDL-drug
conjugates using SDS·PAGE, EM, and DSC.
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1.10. 6. Us e of biol ogical transfer catalysts
A number of loading techniques have been discussed earlier. With all of these
techniques, the key question is whether it is possible to incorporate a lipophilic drug into the
core of a lipoprotein particle, in sufficient concentration, and without disrupting the native
integrity ofLDL. Exploiting a suitabl e promoting factor bas been considered essential for
successful dru g loading into LDL particles. An insect lipid transfer particle will be examined
as a promoting facto r in the loadin g strategy and the rationale for this is discussed here.
The movement of hydrop hobic materials associa ted with lipoproteins in the
circulatory system is a dynamic process that is mediated by transfer factor[5]. In humans . a
67 kDa glycopro tein called CETP mediates the exchange and transfer oCCE and PL amo ng
lipoproteins [fall. 1986]. Human microsomal TAG transfer pro tein [MTPJ is respons ible
for TAG lipid movement in VLDL fonnation within the lumen ofmicrosomes [Wilson et
01.• 1991; Breiter et aI., 1991]. In insects, lipid transfer between insect lipoproteins
(lipophorins] is accomp lished by a transfer factor found in hemolymph and other tissues. In
the tobacco homworm, Manduta sexta, a high MW protein cal led (LTPl was discovered to
be a multifunctional lipid transfer catalyst [Ryan 1986a-b]. Preliminary experiments suggest
tha t part of LTP has a functional similarity to a subunit of human Mfp. It has been
suggested that one of the three subunits ofLTP [apoLTP Ilj, 55 KDa] might function like
protein disulfide isomerase [PDI], which is involved in the process of protein folding and
unfolding [Wetterau et al.• 1992; 1991]. This mechanism may be responsibl e for the
carrying capacity ofLTP for its substra tes .
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The rate of spontaneous exchange of lipophilic molecules between lipoproteins is
slow [Ekman and Lundberg, 1987]. Howev er, the addition oftraosfer mediators like CETP
[Tall . 1986] can appreci ab ly increase the transfer rate. A corresponding approac h may be
applicable to incorporate lipophilic drugs into LOL particles altho ugh eETP was not
successful in enhancing drug incorporation into LDL particles {de Smidt and Van Berkel,
1990]. The reason for this failure could possi ble be the high substrate specificity of the
human CETP . Com pared with human CETP, insect LTP has uni que characteristics. LTP
can transfer lipids almost uni direc tionall y from one lipoprotein to another. The rate of this
transfer process is muc h faster than tha t of human CETP . LTP was found to be efficient in
loading hydrophobic compo unds into a tightly packed LOL parti cle. The various substra tes
transferred by LTP include diacy lglycerol [nAG], TAG, PL. cho lestero l and CE, and
hydrocarbon wax (Liuctal.. 1991; Singhct al., 1991; Ryan, 1990; Ryan et aI., 1990;]. The
lack of substrate specificity ofLTP provides a good ground to spec ulate that the transfer of
hydrophobic anticanc er agents into LOL may be poss ible using LTP as a transfer catal yst
When human LDL was used to accept the lipids associated with other lipoprotein subspec ies,
the capacity of LDL as a lipid sink was greatly enhanced by LTP [Ryan et aI., 1990]. It was
found that each LDL partic le could bearan additional 600 DAG mo lecules [MW 665J inside
the lipid co re without alterin g its basic struc ture [Liu and Ryan, 1991] . It is likely that the
eight intramolec ular disulphi de bridges in the apo B protein [Innc rarity et 01., 1979], which
has 4536 amino acids, forms a protein matrix for the LDL particle, may undergo significant
conformational changes by an unfoldin g/refolding process in order to accep t additional lipids
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into its core. Ifthis holds true, the risk of dilutio n oftbe LDL-drug conjugate, via exchange.
or redistribution of the drug into the circulatory LOL lipid pool would be reduced.
1.10.7. Biological eval ua tioDof LDL-d rug conjugat es
Our long term goal is to establish LDL as a targeted carrier in cancer chemotherapy.
Before the onset of a preclinical trial in an appropriate animal model, evaluation of a
formulation in a suitab le tissue culture model is essential Biological evaluation of this
formulation in cell euture was important to verify my hypothesis that LDL-Dox co njugates
were internalized by a receptor mediated endocytosis process by cells . Therefore. this new
LD L-Dox formulation would be more effective than existing formulations ofDox. J propose
to evaluate different formulations of Dox in a well characterized tumo r cell line. HeLa In
addition., a modification of LDL by acetylation was found to be effective at selective ly
targeting cancer and/or infections involving macrophage cells (Shaw et aI., 1988; 1987). I
hypothesize that if LOL is modified by acety lation, when drug is incorporated into this
modified LOL , the modified LDL·drug conjugates will be, preferential ly, taken up by a
mouse M¢t cell lin e, J774.Al .
1.10.8. Dru g interferen ce in pro teiDassa y metho d
In LOL based phannacologic and experimental therapeutic research, it is often
neces sary to quan titate the apo B protein associated with LDL-drug conjugates. Common
methods for the assay of proteins in biological fluids include Lowry, Bradford, and the BeA
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assay methods. All ofthese methods are potentiall y interfered with by a variety of chemical
components. including drugs . buffers, and metal ions. It is imperative that the method used
to determine protein concentrations is not interfered with by any component other than
protein Before selecting any colorimetri c protein assay method, I propose to test all dru g
candidates for any po ssible interference in the analytical method. Thi s forms the basi s for
drug interferen ce studies using common protein assay kits.
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1.11 . Specific objectives oftbe5c studies
To examine LOL as a potential targeting carrier for cytotoxic agents in cance r
chemotherapy, my specific goals were as follows:
A. Physicoch emical charac terization ofLDL-drug conjugates.
A. t . To investigate hydrophobic binding of Dcx with human lipoproteins and
inv estigate the suitability of'D cx as a candidate for loading in LDL.
A.2. To load Dox into LOL and evaluate drug incorporation techniques in terms
of incubation conditions [temperature, time. stoichiometry of LDL-dru g
conjugates]. process parameters [the dry film method with or without wetting
agents] . and formulatio n parameters [liposomal, aque ous suspens ion or
solu tion of drug formula tions].
A.3. To characterize LDL-drug conjugates using phy sicochemical and advanced
techniques such as 80S-PAGE. EM, and DSC.
B. To optimize vari ables in enhancem ent cf Dox and CI loading using insect LTP .
Human CETP was also considered as a pos sible transfer facto r.
C. To evaluate the cytotoxicity of LDL-Dox conjugates compared to corresponding
conventional formulation, DoxHCL in saline in vitro on tumor cells; HeLa cells ,
using [3.(4,5.-dimethylthiazoyl·2·yl]·2,5-diphenyl.tetrazolium bromid e], (M1T],
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assay .
D. To modify LDL via acetylation and in vitro characterization of modified LDL-Dox
co njugates physicochemically and bio logically in a M41ce ll line, J774.A I.
E. To assess drug interference in protein assay using conventional kits [Lowry,
Bradford, and the BCA assay kits].
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CBAPTER2:
EVALUATION OF FACTORS AFFECfING DRUG LOADING INTO LDL
PART ICLES
2.1. In tro du cti on
A number of particulate systems such as antibodies [Moo and Huang, 1995; Edwards
and Mcintosh, 1986], microspheres [Jalil and Nixon, 1992; Juliano , 1985J, liposomes [Allen,
1995; 1994 : Mayhew et al., 1984] and other macromolecules [Duncan, 1992; Sezaki and
Hashida, 1985] have been proposed as targeting carrie rs to deliver cytotoxic drugs. There
are many obstacles to the successful deli very of drugs usin g these carrier moieties. Ideall y,
the drug-carrier conjugat e must avoid unwanted uptake in vivo by the RES. Thi s is
espe cially important for a carri er design ed to target non-RES cell s. such as tumo r cell s of
non -RES ori gin. Ce lls of the RE S are extremel y effective in remo ving foreign materi als
from the blood. These carriers (>100 nm] are rapidly removed from the circulation in a
single pass through the liver [Illum eraI., 1984]. These particulate carri ers must also have
the correct surface cbaracteristic s to avoid opsonization, complement acti vation, and uptake
by the RES (Davi s and Illum, 1986, Poste, 1983]. The particulate carriers must also be able
to escape from the vasculature in order to reach their site of action; particl es (>50 nm] are
unable to achieve this except in the liver, spleen, and bone marro w where the endothelial
cell s of the blood capillaries are disc ontinuous. Also , the large scale manufacturing of
artificial carrier systems poses another obstac le for their potential applicati on in therapy with
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regards to the safety . validation. reproducibility. and scaling up. This implies that an
endogenous partic le [<SO DID] wi th natural abundance and availability, and a capacity to
cany drugs. may solve many problems related to artificial carrier systems such as
immunocomparibility. targeting and large scale manufacturing. An endogenous cholesterol
carrier , LDL, bas been proposed as one such carrier system 10 deliver cytotoxic agents. Tbe
potential of LOL as a drug carri er has been discussed earlier [see Chapter I]. However ,
despite man y efforts. DO practical regime:of a cell selective delivery ofa LDL-drug conj ugate
has so far been marketed. Failure to obtain stabl e, therapeuticall y effective LDL-drug
conjugates, is one of tbe majo r reasons.
I have mentioned earlier that the physico-cbemical facto rs of drugs may infl uence
the ir entrapment into LOL particles since the transfer of drugs into LDL particles is
accomplishcd by either by means of physical diffusion or a partitioning of the drug between
the different phases of the LDL. Hydrophilic drugs;will not attach to the lipoproteins or
diffuse into the lipid core ofLDL. Lipophilic dru gs are.therefore. good candidates for this
approach of drug delivery.
An anthracycli c derivative. Dox, was consi dered in thesestudies [Figure 2.1]. As
indicated earlier in Chapter 1. the clinical potential ofOox is often limited by its toxicity . and
considerable efforts have beenmade in recen t years to find new derivatives or delivery
vehicles for Dox with a more favo rable therape utic index (Lameb et al., 1988; Seshadri et
al. , 1986; Isreal et 01. 1985; Isreal and Potti, 1981; Isreal and Modest, 1977; Arcam one et
al., 1974; 1975]. To achieve site specific drug delivery ofDox to tumor cells, attempts have
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been made to load Dox or its lipophilic analogues in LDL [Wcstesen et 01.,1995; Masque liec
et aI.• 1985; Shaw er01.,1984J. Although in vitro data for cytotoxic agents using LDL were
encouraging, once tried in vivo the efficacy was not as promising [Tckui et al., 1995; De
Smidt and Van Berkel, 1990]. In the present study. attem pts were undertak en to load Dox
in a favorable way so that the LDL-drug conjugates would follow the nonn al metabolic fate
ofLDLin vivo.
In thesestudies, the effects of different physical factors to enhance drug loadin g into
LDL particles were examined in terms of incubation time, temperature, and LDL-drug molar
ratios [stoichiometry]. The dry filmmethod was most efficient in terms of generating LDL -
drug conjugates which are similar to native LDL in vitro and in vivo [De Smidt and Van
Berkel, 1990J. This method was considered to evaluate the effect of different surfactants
and additives in dru g loadin g. Additionally, a comparison was made among diffe rent
formulations of Dox suc h as aqueous solution or liposo mal preparation to examine their
effects on drug loadin g into LDL particles. In short, I investigated different physico-
chemical factors which influence drug loading into LDL particles. The physico-chemical
characterization of LDL-drug conjugates using advance d biochemical and biophysical
techniques such as SDS.PAGE, DSC, EM will bediscussed in the proceeding chapter.
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2.2. Materials a nd methods
2.2.1 Mate rials
Dox [Dcx-HCl, Adriamycin 1 was purchas ed from Adria Laboratories Ltd.
[Mississa uga, Canada]. High purity EVPC . oleic acid, Spans, Tweeas [20.40, &0 and 80J.
Celite 545, Triton-X were purchased from Sigma Chemical Co. [St. Louis , MOl . All HPLC
grade solvents were from Fisher Scientific [Ottawa, Canada ]. Two buffers cvere used.
Phosp hate-buffere d saline (PBS] whi ch consisted of 137 mM NaC l, 3mM KoCl. 8 mM
N~HP04' and 1.5 mM KH2PO•• adjusted to pH 7.4 with 2M NaOH [Fisher Scientific].
Dialy sis buffer [Tris ] co ntaining 150 mM NaCl , 50 mM Tris, and 0.3 mM EVTA, was
adjusted to pH 7.4 with 2M Hel [Fisher Scientific].
2.2.1:. Prepa ra tion ofLDL sam ples
Fresh human plasma wasobtained from the Canadian Red Cross [St. John's, Canada].
To avoid multip le enzymatic degradations, a cocktai l [2 mL sodium azide 2.5~. 0.5 mL
benzami de 1M, 2.5 mL phenylmethylsulfonylfluoride [pM SFJ. 0.2 M] was in::unediatel y
added to 500 mL of the plasma as describe d befo re [Edelstein and scene, 19::86]. LDL
(density 1.019-1.063 glmL] was isolated from plasma by density gradient ultracenrtrifagaticn
in KBr us ing a L8-70M ultracentrifuge [Beckman, Fulle rton, CAl with a Ti-60 :zone rotor
at 37,000 rpm and 8°C for 40 boUIS. To remove excess KBr, the LDL was dialyz:ed against
the dialysis buffer for 24 bOUIS followe d by filtration thro ugh a Mill ipore mem brane filter
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[0.20 I!M pore size] (Milford.:MA]. The LDL was stored at 2_8°C for no more than two
weeks before use.
2.2.3. An aly s is ofLDL
The LOL protein content in native or LDL-dru g conju gates was determined by the
Bradford method using bovine serum albumin (BSA] as the standard . Cho lestero l and TAG
were measured using Sigma reagent kits based on procedure numbers 352 and 336 of Sigma
respective ly. Lipo protein purity was assessed by 8DS-PAGE [see Chapter 3. section 3.2.3].
The presence of a sing le hand was cons idered to indicate the absence of any additional
proteins as contaminants or degrada tion by-prod ucts.
2.2.4. HPL C assay or Dox
The Cox concentrntion in LDL was measured by reverse phase HP LC. The Beckman
HPLC system consisted of two 110 pum ps. one Detector 166, one Autosampler lOS and in-
line System Go ld software for running the system and for quantification [Beckman,
Fullerton, CAl . A Pbenom enex ell Bondclone [3.9XI50 mm ] wi th a guard column [3.9X30
nun] was used (Pbenomenex, Torrance, CA l. Dox was eluted with ace tonitrile : 40 mM
phosphate buffer . [28.5:71.5. v/v ] pH 4.0 at a flow rate of 1 mUmin [Brown et al., 1981,
Eksborg et 0/ .• 1978; Isreal et of.• 1978] . The compound was assaye d by a UV detector at
254 nm. Standard curves were made using standard so lutions of Dox in the mobi le phase
ranged 0.20 to 10 ~g/mL. Five to 50 ~ of samples were injected in duplicate. All
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measurements were based on pealearea response ofthe drug as calculated using the system
Gold Beckman software for-HPLC. Standard curves wac madein every set of experiments
to ensure the accuracy oftbeanalysis.
2.2.4 .1. Ge ne.... utnetioDmeth od : Fifty ~ DoxHel [3.45 mmoles] was
made alkaline with 100 J.1L 0.05 N NaO H and extracted wi th 2 mL chloroform. The
precipitated porti on was removed by centrifugation at l ()()()xg for 5 minutes. Theextraction
was carried out three tim es followed by centrifugation as mentioned before. The com bined
organic layers we re evaporated 10 dryn ess under a stream of nitrog en. The dried sample was
then reco nsti tu ted with the appropriate solvent to make standard Dox so lutions.
To extract Dox from biological samp les such as plasma or LOr.. SO .,r. NaoH [0.5
M] was addedto 1 mLsamp les. Acetonitril~. l M H.PO~ [4 : l] (0.5 mL] was then added
to the samples [0.5 mL] in a stoppc:rcd centrifuge tube; the mixture was vortcx -mixcd for 30
seconds then centrifuged at 1000x g for 5 min to pellet the precipitated protein. The
superoaLan1 [5 to SO.u.] was chromatograpbcd and the peak areaswere compared.with those
&om standards prepared by the addition ofdrug to a centrifuged LDL- or plasma-acetonitrile-
0.1 M H)PO. [5 :4:1) mixtwe.
The exten t of recovery of Dox from plasma and LOL [Isreal et al., 1978], was
detennined by comparing the slope of the regression line aCthe plasmalLDL extrac ted Dox
with that obtain ed in the stan dard solution ofDox.
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1 see eve ey -L oo X Slope of p l asma extracte d Dox
Slope of t h e sta n da r d Dox
1.1.4.1. n ata analysis: Calibrationcurvesof peak area \'S c:oncentration ofOox
wen: analyzed by linear regression analysis to obtain the equation ofbe:sr:tiL The correl atio n
cocffi cientofregression. [R:I:j. was calculated. lnterda y variations in tbeanalytical precision
were asses sed by using a two-way AN OVA regressio n model wi th the calculation of p
values. Intra-day comparisonswere done by a Student's t-test and by calculating the P values.
When p>O.05. the difference in the mean values of the groups [two groups in student's t-test ]
was not consi dered statisticall y significant.
2.1.5. Determinati on of parti tio D coefficien t [PJ
The method described in Bijsterbosch ttl aI., [1994] was followed. Aliquots of 10
IlglmL ofextracted Dox or DoxHQ was dried in a 4 mL stoppered glass vial Then. 1 ml
l-octanol and I mL PBS buffer [pH 7.4] were added,and the mixtures were shakenfor 16
hours at room temperature by a Wrist Action Shaker [Burrell , Pittsburgh, PA]. Samp les of
the octanol and the aqueous phasewere then assayed by HPLc. and the P [coocentration in
octanoVconcentmtion in PBS] was calculated.
2.2.6. Incorporation of dru gs int o LDL
The dry film method was modified to enhance the efficiency of drug loadin g.
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Dox-Hel [3.45 mmo les] was converted to freeDox with NaOH (0.05 M] and then extracted
with chloroform.. An aliquot oCthe chlo rofonn solution offree Dox was dried down UDder
a stteam of nitrog en gas in a test tube. When the chloroform was completely removed. the
drug fonned a thin dry film at the bottom of each test tube . LDL was then addedand the
mixture was incubated in thedarkwi th continuous gentle sbalciDg at 37 °C for up 1024 boun.
In anotherexperiment. DoxHCL was directly added to LOL for incubation [direct addition
method ]. The LDL -drug conjugates were isolated by a single ultracentrifu gation step at a
dens ity of 1.06 3 gfmL at 40,000 rpm for 40 bours using a 60 Ti or 75 Ti Bec kman rotors .
The LDL-drug band at the top was then aspirated and subjecte d to dialysis for 24 hours to
rem ove KBr and free dru g. The LDL..drug conjugates were filtered thro ugh a O.20J.U11
MiUipore filter and stored at 2 to goC for no more than two weeks before use. The
identification of the LOL was accomplished by a protein, a cholesterol and a TAG assay.
The concentrations ofDox was determined by the HPLC method as described above.
1.2.7. Usc of wetting . geotl
A num ber of wetting agents were examined for their effects on the drug loading
efficiency of Dox.. First.a wetting agent. i.e., Tween 20 was added to the chloroform
solution of Dox.. The mixture was thoroughly agitated with a ve rtex mixer, the solvent was
evapo ra ted und er a stream of nitrogen. and saline (0.9% NaC I] was added such that the
Tween 20 constituted less than 3% of the final volume. The solution was vortexed again and
placed briefly under nitrogen to remove any residual chloroform. LOL was thenadded to the
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drugs suspen ded with Tween 20 and incubated as mentio ned in the dry film method. Other
wetting age nts includin g different grades of Tweens and Spans. Triton X, or surface
increas ing agen t, i.e ., Celitc 545 were examinedusing the same protocol.
2.2.8. Preparation of multilameUar vesicle s [MLV]
The preparati on of homog enous and multi-layered vesicles of E'YPC:Dox [15 :1]
mixture in Tris buffered solution, [145 rnM:NaCl, 10 mM Tris-HCl, pH 4.0], was done by
extrusion of emulsions. A chloroform/methanol mixture [1:1. vlv] co ntaining Dox and
EYP C was eva porated to dryness under nitrogen at 4Q-45°C. The lipid-drug film was
evaporated for at least 2 hours . Subseq uently, glass beads and the hydrati on medi um. [pH
4.0J were added. Nitrogen was passed thro ugh the hydration buffer for about 15 min. The
film was vortexed three times with 1 minute interval s at 55"C and left. after com plete
dispersion. in a refrigerator for one night. At this stage , 1 mL of the dispe rsion contained
about 40 umol ofphospboli pid [EYPC] and 2.5 mg ofDox. This suspension was incuba ted
wi th LOL to make LDL-Dox conj ugates . The Ilposomes , mainly MLV . were sized by
sequential extrusion through a double polycarbona te membrane filter, wi th pore diameters
ofO .22 I-U11 [Milli pore] undernitrogen pressure s of up to 15,000 psi. This was done at least
10 time s to obtain homogenous MLVaccordingto Olsen et al , [1982].
2.2.8.1. Separa tion or rree DOli:: Free Dox [nonliposome associated Dox] was
removed by dialysis at 4°C. The dialysis mem branes [MW cut off, MWCO, 12,000-1 4,000]
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weresoaked wi th deionized water for at least 15 minutes and rinsed extensively before use.
Aft er this, less than 10% of the total amount of Dcx was in the free form. Allliposome
dispersions were kept protected from light at 4-6°C unde r N2• Freshly prepared liposomes
were used for loading experiments.
2.2.8.2. Det ermination of loadin g capadty: The separatio n of neutral liposomes
was achieved by ultracentrifugation for 3 hours at 40,000 rpm using a Bee kman 75Ti rotor .
Afte r destruction oCthe liposomes by addition of Triton X- loo and subseq uent heating , Dox
was assayed by HPLC. Phospho lipid content was determined according to the proced ure of
Rouser et ai. [1966J_
2.2 .8.3. Sta b ility of lip osom es: The ratio of free Dox to liposome associa ted Dox
was measured as described above . In the case of plasma incubatio ns, freshl y prepared
liposomc dispersions were mixed at a 1:1 ratio with hwnan plasma and incubated at 37°C.
Chemical stability was monitored using HPLC .
2.2.9. Distribution of DOI over p lasm a [lipolprote ins: Sequential n ot ati on
ultnu:cntrifugation
For the redistri bution studies. DoxHCI [100 ~g} was added to 2 mL ofhuman plasma
and the so lution was incubated for 4 hours at 37 °C under N2 while shaking continuousl y.
In a separate study , plasma was preincubated with oleic acid [20 mglmL of plasma} for 2
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hours before incubation with plasma. After the incubations were complete. the samples were
transferred to polycarbonate centrifuge tubes . Their solv ent densiti es were adjusted to 1.006
glmL by KBr. Followin g centrifugation [L7-65 Beckman Instrument] with a 75 Ti rotor at
50,000 rpm for 17.5 hours at goC the VLDL-rich and VLDL-deficient fractions were
recovered. Followin g thi s initial spin the VLDL-defic ient fiaction was adjusted to a solvent
density of 1.063 glmL with KBr and respun at 40 ,000 rpm for 17.5 hours at SoC to separate
the LDL-rich fraction from the rest ofthe fractions containin g HOL and LPDP. The latter
fracti on was adjusted to a solvent densi ty ofl .21 g/mL with KBr and respun at SO000 rpm
for 21.4 hours at SoC to separate the HDL and LPDP fractions. All isolated lipopro teins and
lipoprotein defi c ient fracti ons were dialyzed against the dial ysis buffe r [2 L] for 18 hours
be fore analy sis . .Th e MWCO ofthe dial ysi s tubin g used was 12,000-14 ,000.
1.3. Results
2.3 .1 . Chemical ahalysis oflipoprotelo
No significant difference between native LDL and LDL-drug conju gates were found
in terms of pro tein. total cholesterol, and TA G content. The resul ts from LOL preparations
usedin this study in Table 2.1 are inagreement wi th reported literature data (W estesen et al.,
1995).
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2..3.2. HPLC a nalysis of DOl:
Typical chromatograms are shown in Figure 2.2a to 2.2.c. Figure 2.2a shows the
chromatogram of Dox in mobile phas e. and Figure 2.2b shows Dox afte r being extracted
from plasma and Figure 3.2c shows the chromatogram ofa Dox spiked human LDL sample.
The retention time of Dox was 4.77 minutes. A calibration curves for Dox is shown in
Figure 2.3. Peak areas obtained with human plasma samples with the five different
conce ntrations of Dox over the concentration range of 10 to 300 ngIlO ilL were linearly
related to the spiked concentrations. The equation of best fit for the line was:
y ", - 0.206 + 1.67 X 10-' X R 2 = 1.00
Where Yis the peak area of'Dox andXis the Dcx concentnlti.on{Figure 2.2]. The coefficient
of determinations ranged from 99.7 to 99.9"/0, an d the CV of the slope determined on five
separate occasions was 2.02 % [fable 2..3]. The minimum detection limit for Dox was
found to be 5 ng [10 J.LL from 0.5 IlglmL standard so lutions]. The peak height detected at
this minimum conce ntrations was more than three times that of the noise .
The % recovery was calcula ted (n=5) and found to be more than 92% from plasma
and 94% from LDL . Peak areas obtained with LDL spiked wi th four and five different
concentrations of drug over the standardconcentration range [fable 2.2] were linearl y rel ated
to the sp iked conc entrations. The reprod ucibi lity of the method was determined by both
intra - and inter-day variability studies [fable 2.4J. The %CV's for the interday variability
were4.19,125, and 3.67 for the spiked Dox of I, 5, and 10 IJ.glmL respectively. A two-way
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ANQ VA regression model showed no significant diffe renc e [p>O.OSJ between
determinations performed from day to day, over fifteen days. The intra-day % CV (n=6] for
threetest samples was 6.35, 3.29 and3.77. respectively . Performance of one way ANaVA
on intraday measurements showed no significant variations [p>O.OS]. Thus , the HPLC
method described here was statistically vali d and proven appropriate for my experimental
protoco ls.
2.3.2. P of candidate drup
The octanollPBS partition coeffcient (P) gives a measure of the lipophilicity of the
candidate drugs. Dox [2.5 ±O.12. P values are expressed in mean ±SD of three
determinations] in the free form was found to be more hydr ophobic [> 5 fold] than the salt
form [Dax-Hel] [0.052 ±n.03]. Thi s difference in their lipophilicities should result in a
different affinity for LOL.
2.3.3 . Method of drug loading
I have co mpared the incorporatio n rate ofOox into LD L particles by different loadin g
methods. The incorpo ration was performed by the contac t method . I have loaded Dox
[average 35 mo leculesILD L particles] more efficiently into LOL compared to its close
analogue, daun omycin [DNM] [7 mo leculesILDL particle] [Shaw et 01..1987 J. Figure 2.4
shows the efficiency of density ult:rneentrifugation to separate LDL-drug conjugates obtained
by the dry film method from the incubation mixture . In add ition, dialysis was used to
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remove excess free drug from the LDL-drug conjugates after incubation or
ultracentrifugation [Figure 2.5]. The essential step of this loading method is the partitioning
ofthe drug from a solid surface to the lipoprotein. The contact area can begreatly enlarged
by using glass beads or Celite, the latter being used for this series of experiments. All
conjugates were successfully prepared by the dry fibn method and were passed through 0.20
um filters with neg ligible losses of apo B.
2.3.4 . Factors influencing drug lo.dina;:
2.3.4.1. Incub atioDtime: I studied the effectof incubation time on Dox loading
[Figure 2.6J. Drug loading is mainly a partition or diffusion mechanism which is a time
dependent phenomenon. r investigated the effect of drug loading on incubation time up to
24 hours. It was found that drug loading reached a plateau after 5-6 hours . In the literature,
different incubation times were reported ranging from 2 to 24 hours [Tokui et al., 1994;
Hossaini et al., 1994 ; Scbultis et al., 199 1; Vitals et ai., 1990; Samadi-Baboli et al., 1990;
Shaw et al., 1987; Masquilier et ai., 1986]. I observed that about 50% aCthe drug was
incorporated within the first 30 minutes and an additional 25% of drug was loaded in the next
90 min utes of incubation [Figure 2.6]. This suggests that the strength of the strong
hydrophobic Interactions of the drug with LDL may be the rate limiting factor in dru g
loading. A further tim e dependen t improvement [25% of total loading ] of drug loading
occurred in the next 24 hours which was assumed to be mainly due to partitioning and
diffus ion processes of the drugs into LDL. Since approximately 70% of the drug was
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incorporated within 4 hours, an incubation time of 4 to 6 hours was adopte d for subsequent
loadin g expe rim ents . I suggest that incu bation tim e may be a factor which needs attention
in orde r to optimize loading parameters.
2.3.4.2 . Incubation temp erature: Most drug loading studies reported were
conducted at the normal physiological temperature of 37°C. The usc of physio logical
temperature is relevant as the final preparations will encounter this temperature in vivo .
Temperature was expec ted to be a factor influencing the drug loading into LOL, because
increased temperature results in an increase in molecular motion and subsequently infl uences
the interacti on between drug molecules and LDL. Also, temperature has significant
influence on the fluidity oftbe LDL parti cles. and as a result. affects the molecul ar dynamics
of the particles. I tested drug loadin g at different tempera tures incl uding 4°, 22 °, 37", and
60°C [Figure 2.7]. A further increase in temperature was not considered as apo B protein
was found to undergo irrev ersible dena tura tion at Boac (Prassl et ai., 1995]. Figure 2.8
shows DSC thermograms of native LOL which starts to dena ture at temperature abov e 45°C.
As specul ated, a higher drug loading with a higher tempe rature was observed [Figure 2.9 ].
This observed effect could best be attri but ed to the thennal transition behavior of LDL
compo nents at differe nt temperatures as will be discussed in the next chap ter, section 3.3.4.
2.3.4.3 . Use of Wetting agents . Drug loading using the dry filmmethod was not
efficie nt. I hypothesized that drug transfer fro m an aqueous solution or suspension would
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be bette r compared to drug transfe r from a solid surface into LOL particles. To make an
aqueous suspensions oflipopbilic Dcx, I used a variety of wetting agents andexaminedtheir
comparative efficiency in loading Dox into LOL particles. All ofthe wetting agents resulted
in a higher incorpo ration rate than the dry film method [Figure 2.9]. However, I observ ed
significant differe nces in the incorporation rate of drug as a function of the nature of the
wetting agent. The rate of'Dox incorporation ranged from 7 Ilglmg LOL protein to 30 Ilglmg
LDt pro tein corresponding to an average of approximate ly 6 to J2 molecules of DaK
incorporated by LDt particles [Figure 2.8]. The results obtained with Tweens in
formulating Dox prior to their incubation with LOt were equivalent or superior [in term s of
recovery of Dox and LDt protein] to those obtained with other agents such as sodium
deoxyc ho late. Spans, and Triton X-lOO. The loading efficiency with different grades of
Tween was not statisically significant (p>O.OS]. However, the latter experiments were
performed using Tween 20 as the wetting agent. Tween 20 is being used in a variety of
pharma ceutical formulations to suspend drug and is an approved excipient for parenteral use
[Leyland , 1994].
2.3.4.4. Use ofl iposomal prepa rati ons: Liposomes were used as a del ivery
vehicle to load LDL with Dox to see whether a better loading in LDL particles could take
place . Liposomes , mainly multilamellar vesicles (MLV), were made without cholesterol
[unstab le liposomes] so that they would release their contents once in contact with LDL
particles [Storm et ai., 1989]. MLV were chosen as the encapsulated aqueous volume is of
66
minor importance to achieve a high loading capacity as Dox associatedwith the lipid bilayers
(Ga bizon, 199 5; 1989; Rahman et aI., 1989; Crommelin and Bloois, 1983; Goo rmaghtigh
et al., 1980; Goldman et al., 1978]. The preparation ofMLVs was first reporte d by
Bangham and coworkers [Bangham et aJ., 1965]. The ir methodhas proven to be very
pop ular and suitabl e for the encapsulation ofa variety ofsubstances. MLV were considered
appropriate for my studies as they had higher incorporation effici ency in loading lipophilic
drugs [Basu,.1994]. Th e extrusion me thod was adopted to obtain a unifo nn size distribution
ofliposomes. An acidic hydration medium. waschosen for the preparation of'Dox-lipcsomes
as pH 4.0 is favorab le for extrusion compared to pH 7.4 {Crommelin erat. 1983 ] an d and it
was repo rted that the decomposition rate ofliposomal Dox is much higher at pH 7.4 than at
pH 4.0 [B e ijn en et al., 1986; Janseen et aJ., 1985]. Dialysis is a common procedure to
rem ove free drug from the liposomal drug, even though thi s pro ced ure is time-consuming,
it is simple and effective and was used in this study . The following aspects concerning the
stability oftbe liposomes were examined : [I J retention of entrapped contents; [2J infl uence
of plasma on the release rate of Dox from liposomes; [3] chemical stability of the
encapsulated drug.
Aggregation occured during storage at 4-6 °C for over a period of 4 weeks . The
absence of electrostatic repulsion is like ly to account for the tendency of the liposome to
aggregate. About 35% of the amoun t of drug was lost over a a-week period [fable 2.6].
Plasma induced leakage was rather high for the Liposomes. The highest incorporation was
achieved when this Iiposomal prepara tion was incubated with LDL [Figure 2.10]. Ibis is
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likely because of the better interactions ofliposomes with LDL. The phospholipid layers of
Ml.vs interact because oftbeir instability with the LDL and drug is presumably released on
the surfac e or in the vicinity of LDL. from where it diffuses easily into the core of LDL
[Vingerboeds et al., 1994J. This study demonstrated the use ofliposomes as a lipid drug
donor in drug loading studies with LDL. The highest amount ofdrug incorporation was
possible with the:MLV preparations [Figure 2.10] and this method may be expan ded to
incorporate lipophilic drugs into LDL particles .
2.3.5. Stoichiometry ofLDL-d rug conjugates
To study the stoichiometry of the incorporation procedure. I added different amounts
ofdrug to fixed amounts offreshly isolated LDL [Figure 2.11 l- As the amount of drug was
increased, the drug/LDL protein ratio of the conjugate increased until a plateau was
approached at approximately 30 ug Dox per mg LDL (32 drug molecules per LDL particle]
[n=5 ] [Figure 2.9J. In all cases. the stoichiometry ofLDL drug levels was confirmed after
reflotation at a density of 1.063 g1mL. HPLC analysis revealed that the compound did not
dissociate nor degrade and constituted more than 95% ofthe incorporated drug . This study
indicates the need to optimize the molar ratio of a drug and LDL to maximize the loading
efficiency.
2.3.6 . Stability ofLDL-drug conjugates afte r ultracentrifugation aDd d ia lysis
The colloidal stability of the LDL-drug conjugates was excellent and no change in
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particle size or any aggre ga tion was noted during storage of sterile preparations at 4 °C for
sev eral months . However , for this study. all preparations were used within I week and
during this period oftime no change in physical characteristics was noted.
LDL-drug conjugates showed good physical stability as examin ed by density
gradien t ultracentrifugation [Figure 2.4], in accordance with the results obtained with Dox.
The recove ry of apo B in the final LDL-drug preparations was very good [-90%]. The
values [mean ± SEM] for tbe recovery of Dox was sati sfactory: 84 ± 4% [n-4]. In fact, the
high recovery of drug is an important advantag e of the contact method .
When the LDL-Dox preparation was subjected to ultracentrifugation,.a uniform peak
was found [Figure 2.4]. In vari ous preparations the incorporation of Dox vari ed from 0.2 to
0.6% of the added dru g.
2.3.7. Plasma protein binding of Dox: sequential Dotation uUraeentrifugatioD
In order to analyze th e distribution of Dox in plasma, the compound was incub ated
with 2 mL of freshly prepared human plasma for 4 hours at 37°C. The solution was then
analyzed by densi ty gradient ultracen trifugation [Figure 2.12J. Approxim ately 78% ofDox
was recovered in the fraction at densi ty>1.21 g1mL [lipoprotein deficient. albumin rich
fracti on]. The other 22% had distributed over the lipoprotein-eontaining frac tions.
Pretreatm ent of human plasma with oleic acid and subsequent incub ation with Dox
resulted in a significant decrease from 78 to 33% in Dox in the fraction having d>1.21 g1mL
[p<O.OI] [Figure 2.12]. The HDL- and LDL-eontaining fractio ns show a 3·fold increase in
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Dox activity, and the VLDUchylomicro n-eo ntaining fractions [d<1.006J show more than
2.5- fold change in Dox co ntent (Figure 2.12]. A concentration depende nt increse in
redistri bution pattern was observed wi th preincubation with differen t amount of o leic acid.
With 1 mg oleic acid prein cu bation. the effect was less pronounced [data not shown] than
that achieved with 3 mg oleic acid preincubation (Figure 2.12]. Theredistribution afDox
in different plasma lipoproteins by oleic acid demonstrated that Dox had preference for
lipoproteins .
2.4. Discussion
The use of the LDL receptor pathway has not been tested adequately in site specific
drug de livery due to lack of a suitabl e loading procedure to prepare a stable LDL -drug
conjugate [Firestone , 1994]. A number of loading methods have been described [Lundberg,
199 1]. The major limitation of the methods is either instability ofLDL-drug co njugates or
low incorporation efficiency. Extensive processing ofLDL via reconstitution was reported
to increase drug incorpo ration during their loadin g [Shaw et at. , 1987]. These include
extraction ofthe lipid co re by use oforganic solvents, detergents, or enzymes, and the use
ofmicroemulsions to reconstitute LDL particles [Samad i-Baboli er al., 1990; Masquelier et
af., 1986]. These reconstituted particles were found to be larger in size [more than 45 nm,
twice the size of native LDLJ and less stable than native LDL . The dry film method was
considered to be the method ofchoice and was used for the first time in human trials with
vincristine. [Filipowska et aI., 1992; Breeze et at., 1994 J. However, organic solvents were
70
used in these studies which is viewed as a disadvantage because ofthe possibility ofprotein
denaturation.
Wetting agents were used to incorporate very hydrophobic compounds such as CI [De
Forge erai., 1991]. I attempted to develop a bettermethod of incorporating drug molecules
into LDL particles. An aqueous suspension or solution of a drug was found to be better
compared than solid drug in loading experiments with the LDL . J speculated that this was
due to better interactions and bonding of drug s with the LDL. In the dry film method. only
a limited surface area is available for interactions with LOL and diffusion of drug s from the
solid surface is limited. In this case, the interaction ofa drug and the LOL should be stronger
than the interactionoftbe drug with the attached materials such as glass orpolycarbonatc to
allow the drug to diffuse from the dry film surface into the core ofLOL particles . However,
when drugs are in solution or suspended in a medium, a large increase in surface area is
achieved and diffusion of drugs from the media into the LOL is more favorable . In the dry
:film method, drug diffusion into the LDLoccured mainly from the monolayer ofthe dry film.
whereas in solution or suspension. drug diffusion occurred from all sides.
Liposomes are lipid vasicles like LDL and therefore their interactions are assumed
to be thennodynamically more favorable. When the Dox was incorporated into MLV and
the latter was incubated with LDL. drug particles were presumably released on the surface
of LDL particles from where they could diffuse into the core or intercalate inside LDL
particles . Liposomes were unstable in nature as they disintegrates when in contact with
lipoproteins. Expulsion of drugs from the Iiposome in the vicinity ofLDL may be the main
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reaso n for higher drug loading efficiency_However, stealth or sotable liposomes, which are
stab le in plasma.may DOt serve as drug donors for LDL
The physical properties of the LDL-dNg complexes were identical to native LOL .
In this smdy, the Dox loading using a modification oftbe dry film or contact method bas
been significantly improved. My procedure doesDOt involve rocoostitution or the use of
organic solvents in the final preparati on.. The simple incubation of drug solutions or
sus pensions wi th LOL gave incorporation only of 0.2% to O.lti% of the dru g added. In
addi tion to higher inco rporation efficiency, LDL-dru g preparatioOns were stabl e .
Dru g incorporation involve s incubation of drug and LlDL for a defin ed period of
time. Various incubation times were reported in the literature fer different compo unds , as
mentio ned above. I was interested in seeing how incubatio n -time could influence dru g
loadin g. If drug loading is time dependen t it may give insights into the hydrop hobic
interactions or diffusion ofdrugs into LDL particles. Incubation &m e is important clinically
for a more beneficial fast loading technique in wbicbthe patient 's own LOL may be infused
bade. with the loaded dnJ.g [plasmapheresis].
TemperaIUl"C is aootbc:rof the major factors which influences drug loading and all my
loadin g experiments were c:anied out at physiological tempera nsre. Temperature may also
affect apo B interactions wi th the LOL receptor by modulating: the physical properties of
lipids and/or prot ein. To observe the influence of temperature o n LDL lipids and pro te ins
I used DSC and found no signifi can t al terations in LDL -drug conjugates due to dn1g loading
below 40°C. Thi s will be discussed inmorc detail in Chapter 3. section 3.3.8.
72
In order to examine the distribution ofOox over the different plasma lipoproteins.
drug was incubated with human plasma [direct additio n method] and the mixture was
subsequcn dy anal)'7M by density gradient ultracentrifugation. Seventy-ei ght percent: oftbe
co mpound was recovered in the LPDP . and 22% associated with HDL, LO r.. and
VLDU chylomicrons.. As albumin., which is one of the main prote ins in the LPDP fracti on.
is kn own 10 bind a vari ety of endogenous and exogenous compounds, I tried to examine
whether a redistribution of Oox association with albumin can be don e in vitro. Albumin is
known to have high affinity sites for fatty acids [Goodm an., 1958]. After saturation of these
binding sites by pretrea tment of human plasma with a sol ution of oleic aci d and subsequent
incubati on with Dox, a significan t decrease [from 78 to 33%] in the amount of Dol'
recovered in the albumin density fraction was observed. This was accompanied by a strong
increase (from 22 to 61%] in the am ount ef Dox assoc iated wi th HDL and LDL. The data
suggest tbar:an equilibrium exists between Dox bound to fatty acid binding sites on albumin
and lipo pro teins present in plasma.. The equilibrium can be influenced by compounds tha t
compete for the fittty acid binding sites on albumin. This data suggest that drug distribution
among lipoprotein subspec ies could be achieved; this redistri bution pattern may help to
diminish adverse effects or increase the therapeutic activity o f som e drugs. For exam ple, if
Dox association with plasma albumincan be refashioned to LDL or other lipoproteins, it will
help to diminish the cardiotoxic ity ofOox which is relat ed to the rap id association of Do x
with plasma albumin in vrvo. Simultaneously, Dox delivery to cancer cells wi ll possibly be
increased. In short, this study demonstrated the significant ro le of various physical
enhanceme nt factors that affect incorporation of drugmolecules in LDL.
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Table 2.1. Che mical compos ition of LDL and LD I,;DoI conjugates
Cooccnttation Ratio 's ·
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Sample
[mg of protcinfmL]
Cholesterol TAG NwnberofdnIgmoleculesILDL
Moan [SO ) [n-S ]
Literature"
LDL-nativ e [3.15]
LDL-Dox" (4.55 ]
1.8
1.1
2.0
0.2
0.3
0.6 35 [10]
a. Concen tra tion [mg/mL] ratios of cholesterol or TAG, to protein
b. Westensen et al., 1995.
c. The conjugate was made by the contact method with the aid of Twee n 20.
T able 2.1. HP LC aa alyti c:a.lproflles orDo );
7S
HPL C parameters Mean values (1125 , CV s 10%)
Retention time [minutes] 4.n
Detectio n limit [pglmL) 0.15
Linear range Wg/mL] 0.50020
% Recovery from LDL samples >94
% Recovery from plasma samp les > 90
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Table 2.3 . Caliblll tioa coeffi cient of variatio. of Dol: in HPLC
Co~ 10 20 Slope R'
,gImL Peak areas
Day 1 0.386 0.597 1.252 2.890 8.844 l.n4 0.97
Oay2 0.377 0.587 1.438 3.9] 1 8.5 16 1.742 0.99
DayS 0.379 0.582 1.425 3.943 8.147 1.667 0.99
Day lO 0.379 0.567 1.476 3.973 8.149 1.667 0.99
Day lS 0.374 0.595 1.481 3.867 8.262 1.684 0.99
Mean 0.37 1 0.583 1.45 3.916 8.149 1.666 0.99
SO 0.012 0.12 0.03 .048 .083
CV [%] 3.1 2.1 2.1 1.1
Ta ble 2.4. IDle......d iDtra day " ari atiou or 001
Spiked amount
ln ccr-day n ria tio D [individual va lues, pea k area)
10
n
Monday 0.95, 0.97 4 .92, 4.85 23.52,24..22
Tuesday 0.96,0.98 4.95,4.78 24.85.25.12
Wednesda y 0.99,1.0 4.90,4.93 23.56,24.89
Thursday 1.01,1.1 4.95,4.90 25.15, 25.56
Friday 0.98,0.99 5.00. 4.95 26. 5, 25 .42
Mean [SD] [0- 10J 0.99 [0.04) 4.41 [0.06] 24.87 [0.9IJ
%CV [n= l O] 4.19 1.25 3.67
Two-way ANO VA
p value 0.119 0.086 0.457
IntJ'a-day variatioa [pea k areal
All sampl es 0.9S. 0.96 , 0.98 4.92, 4.87. 5.12 23.56. 24.5 1, 25.10
Friday 1.I2, .98• .97 4.65,4.75,4.89 24.50, 25 .84,26.23
Mean (SD] [0:06] 0.99 [0.6] 4.87 [0.16) 25.11 [0 .95J
%CV [n=4 ] 635 3.29 3.77
AN OVA,. P value 029 0.12 0.18
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Tab le 2.5. Pbysico-c:bemi ca l p roperti es or lipo somal Dos;
Loading capacity"
Stabilityi' at 4-6OC I day
I week
4 weeks
26:, 4 mmol Doxlmol PL
5 % 4% leakage
20% l o-A,leakage
40% 15%leaJcage
Stability" in plasma at 37°C 15 minutes 15 :, 5% leakage
60 minutes 30 :, 100/0 leaka ge
• Values represent the amount ofDox bound per mole phospholipids {EYPe] in the fi.naI
product,
• Leakage criteria are related to the amountofliposome-bound Dox at day 0 or at the start
of the incubation.
o
13~-C~20H
····'OH
8
oc~o5~~H""'0
e' 51
CH3 3' I'
N~
HO
Fl.ure 2.1. OemkaJ ItnIdure orDos.
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Firun 1.2.. Cbro m.tograms of DOI in mobile pb ue using HP LC.
Figures 2.2a. Dox in mobile phase.
Figure 2.2b. Dox extracted from plasma, and
Figure 2.2c. Dox extracted from LDL
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HPLC chromatogram of Do. extracted from LDL
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Peak area - 1.666 • Concentration . 0.205 R2 - 1.000
6
O+---r-,---r-r--r-r--r-~~-,.....J
0.0 0 .5 1.0 1.5 2.0 2.5 3 .0 3.5 4.0 4.5 5 .0
Concentration, (J.1g I mL)
Figure 2.3. Calibration curve.r peak aru venus concentration of spiked standard
soluno ns of DOL Each point represents the mean %SO of five
determina tions.
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Figure 1.4. Sta bility of LDL-DoI. conjugates afte r ultracentrifugation. Density
ultracentrifugation of solutions of Dox that were incubated with LDL
according to the contact method with Tween 20. After density
ultracentrifugation at 40,000 rpm, 8°C, for 30 hours in a 75Ti (Beckman
rotor) 0.5 mL fractions werecollected from top to the bottom of the tube .
Each fraction was assayed for Dox and protein concentration using HPLC
and the Bradford method. respectively. Each point represents the mean ± SO
of three detenninations.
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Fip re 2.5. Effect of dia lysis Oil the Itllbility of LD.....Dn co Dj uga tes. WL-Dox
prepared as mentioned. in Figure 2.3 . The top fraction wascclljected aDd
aliquots of 0.5 mL were subjected to dialysis for the indicated time and
withdrawn fordrug and protein assay were performed using HPLC (for Dox)
and Bradford assys. Dialysis VIllS perform ed at 2-8°C against2 L of dialysis
buffer. The unbound drug or salt was removed during dialysis . Each point
represents the mean ±SO ofthrcc determinations.
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Figure 2.6. Erred oriD cu.b.tioD time Oil DOl:loading. Five hundred J!g Dox coated on
a g1as:s vials wen: suspended with Tween 20 (>3% of final concentratio n) and
wereincu bated \O¥ith 500 118LOL up to 24 hours at :n·c. After incubati on.
LDL-Dol(conjugates wereisola ted from the me dnJg by ultracentrifu gation
followed dialysis. Drug and protein assays wereperfonned as men tioned in
FiiW'C2.S. Eac b poin t represen ts the mean :i:.SDofthrec determinations .
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Figu re 1.7. Differu da l samninC calorimetry of native LDI- Samp les were scanned
at O.soC I min from 10 to 50"C . DSC sensitivity was the same for all runs .
For all samples. the protein concentration was more than 1.50 mg I mL.
Buffer baselines were subtra cted. The data were normalized to the protein
concentrati on. Similar DSC thermograms were obtained (Simi lar T.. and
variable transition enthalpy for samples) for LDL-Dox conjugates . Thus.
DS C thennograms for LDL-Dox were not shown.
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Fipre 1.8. Errectof lDcabatioB temperature 00 Dos:lo.diDl- For explanation see
Figure2.6. Eacb point represents the mean :t:SD cf threedeterminations.
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Figure 1. 9. Rela tive ioeorpondoD df"tcieocy or d elergents ia loadiag DGs: in LDL
Miag coatad meth od. Control indicates me dry film.metbod.ln Ihe ecatect
method,me dry film rmduc: was suspended with me agents indicated before
incubation.. lncubatioo cooditions were mentioDcd in Figure 2.6. Each poinl
represents the mean:!:SO of threedeterminations..
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Figure 2.10. Relative ioc:orponltion efficiency oCdifferut mdhods in loading Oox ill
LDL p.rticles. See material and methods for detai ls. The dry film. and the
contact method with Tween 20 were describedbefore. Liposo mal Dox was
made using EYPC (Dox:.EYPC-l: 40) by the extrusion method and free dox
was isolated from liposomal Dox by dialysis method. Drug loadin g
efficiency of liposome was 24%. DoxHCL or liposoma! Dox was directl y
added to the LDL (the direct addition method) and was incubated accordin g
to the conditions described in Figure 2.6. Each point represents the mean
±SD of five determina tions.
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Figure 2.11. Stoh:biometry or LDL-Do1 conjugates. LDL·Dox conjugates were
prepared using Vox and constant amountsof LDL by the contact method
using Tween 20 at 37°C (see Figure2.6). Each point representsthe mean
±SD offive determinations.
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Figure 2.12. Effect of preiDcubatioD of human plas ma with oleic: acid OD the
associatioD of Dos. with p lum. (lipo)proteins. LDL-Do x conjugat es were
incubated for 4 hours a137 °C with 2 mL of human plasma (normal), or with
2 mL ofhwnan plasma that was preincubat ed wi th 3 mg oleic acid. After the
incubation., different lipopro tein frac tions were seque ntially isol ated from
plasma using sequential floatation ultracentrifugati on. All lipoprotein
fracti ons were analyzed for Dox conten t by HPLC. Each point represents the
me an .±SD of three determinations. The asterisk (.) indicate s statisti cally
signifi can t difference between two groups when analyzed by stude nt 's t-test
[p<O.OS].
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CHAPTER 3:
PHYS ICO-CHEMICAL CHARACTERIZATION OF LDL- DRUG C ON.JUGATES
3. 1. In troduction
The suitability of LOL as a carrier for Dox was tested further by inv estigating the
interactions of the LDL~Dox conjugates with plasma lipoproteins. I have demonstrated that
OaK can be loaded into the lipid core of LDL particles. If the LDL -Dox conju gates are
unstable in plasma, the released free drug will be rapidly distributed to plasma albumin.
Therefore, a targeting effect will not be achieved. In addition., Vox loaded insid e the LDL
should not undergo leakage, or redistribution., or exchange with lipoproteins present in
plasma This kind of premature release or leakage of the drug would make the LOL-
mediated approach null and void . I tested the carrie r capacity ofLDL in which LDL-Dox
conjugates would be incubated with plasma and the drug distribution between different
lipoprotein fractions would be monitored using sequential flotation ultracentrifugation in
conjunction with HPLC.
Extensive processing during drug loading was reported to influence physico-chemical
properties, surface properties, and the receptor affinity ofLDL (Shaw et al.• 1987]. If their
nativ e integri ty is changed, they would be recognized by the RES. Thus , it is important that
LD L retains its native properties even after drug incorpo ration. With the aid of different
biophysical techniques, it is now possible to characterize LDL molecules and establish their
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native integrity . For example, the size and the physical properties of the LDL-drug
conjugates can be evaluated using EM and DSC . By using electrophoresi s. the native
integrity ofapo B protein in terms ofprotein degradation can be evaluated. In Chapter 2, I
have studied Dox loading in LDL . In thischapter. LDL-Dox conju gates were studi ed using
SDS·PAGE, EM and DSC.
3.2 . M ateri als and method s
3.2 .1. M ateria ls
Human plasma, LDL. Dox, LDL-Dox conju gate s were descri bed in Chapter 2.
3.2.2. Ca rrier capa city of LDL-DoJ: eonjugat es in pla sma
In order to examine the carrier potential ofLDL for Dox, LDL-Dox conjugates were
incubated with plasma for 2 hours at 37°C. After incubation, the distribution of Dox over
plasma lipoproteins was determined by sequential flotation ultracentrifu gation as described
in Chapter 2 [sectio n 2.10].
3.1.3. SDS-PAGE
The electrophoretic mobility of LDL and LDlArug conjugates was examined by
80S-PAGE. A 5% gel was run acoording to tbe methodofLaemmli (1970] and stainedwith
Coo massie Brilliant Blue R-250 using Mini-PROTEAN II electrophoresi s cell [Biokad,
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Hercules.CA].
3.2.4. EM
The partic le size ofnative and LDL-drug conjugates was measured by EM. LDL-
drug conjugates were prepared according to the method of Forte et al. [1968] This was
performed on a Philips EM 300 by Lisa Leeand Howard Gladney [EM unit, Medical Schoo l
Laboratories, Memorial University of Newfo undland. Canada ]. Samples [2040 jJ.g/mL]
we re negatively stained with 1% urany l aceta te and photographed at magnifications
[cali brated] of 10,000 or 50,000 or 75,000. The diameters oflipoprotcins were measured on
Sx enlarged photogra phic prints.
3.2.5. DSC
Both native LDL and LDL-Dox conj ugates were run acco rding to the procedure of
Keough et al. (199 1] on a Microcal2 {model MC ·2. Amherst,. MAl operating at a scan rate
ofO.S oC/min.. The protein concentrations of all samp les were maintainedat 1.78 mglmL. By
integrating the areas und er the trans ition curve using Microcalsoftware. transition enthalpies
were readily determined.
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3.3. Resu lts
3.3.1. Carrierupacity ofLDL olDoI in plas ma
Ideally WL.Doxconjugates should not release drug, which would then bedistributed
in plasma.. Such stability of tbe LDL-Dox conjugates was tested by incubatio n of LDL-drug
conjugates in human plasma. More than 75% of the added drugs [Dox] in the form of LDL--
dru g conju gate s was found in the LD L fractions of plasma following a 2 bour incubation at
37°C [Figure 3.1]. Ultracentrifugation of theplasma at different densities was carried out
to iso late different lipoprote in fractions; free drug quantities in all tho se fractions we re
anal yzed by HPL C . All other fractions co ntain ed a low quantity of dru gs [les s than 15%]
[Figure 3.1] . The se results suggest that the drug, in the LDL parti cle. rem ained non-
exc hangable in plasma. Thi s is especially important in respect to potential appl ications of
L DL-drug conju gates in therapy in which LDL-dmg conjug ates will not dissociate or
exc hange in the circulatory plasma befo re being taken up by cancer cells.
3.3.2 . Electrophoretic mob iJity
The electrophoretic mobilities [a single band] ofLDL -dru g conju gates weresimi lar
to th e mobility of nativ e LDL on 5% pol yacrylamide gels, indicating that particles had an
identical size [Figure 3.2]. 80S-P AGE did not show any apo B fragm entation. "Ibis
su ggests th at the drug loading procedure did not indu ce any protein degradation.
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3.3.3. EM
The mean diam eter and the size distribution ofLDL-drug conjugates compared to
nativ e LOL was determined by EM Negativ e staining of the different LDL systems with
ucanylacctate revealed a homogenous size distribution for the native LOLs and the drug-
loaded systems [Figure 3.31- Particle size measurements revealed that the conjugate prepared
by methods used in this study hadsize close to native LOL [Figure 3.4] whil e LDL-drug
particles prepared according to Kriger et al . [1978) were reported to be larger [-45 nm].
Isolated particles appeared to be spherical in shape, but adjacent particles were
anisometricaUy deformed. The mean particle diameters were obtained from photographs
[magnification x 75000] after another x 1.5 magnification by copying. Average
measurement of 100 particles for each sample yielded a mean diameter 0£22 nm for native
LOLs [20.43-22.52 om], and LDL-Dox [20.34-22 .61 nm] [Figure 3.4].
3.3. 4. DSC
I monitored the thermal transition oCLDL lipids by DSC which gave some insight
into the effect of temperature on drug loading as well as the site of the drug in the LOL
(Table 3.1]. LOL cho lesteryl esters undergo a thermotropic transition close to physiological
temperatures, 30"C [Figure 3.5J. Below the melting temperature, [Tm], which is 25"C . the
CE exist in a radial smectic state, while they exist in a liquid state above Tm [Deckelbaum
et al., 1977] . The fact that the Tm depends on the core TO content suggests that the physical
state of the core lipids will change above Tm. This may explain why drug diffusion increases
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with an increase in temperature above Tm.. However, ifdrug resides in the core and disrupts
the binding ofcore lipids, a different transition may be speculated.
Typical DSC thermograms ofLDL samples alone [Figure 2.7J and in the presence
ofDox, were studied. A broad transitio n ofcore lipids was observed in the range of24-27<'C
with all preparations [Figure 3.5 }. This non-cooperative transition behavior is inhere nt to
LOL samples . The apparent change in transition enthalpy of LDL samples due to drug
loadin g could be explained in terms of their miscibility with core lipids . When OaK was
loaded in the LOL, a decrease in transition enthalpy was observed [fable 3.1]. This result
sugg ests that Dox intercalates with LOL core lipids and existsas a separate entity in the core
lipid. Since Dox is not misci ble, it perturbs the packing of core lipids which start to loose
som e oftbeir transition enthapy. This may be the reason for the low transition enthalpy of
core lipids of LOL-Dox conjugates. The packing of core lipid is very important as it may
influence the surface structure ofLDL and hence interaction of apo B with cell membrane
LDL receptors . An altered LOL surface structure could also affect the interaction ofLDL
with tissues by recepto r indcpendent mechanisms as well as its susceptibility to in vivo
modification.
Cholesterol increases the order of the surface PLs of native LDL . Philips and
Schumaker [1989] have shown that approximately 70"/0of the total unesterified cho lesterol
is present on the LDL surface . These cholesterol molecules interact particularly strong ly
with LDL phospholipids in part because they have a high content of satura ted PLs and
sphingomyclin. ApoB and core lipids have a majo r influence on the surface order . An
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analy sis of the amino acid sequence of apo B shows that there are numerous domains
throu ghout its sequence which can interact with the lipid domain. An analysi s of the lipid
bindin g propertie s ofpIOteolytic fragments of apo B bas shown that lipid bindin g regions are
widely distributed within the protein. In my studies the native integrity ofLDL was restored
as no degradation products appeared on gel for LOL preparations [Figure 3.4].
The incubation temperature at 37°C seemed to have no adverse effect on physical
properties of LDL. Nevertheless, drug molecules were found to have loaded effici ently into
the core of LOL particles as evide nt from their transition enthalpy . Whether this drug
binding will affect receptor binding properties of LOL could be examined in vitro by
biol ogical evaluations of the conju gates in tissue culture s. My DSC results with different
sam ples reconfirmed previ ous findings . The magnitude of this change is similar to that
observed durin g the liquid crystalline 10crystalline phase transition ofPL bilayers. At higher
temperatures, for example. 6O"C. a higher loading of drug s was achievabl e (Figure 2.8]. This
was probably due to a more fluid nature of LOL and more molecular motions of the drug
during Brownian diffusion into the LDL particle s.
I conclude that neithe r the conformation of apo B nor its abili ty to bind to the LDL
receptor is likel y to be affected by temperatures below 4O"C. Drugs were loaded at least in
the core ofLDL particle s.
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3.4. DiKussioD
The use of LOLs as drug carriers is dependent on drug loading that does not
drastically altering theirstructure . The LDL-drug conjugates must not be recognized by the
RES, and the receptor mediated uptake by cells must not be affected , sb:tce the main aim in
the use of LOt as drug carriers is their uptake by cancer cells. For this reason. I have
monitored the structuralcharacteristics of the drug-loaded LOL and SODle of their dynami c
properties. as well as the state of apo B. The major finding of the preserrt study is that, about
0.3 weight (wt) % of drug can be incorporated without any detectable disturbanc e of the
structure of the LOLs. The leakage o f drngs from LDL-drug conjugates was not significant.
These findin gs imply that LDL-drug conjugate s will be effectively recognized as native LDL
by the ape B receptors that are enriched on tumor cells. Once recograized, the LDL-drug
conjugates should be intemalized and release the incorporated drugs int:raeellularly . In this
way. a targeting effect may be achieved [see Chap ters 5 and 6].
To observe the influence of temperature onLOL lipids and prctesins I used DSC and
found no significant alterations in LDL-drug conjugates due to drug loading at temparatures
below 40°C. The LDt particle provides several sites for the Insertion, of drug molecules.
depe nding on their lipid solubility. The core is by far the best site because ofits capacity and
ab ility to shield the drug from the extracellular enzyme s. A second site oor drug intercal ation
is the PL monola yer. Agents that have both polar and lipid soluble components may partition
in the monolayer. between the apolar core and the aqueo us environmemt. However. in this
location they would beless well protected from plasma hydro lases and 'water. Further, they
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may be able to stimulate the immune system to remove the W L-drug co njugate from the
cin:ulation. My DSC results showed that Do x perturbsthe thermaltransition of core LO L
lipids. This suggests that the drug was loaded inside the core ofLDL
The LOL used in this study had an average diameter of 2 1.9 ± 1.21 nm lo> lOO
particles l, in agreement with previously pub lished resul1s[Tucker and Florence., 1983] . After
drug incorporation, the average LO L diameter alsodid DOt increase significantly. The
amount of drug inco rporated in LOL did not chan ge its size signifi cantly. Thi s implies that
the incorporation of dru g does not greatly deform LOL structure.
Th e pre sent study showed that apo B protein of the LO L preparations retain ed its
native conforma tion when the drug was incorporated by the proced ure descri bed above. The
LOL receptor-mediated endocytosisofcytotoxic LD L-drug conjugates might provide distinct
advantages over the trapping of antineoplastic drugs in Iiposomes. The main reason for this
stalement is that liposomes are subjected to dCSlJ'UCtion by blood components, primarily by
lipoproteins (Wasan et aI.• 1996] and to a fast clearance: from the circulation by the RES
[Janknegt. 1996 ; Basu, 1994] . Since the loading oftbe particles with drug molecul es does
not influence the conformation of the protein component of the LOL , this preparation is
expected to follow the same in vivo fate as native LOL particles in animal or human studies.
Thi s is very important, as the use ofLDLsas drug carriers depends upon the preserv ation of
the particl es' characteristics., sucb as receptor recognition and RE S avoidance. The present
study indica tes that. in favo rable case s, such as loadin g with the lipophilic drug, the
charac teristics of the LDL structure and its dynami c properties are entirely preserved despite
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the incorporation of significant amounts of drug {about 0.5 wt %] . In conclusion, it is
possible to load Dox efficiently into WL particles without perturbing some of thephysico-
chemical prope rties ofLDL.
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Ta ble 3.1. Calorimetri c parameters of LDL pr epara tioDs *
Sampl e
LDL
LDL-Dox
Tm(CE), OC
25
26.6
6 H ... (KJlKgofapo B)
6.473
1.474
• The values are the average of several beatings ; the experimental erro r is within :t::lO"/o. Thi s
refers to the transition of core lipid peak.
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Figure 3.1. Ca rrier up.city of LDL for D OL LDL-drug conjugates were incuba ted
with p lasma for 2 hours at 37"C . Different lipoprotein fractions were isolated
using sequential ultraflotation method and drugs were analyzed by HPLC
methods. Plasma was sequentially adjusted to d=l .OO6, 1.063. or 1.121 g/mL
by KBr and ultIaccntrifu ged for 40 hours at goC for seque ntial isolation of
e M + VLDL (d=I.006). LDL (d=l.063), and HDL (d=1.21). Drug was
assayed using HPLC methods. The total amount of drugs recovered in
different fractions was considered 100%. Each value represents the mean
±SD(n=3).
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Figure 3.2. SD5- PAGE or w L, and LDL-drug con jug_ tes. A 5% acrylamide gel
loaeded wi th LDL samp les was elcctropboresed at 30 mA constant current for
30 minutes. The pos itions ofa broad range ofMW standards from BioRad
are shown with arrow marks . Samples were Incubated for 4 hours at 37'"C.
The LDL- Do x conjugates were scpara1edby ultracentrifugation followed by
dial ysis. Aftcr di alysis, samp les were ubjected to 5 0S-PAGE. Lane I , broad.
range MW markers ; Lane2.native LOL (S fJg); Lane 3. LDL-Do x conjuga tes
[5 J1gprotein and 0.15 fJgDox] andLane 4, LDL-CI conjugates [discussed
in Chap ter 4] [LDL-drug conjugates were prepared by the contact method
with Tween 20 J.
MW X10- 3
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Fipre 3.3. Electro n m k rocnpb or LDL preparatiollSo The LDLpreparati ons (1()..40
~g protcinfmL) wac appli ed to carbo nform var membranes aDdnegati vely
stained with 2% phosphotungstate solution. They were cxamiDed on a
Pbilips 300 instrument at_magnification 75.000 X.the bar represent 100 DID.
Panel A. native LDL; Panel B, LDL incubated with Tween 20; Panel C. LDL
incubated with DoX"HCI [the direct addition method]; Panel D. W L
incubated with Dox with Tween 20 [the contact method].
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Fipre 3.4. Particle size or LDL preparations measured by EM. Samples were
uegarively stained with 1% uranyl acetate and pbotographed at
magnifications, 7S,OOO x 3. Results were mean diametc:r:!:SD ofat least 100
particles diameter.
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Fipre 3.5. DifferentW. seaaaiDg calo rimetry of LDL-Dol: conjugates. LDL was
incubated with Dox for 4 beers at 3T'C (the dim:tadditiODmethod) . LDL-
Do x conjugates were: separated from the incubation mixture by
ultracentrifugation followed by dialysis, Samples were scannedat O.soC /
min from 10 to Sooc. DSC sensiti vity was the same for all runs . For all
samples. the protein concentra tion was more than 1.50 mgImL. Buffer
baselines were subtrac ted. The data are normalized to the protein
concentration. Similar DSC the rmograms were obtained (Similar Tc and
vari able transition enthalpy for sam ples) for all other LDL-drug conjugates.
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CHAPTER 4:
EVALUATION OF BIOLOGICAL TRANSFER CATALYSTS IN ENHANCING
DRUG LOADING INTO LDL PARTICLES
4.1. Introduction
I have demonstrated earlier that drug incorporation into LOL particl es can be
increased by mod ulating physico-ebemical factors and by designing lipophili c prodrugs.
Still. a further increase in loading efficiency without signifi can tly changing the integrity of
LDL particl e is desirable. In this section. I investigated the potential of biological transfer
catalysts to further impro ve drug loadin g.
Biological transfer catalysts are widely distributed in both invertebrate s and
verte bra tes. Amo ng the catal ysts, only lipid transfer prote ins are considered in this stud y .
These catal ysts facilita te the transfer of a variety of lipid components amon g lipoprotein
particles in vivo. LDL may act as donor or acceptor for these proteins. My primary aim was
to load cytot oxic dru gs in an endogenous lipid particle . LDL. Any foreign molecule, if
transported by these prote ins , is expected to follow simil ar transfer kinetic s as the natural
endogenous substrates . However , these transfer proteins in higher animals, like humans, are
substrate specific, presumably to meet bigher and spec ific biological deman ds of mor e
complex biochemical systems [fsucbida et al., 1995; Ryan, 1990]. In contrast, invertebrates '
transfer proteins are generally less selecti ve due to simpler bioche mical systems. To
investi gate the potential of biological transfer cataly sts to transfer cytotoxi c dru gs in LDL
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from a drug reservoir. transfer proteins both from humans and insects were selected for this
study .
Two different lip id transfer prote ins have been identified in human plasma. One is
known as CETP [Obnishietal., 1990; Morton. 1990; Morton and Zilversmit, 1982;] and the
other is phospholipid transfer protein [PLTP] [Tollefson et a1., 1988; Tall et a/., 1983].
While PLTP catalyzes only PL transfer between plasma lipoprot eins . CETP catalyzes the
transfer of CE, TAG , and PL. When two different cytotoxic compounds, dioleoyl -
floxuridinc and dioleoyl-mcthotrexate, were tested to determine their potential transport into
LDL by these transfer proteins from a drug reservoir, a negligib le or low incorporation
efficiency was observed [Lundberg 1992; De Smidt and Van Berkel, 1990]. In order to
examine the apparent selectivity of CETP against foreign compounds, I chose to use this
prot ein in my studi es.
Recently, insectlipid transfe r proteins [LTP] have been investigated for their role in
transferring different lipid components among lipopborins (inse ct lipoproteins] and human
lipoprote ins [Singh et aI., 1992J. One such protein bas been isolated from the hemolymph
of the tobacco born worm, M sexm(Ryan, 1990a; 1986a,bJ. This protein can facilitate net
vectorial transfer of lipid mass among lipoprotein particles . Evidence ofLlP·mediated net
transfer has been obtained from studies with insect hemolymph lipophorins (Ryan et al.,
1990a; 1986a,b; Ando et aJ.,199OJ, apcproteia -stabilized TAGIPL microemulsions [Ando
et al .• 1990J, humanHDL [RyanetaJ.,1992; Silver etal., 1990J,and hwnan LDL [Singhet
al., 1992] as substrates. Net lipid transfer occurs from the lower dens ity lipophorin to the
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higher densi ty lipopborin in the presence of LTP , producing, at equilibrium. a single
lipoprotein population intermodiate in density between the starting lipoproteins [Ryan et 0/..
1986a. b; 1985]. LTP bas also beensho wn to catalyze net transfer ofPL and TAG from a
buman apoprotein A-I-stabilized PUtrioiein microemulsion to human LOL [Ando et al.;
1988]. Facili tated net transfer orCE. free cholesterol, and PL 0CCWTCd to a much lower
extent than DAG net transfer, iDdicating that DAG is the preferred substratefor this protein.
However , LIP was found to transfer a number of endoge nous panicles with a variety of
different chemical structures. This suggests that L1P mediated transport is not substrate-
spec ific . I wanted to extend this approac h to the loading of foreign compounds such as
cyto toxic drugs into LOL panicles.
Insect LTP appears to be distinct from other plasma lipid transfer catalysts described
IOdate. First, it exists&S a Vet)' bigh density lipopro tein of high MW [Mr> 670 ,000]. LTP
has three apoprotein components and 14% lipid in the native particle [Ryan et al .. 1988 ].
Although it bas been shown that the lipid component ofLTP is in equilibrium with that of
potential do nor or accepto r lipoproteins [Ryan et al .. 1990), the precise ro le of individual
LTP apo protcins is not clear . A second distinguishing feature ofL11' is its propensity to
catalyze unidirectional oct lipid transfer versus homo or hetero exchange of lipid lD
contrast, human CETP catalyzes reci procal random exchange ofCE and TGA (Ohni shi et
at.• 199 5]. LTP catalyzed net transfer establi shes an altered final equili brium lipid
distribution that results in chang es in the total mas s of lipid associated with lipoprotein
substrates rather than redistributi on of lipid classes via a simple exchange process.
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L1P may provide a useful method to alter the COR: content oflipoproteins depending
on the donor and acceptor composition. I proposed to load hydrophobi c foreign compounds
via LTP mediated trans fer into human LDL. The reaction may produce drug enriched
lipo protein partic les as stable end products. In an attempt to understand the catalytic
properties of biological transfer catalysts I have examined the ability of human and insect
transfer proteins to catalyze transfer betweendrugs and human LDL. In addition to Dox, I
proposed to load a CE analog, CI, into the LDL partic le. This is greatly simp lified by the use
ofradio labeled derivatives oCCI [e.g. Illr..cI]. The utility ofcompounds oftbis type has been
amp ly illustrated by Stein et al: [1988J. I adopted the radioiodination procedure to
radiolabelled CI acco rding to the procedure ofWeichert et al., [1986}. The radioiodination
of this compound will help to quantify this compound even when CI incorporation is very
low. In short. the potential utility of biological transfer catalysts as tools to transfer drugs
into human LDL is investigated in this chapter.
4.2. Materials and methods
4.2.1. Materi als
LTP and high density lipophorin [HDLp] from M sata were gifts from Professor
Robert O. Ryan, University of Alberta, Edmonton, Canada. Human LDL and LPDP were
iso lat ed from plasma by using sequential flotation ultracentrifugation method described
earlier (Chapte r 2, section 2.10). Dox was also described in Chapter 2 (section 2.1).
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Nonradioactive CI was a gift from Professor Raymond E. Counsell [the University of
Mic higan, Ann Arbor, MIl. The Ill! used was a no-carrier-added solution of Na lllt [5
mCiJO.l mL] in red uctan t-free 0.1 N NaOH obtained from DuPont Caeeda Ltd. [Ontario,
Canada}. Tetrahydrofuran [IHF] was distilled fromL~ under helium iimmediately prior
to usc. Unless otherwise noted. starting materials, reactants and so lverats were obtain ed
commercially and were used as such or purified and dried by standard means.
All radioiodinarion reactions were conducted inside a plexiglass glove box vented
with a radio -iodine trap . Thin layer chromatography [1LC] analyses were performed on
Merck silica gel GF254 plates. The plates were monitored by UV fluorescence, or staining
with iodine vapor . The solvent system was hexane : ethyl acetate, 5:2 for CI . Colwnn
chromatography was pe rformed on Merck silica gel-60 [230-400 mesh] elueed with the same
solvent system . An HPLC system in conjunction with radioactive coumting was used to
determine radiochemical purity and specific activity oCCI wascalculated. The HPLC system
was described in Chapter 2 [section 2.4].
4.2.2. Pr epa ration o( u5I..cI
The radioiodination of CI was carried out using an isotope exchaange reaction in
pivalic acid as described by Weichert et al., 1986 [Figure 2.4]. Briefly, 4_80 mg of'Cl was
placed in a 2 mLplasma vial which was then sealed with a teflon-lined nabber septum and
analuminwn cap. Freshly distilled THF (100-200 IJ.L] and aqueous Na ' 2S1 (10-50 IJ.L] were
added in successio n via a micro liter syringe and a gentle stream ofNz was applied to remove
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the so lvents. When the residue appeared dry , the seal was removed and so lid pivali c acid [5-
20 mg, dried by azeotrope with toluene and distilled under nitrogen) was added . The vial was
resealed and partially immersed in a preheated [l5S-160 °C] oil bath . When the isotope
exchange reaction was essentially complete [usually 1-2 hours] , the reacti on vial wasallowed
to coo l and anhydrous THF (200 J.1L] was add ed with a glass syringe and the vial swir led
gently. A Tl. C test was performed with 1-2lJ1.ofsample and the remaining contents were
transferred to the top of a silica gel-60 column [1 X 10 em] and subsequently eluted with
hexan e/ethyl acetate [5:2] as the solvent system. Chemical puri ty was detennined by HPLC
and radiochemical puri ty was determin ed by HPL C in conjunction with y-counting using an
automatic gamma counter [LKB Wallac 1277 Gammamaster, Turku, Finland] . The mI_CI
was then sto red at 4 "C in a lead casing. The specific activity of the compo und [cpmll!g of
CIJ was counted as follow:
SpecifIC Activity = calculated cpm of the eluent by the y counter
amo unt detected by HPLC, Utg)
4.2.3. HPLC assay or CI
A new reverse phase HPLC procedure was developed to detennine CI. The principle
HPLC conditions are outlined in Table 2.1. A concentration range given in Table 2.1 was
used to make a calibration CUIVe. All standard solutions were in chloroform. Samples were
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extracted from plasma or LDL by a directprecipitation method using chIorofonn. The extent
of recovery ofdrugs from LDL was detennined as described in Chapter 2 [section 2.4 .1J.
4.2.4. LTP assay
The principle of LTP assay is based on the catalytic transfer of CEs from lIDLp
[donor] to LDL [acceptor ]. LDL bas limited capacity forCEs and overloading oCCE by LTP
destabilizes the LDL which aggregates and forms a turbid solution . This turbidity is
proportional to the amount of CE transferred by LTP . This turbidity is measured at 405 om
and used for LTP assay. A time dependent CE transfer is expected which will plateau after
several hours depending on the catalytic effi ciency ofLTP. Also, this transfer is found to be
dependent on the concentration ofLTP {Singh et aI., 1992J. The protocol reported by Singh
et at. , [1m] was used with minor modifications. In brief. standard assays were cond ucted
in 96-we ll microtiter plates. Unless otherwise specified. human LDL [SO~g protein] was
incubated wi th M sex ta HDLp [250 )Jg protein] for 12 hours at 37°C in the presence and
absence ofLTP . The final volume of incubation was 0.2 mL in PBS. During incubation the
plates were read every 30 minutes on a plate reade r fitted with a 405-nm filter. Contro l
samples lacking L'IP were run in parallel and the absorbance at 405 nm of the contro l
samples was subtracted from that ofL'IP-eontaining incubations to obtain the L'IP -indueed
absorbance change.
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4.1.5. P re p8 n1tion of LDL-drug conj ugates llsiDg LTP
Two different methods were used for incorporation oflipophilic prodrug into LOL
using LTP. In all cases experiments were performed in duplicate or triplicat e with
appropriate controls. Contro l samples contained 0.9% NaCl instead ofLTP.
4.2.5.1. Co ntact meth od: Lipophilic CI or free Dox dissol ved in chloroform were
added to glass tubes. The solvent was evaporated WIderN~ at room temperature; the drug
wasthus coated on the solid surface. After comp lete evaporation of all so lvent, LOL was
added followed by LTP or PBS . The mixture was incubated at 37°C for at least 12 hours
under N 2 with continuous shaking. In certain cases , a drop of ethanol or Tween 20 was
added prior to the addition ofLDL and LTP to suspend drugs .
4..2.5.1. Direct additi on: This method was used for DOlcHeI. because Dox is water-
soluble. Appropriate amounts of drug and LDL were added followed by the final addition
of LTP. Incubation conditions were similar to the contact method.
4.2.6. CETP mediated drug loadiDg
This method is based on a method previously described by Blomhoff et ol., [1984 J.
Briefly , 50~ [50 f.lg] of drugs [CI. and Dox] to be incorpo rated in LDL were disso lved in
chlorofo rm and the solvent was evaporated under a stream. ofN2 to dryness in a glass tube.
The residue was then disso lved in50 ilL ofacetone followed by addition of500 f.lLLPDP.
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After evaporation of the acetone wi th N~. 300 vL of PBS was added . The LPDP-drug
preparation was then incubated wi th 500 liS ofLDL at 37°C for 4 hours in the dark with
constant gentle shaking. In the case ofDox:HCI, Dox was directly added to LPDP followed
by incubation with LDL as mentioned before.
4~7. Isolati oD and evalu atioo ofLDL-drug co.jugat es
Once the incubations were completed. the incubation mixtures were adjusted to a
density of greater than 1.063 g/mL with KBr and centrifuged at 40,000 rpm in a Ti60
Beckman rotor for 20-30 hours at goC. After ultracentrifugation, the LDL-drug conjugates
were collected from the top of the tube and extensively dialyzed overnight as described
before. The assay methods for the detennination of the protein concentration {Bradford
method] and the drug concentration [HPLC or liquid scintillation or gamma counting] were
reported earlier in Chapters 2 and 3. The integrity ofLDL·protein was determined by SDS-
PAGE [Chapter 3, section 3.2.3J. Particle size of the particles were measured by EM
[Chapter 3, sectio n 32.4].
4.2.8. UV-visib le scaDoing
To investigate the location ofa drug, Uv-visible scans were made ofthe free drug
and LDL-drug conjugates in the UV-visib !e range using a Uv-vtsible spectrophotometer.
Only LDL-Dox was considered in this srudy. Two standard scans were made : [I ] Dux-He !
in PBS buffer and [2] freeDcx in chloroform. The spectra from LDL·Dox conjugates were
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compared with these two standard spectra. Dox spectra in the two differen t solvents were
considered to be complimentary to Dox in the outer aqueous environment and on the inner
lipid environmentofLDL. Dox, ifpresent in the aqueous surface layer . is expected to give
a spectra similar to the Dox-HCl spectra taken in PBS buffer. However , Dox, ifpresent in
the core, is expected to have a spectrum complimentary to the Dox spectrum.in chlo roform .
4.2.9. Sta tistica l a nalysis
Statistical analys is was perfo rmed between two groups using the student's t-test and
the p value was calculated. Differences between two groups were considered significant if
p> 0.05. All data are expressed as the meen e SD.
4.3. Results
4.3.1. Pr ep aration of t15I·CI
CI was successfully radio -labe lled using l:l'r [Figure 4.2J. Radiochemical yiel d for
CI was found to be excellent [>95 %]. The specific activity of the compound was 2000
cpml jl g Cl.
4.3.2. HPLC assay ercr
The chromatograms of differe nt analogs in standard solutions are shown in Figures
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43a and 4.3b. Typical calibration curve for CI is shown in Figure 4.4 . The equations ofbest
fit for the lines ofCI was calculated. The coefficient of determinations ranged from 98 - 100
%, and the CV of the slope determined on the five separate occasions was less than 5 %.
Peak areas obtained with plasma or LDL spiked with four and five different
concentrationsofdrug over the standard concentration range [Table 4.1] were linearly related
to the spiked concentrations. In all cases, direct addition of chloroform to LDL or plasma
was sufficient to extract more than 95% of the drug from spiked LOL samples. The
minimum detection limit for the drug was 10 ng [10 j.LLfrom I IJ.glmL standard solutions]
and was suitable for my studies. Th e peak height detected at this minimum concentration
was more than three times that ofthe background noise . The reproducibility of the method
was determined by both intra- and inter-day variability studies [Table 4.2]. Statistical
analysis of CI showed no statistically significant Inter-day or intra-day variations of the
samples [p values in all cases were found to be> O.OS}[Table 4.2].
4.3.3. BiologicalaSliay ofLTP
Ina typical LlP assay . initial quantity of lipid acceptor [LDL] is incubated with large
excess amount of lipid donor [lIDLp] in the absence (contro l] and presence of LTP. If LTP
is catalytically functional, lipids will be transferred from the donor to the acceptor. When
the capacity of acceptor [LDL] is reached the excess amount of lipids will promote the
aggregation ofLDL and the solution will become turbid. The deve lopment of turbidity can
be spectrophotometrically quantified In the absence ofLTP. or ifLTP is denatured, no lipid
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movement occurs and the solution will remain clear. My assay to verify the catalytic activity
ofLTP is a modification of a method reported earlier [Singh et aI., 1992J. The development
ofsample turbidity was observed in terms of reaction time and LTP co ncentration [F igure s
4.5 and 4.6] . The results showed that centro l Iipoprotein incubations lacking LTP had a
baseline absorbance, which did not change as a result of incubation, ofabom 0.25 at 405 DID.-
When ca talytic amounts of LTP were added, there was a time-dependen t inc rease following
an initial lag phase , in sample absorbance at 405 DIn . This increase was linear for periods
up to 10 hours and reached a plateau fe r longer time periods [15 to 24 hours]. suggesting a
reaction end po int had been reached. When either LDL or HDLp was omitted from
incubations containing LTP no increas es in absorbance were observed . As expected there
was a concentration depe nden t increase in abso rbance at 405 om due to the turbidity of the
solution was observed [Figure 4.6]. On the other hand, contro l incubations lacking LTP did
not show an increased absorbance at 405 nm. The control absorbance was found to be 0.025
througho ut the time period (Figure 4.5]. These data suggest that LTP was catalytically
effective. However , the catalytic efficiency was less than expected when compared with the
results of Singh et al., [1992]. LTP catalytic activity is also temperature dependent and the
greatest effici en cy was reported at 37°C [Singh et aI., 1992]. Based on these data, I proposed
to use 50 IJg of LTP per mg of LOL protein and long incubation times of 9-15 hours for
studies involving drug loading.
4.3.4 . Ph ysicochemkal properties of LDL-drug conj ugates
The efficiency of incorporati on of drugs into the LOL was evaluated by density
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ultracentrifugation, 80S-PAGE, and EM as discussed in Chapter 3. All LDL-drug
conjugates showed only one band indicative of apo B ofLDL [Figure 4.7]. The particle size
of most LDL-drug conj ugates (24 ± 2 nm] chan ge significantly whe n compared to native
LOL [21 ± I run] [Figure 4.8 and 4.9J. Howeve r. the change in particle size is small in
magnitude.
4.3.5. Cootact met hod
The dry film method is good in generating stable LDL-drug conjugates as indicated
in Chapter 3. The essential step of this method is the partitioning of drug from a solid
surface to the lipoprotein. This method was not found to be very effective in loadin g drug s
in LOL particles. Interestin gly, when LTP was used to enhance drug loadin g, a 3- to 5-fo ld
increase in drug loadin g was observed for Dox [Figure 4.10] . This effect was not observe d
with CI. Figure 4.10 shows tha t LTP has potential to enhance drug loading at least 2 to 5
fold. However. further optimization of this method was necessary to enhance loading with
more hydrophobic compounds such as CI. This prompted me to modify the dry film method .
I considered that increased interaction ofLDL and drug was esse ntial for LTP's activi ty, as
the catalyst would act at the interface of the drug molecule and the LOL particle . In order
to so lve this problem, I proposed to use organic solvents or surfactants to solubilize or
suspend the drug molecules before incubating them with LDL and LTP. Results are
discussed below .
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4.3 .6. Orga nic solvent aided method.
In order to optimize contact between drug and LDL, SO~ ethanol was added to
solubilize the dru g before incubation with LDL and LTP. LTP was found to be
approximately 2-fold more active in ethano l solubilized than the contro l without ethanol for
CI [Figure 4.10]. A smal l amount ofethano l was found not to denature apo B protein. No
degradation bands appeared on gels after SDS-PAGE and no visual turbidity was apparent
[data not shown]. It is worth mentioning that the first clinical trials o[VeR were performed
us ing prepara tions mad e by the dry film method with the aid of an organi c solvent,
dichloromethane [Breeze er al ., 1994 ; Filipowska et ai.• 1992). The results from human
tri als indica ted that small amounts of organic solvents may not induce significant
denaturatio n to apo B protein of LDL. as LDL-drug conjugates had favorab le
pharmacological effects.
The dry film.method is good in generating stable LDL-drug conjugates as indica ted
in Cha pter 3 . The essential step of this method is the partitioning of drug from a solid
surface to the lipo protein. This method was not found to be effective enough in loading
drugs in LDL particles. Interestingly, when LTP was used to enhance drug loading, a 3- to
5-fold increase in drug loading was observed for Dox [Figure 4.10). This effect was no t
observed with CI. Figure 4.10 shows that LTP baspotential to enhance drug loading at least
2 to 5 fold. However, further optimization of this metho d was necessary to enhance loading
with more hydro phobic compounds like CI. I cons idered that increased interaction ofLDL
and dru g was essential for LTP's activity , as the catalyst would wo rk at the interface ofthe
I3S
dru g molecule and the LOL parti cle. In order to solve this problem. I proposed to use
organic solvents or surfactants to solubilize or suspend the drug molecules before incubating
them with W L and LTP. R.esults are presented below.
oC.3.7. OrgaDic: solnDt .idnS method.
In order 10 optimize contact between drug and LOL. SO.u. ethanol was added to
solubilize the drug before incubation with LDL and LTP . LlP was found to be
approximately 2-fold more active than the control under these conditions for CI [Figure
4.10] . A small amo unt of ethan ol was found not to denature apo B protein. No degrada tion
bands appeare d on gels afte r 80S·PAGE and no visual turbidity was apparen t [data not
shown]. It is wonh mentioning that the first clinical trials of VC R were performed using
preparations mad e by the dry film method wi th the aid of an org anic solvent,
dichIoromethane [Breeze et aI.• 1994 ; Filipowska et aJ.. 1992}. 1be results from hum an
trials indicated that small amounts of organic solvents may DOt induce significant
denaturation to apoB protein of WL as LDL-drug conjugates bad favorable pharmacological
effects,
4.3.8. Detergent aided method.
I have already demonstrated tha t the detergent aided method is more efficient in
loading lipophilic drugs into LOL compared to the dry film method. Results from ethan ol
solubilization were encouraging; however. complete solubilization of lipophili c dru gs by
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ethanol was not considered as I observed that apo B denatured at higher concentrations.
Alternately. to suspend the drug, I attempted to use Tween 20 which was already found
effective in loadin g Dox into LDL . This wetting agent was already found suitable to deliver
hydrophobic compounds in suspension. The suitability and safety profile of this detergent
is~c1sewhereintbeliteraturc[Leyland.19941. To test whetbcrLTP worked better
in this system. I have used CI. A 3- to 5-fold difference in loadin g efficiency was observed
[Figure 4.1 11.
4.3.9. Direct ad dition
This method genera tes stable LDL-drug conjugates. It has been reported that the
LDL-drug conjugates were found to leak from the lip id core or to be loosely attached to the
PL outer-layer in preparations using this method [Firestone, 1994; Shaw et al.; 1987;
Lundberg. 1987]. However, in my experience with ce ll culture studies [see Chapters 5 and
6J, I found the LDL-drug conjugates were stab le enough to generate cytotoxic effects in
cultured cells indistinguishable from the effects ofLDL-drug conjugates made by the dry
film.method . The direct addition method was found suita ble to load Dox-HCI. With LTP,
the loading efficiency was improved at least j- to 4-fold [Figure 4 .11]. In one case, the
loading efficiency for Dox in the presence ofLTP was found to be 22·fold higher than that
oftbe contro l without LTP . This result indicates the importance of modifying incubation
conditions in enhancing drug loading in LDL.
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4.3.10 . EDZ)'lDatic tnlU(cr via CETP
Figure 4.12 shows the relative incorporation efficieucy ofdrugs using this method
compared to the contact method with 01"without LTP . Uniform LDL-drug conjugates could
be ge:nernted without any further improvement to the loading efficiency oftbe compounds.
This eece again confirms the previous finding aflow incorporation efficiency of CETP [De
Smidt and Van Berke l. 1990b]. Compared to the dry film method, no significant
incorpo ration was observed (Figure 4.10]. I conclude that CETP was Dot effective in
enhancing dru g loading into LOL under my experimental protocols.
4.3.11 . Location of drug
UV-visi ble scans were carried out in two different solvents to compare the spectra
ofLDL-Dox conjugates. I hypothesiz.edthat Dox in LOt would have corresponding spcctnl
either to the spectra of Dox in chloroform or Dox-HCI in PBS. Dox in the two different
environments behavesdiffcrmtly. Tbere are two different environments in LO L, the central
lipid core and the outer aqueous PL mooolayc:r. UV·visib le spcdm ofLDL-Dox conjugates
were similar to those ofOox inchlorofonn.. Drugs were loadedinto the oily core ofLDL.
UV-vis:J.ole spectra ofDox and LDL-.Dox are shown in Figure 4.13. The spectra #1 and #2
of panel A were the DoxILDL-Dox in the absenceandin the presence ofLTP. Clearly, LTP
induced significant increasesin the amounts of Dox associated with LOt in comparison to
conventional spontaneous transfer . The increase s ranged from 3-4 fold. With further
refining of the conditions (see below), more Dox can be packaged into LDL . When the
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spcctraofDoxILDL-Dox were compared to that ofDo x·HCl in saline.a peak at about 543
om. beeameevident in DoxILDL [#1 and #2J while Dox:HCl [#3 and #4] only showed a very
weak shoulder [panel B). To explorethe possible contribution of thispeak in DoxILDL-Dox
samples, the spectra of different coocentrations cf bcth the Dox base in chloroform and the
Dox·-HO in PBS buffer have been scaoncd (panel C]. The spectra ofDox in chl oroform [#5.
#6 and #7), had 54 3 nm abso rption peaks,while Do x·Hel so lutions in PBS buffer [#8 aDd
IW] only showed shoulders at this wavelength..These results suggested that Dox associated
with LOL was more like the Dox dissolved in chloroform than inaqueous medium. The Dox
might be disso lved in the oily core ofLDL. This is the preferred loca tion where: Dox woul d
not be leaked out in the general circulation while the surface bound compounds woul d be
qui ckl y displaced or exchanged by a very large amount of PLs presented in all the
biomembranes and lipoproteins. The kx:aImtti.on ofDox in the corewasalso predicted from
my DSC stud y discussed previ ous ly in Chapter 3 [secti on 3.7].
4.4. DiscwsioD
The pivalic aci d exchange radioiodination ofCl using a previo usly reported method
[W eichert et aJ., 1986) was successful. The HPLC procedure reponed here was found
sui tab le in my experimental protoco l. Recoveries of dnJg from LDL sam ples were exce llent
[>95%].
I have discussed the fact tha t substrate transferred by LTP is nonspecific (Singh et 01.,
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1992; Singh and Ryan. 199 1; Liu and Ryan. 1991; Ryan. 1990; Ryan et al., 1990]. This lack
ofsubstratc specificity provid es a good basis for transferring vario us hydrophobic cytotoxic
drugs to LOL by LlP. In my studies , I have chosen a variety of structurally dissimilar
molecules as substrates fer LTP. All the compounds were hydrophobic in nature and
Dox .He i was ionic in nature. Both lipophilic and ionic substrates were reported for LTP.
In the biological system, [DAG] had the highest preference for transport by LTP. In my
studie s, there was DO preference was observed for CI although CI was structurally very
similar to eli In all the cases, the drug leading efficiency was found to be2- to 5-fold higher
with LTP compared to control, CI was found to be better candidates. CI due to its close
simil arity with CE was considered a better substrate. In addition. its lipo phi lic nature
presumably made it more interactive with the transfer protein. Thetransport ofDox.HCI by
this protein indicated that there was a preference for ionizable species. One possible
explanation could be better interacti ons of ionic dru gs wi th ioni c PL outer layer. Since the
drugs are availa ble at the interface because of ionic interaction, they are more acce ssible to
LTP . If this ho lds true, then it explains why there was no dramatic differen ce in drug loadin g
efficiency by LTP . Re sults indicate that drug molecules should hav e sufficient
hydrophobicity to be loaded into LDL by LTP .
The contact method is based upon the passive partitioning of dru g from a solid
surface into the LDL. The transfer protein method, described previously for the
incorporation of radiolabelled cholesteryl oleate into lipoproteins [Blomhoff et al., 1984],
utilizes transfer enzyme activity present in plasma, mainl y, CETP . Experimental conditions
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for drug incorporation with these methodswere tolerable to preserve native integrity cftbe
LDL particle because drug incorporation was either spontaneous or protein-facilitated. Dry
film.proc:edures produce LDL-drug conjugaies with low incorporation efficiency. Moreover,
incorporated drug may DOt be assoc iated with the inner core of the LDL particle . Such a
' Ioose" incorponuion was reported earlier with benzo (a}pyrene-LDL complexes obtained by
a similar procedure (Remsen and Shireman. 1981].
The CETP catalyzed incorporatio n method was very successful [up to 800;'
incorporation efficiency ] in the case of incorpora tion of radiola be lled cbolcsteryl oleate .
Moderate selectivity, by a factor of S to 6, was observed in the CETP -catalyzed transfe ror
CE over TAG between plasma lipoproteins. On the other band.the trans fer cCCE by CETP
was highly selective over the negligi ble transfer of TAG . by a facto r of6O to 500. betwee n
microemulsicos witb LDL size [Ohnisbi elal.; 1994-1995]. Thepresenceoffree cholestero l
in thesemicroem uls ions reduced slightly the rate oCCE transfer but had no effect on TAG
transfer . Otbcrsurface active reag ents such as cbolie acid.Triton X-t OOand Tween 20, did
not have an effect on the TAG traosfcr either [Ohnishi et m..199 5]. From this discuss ion
it is clear that the CETP procedure was selective even for endogenous molecul es. In my
studies, density ultraee:ntrifugation showed that dnlgs cannot be inco rporated into LDL with
this procedure, confirming a high degreeof structural specificity whic h explains why foreign
particles were oot transported by this protein . In addition, most of the mammalian proteins
are found to be highly selective and even stereo spec ific for their substra tes [Ryan., 1990;
Ohnishietol., 1995).
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In contrast to CEIP studies.L1P can transfer lipids unidirectionally from one
lipoprotein to another [Singh and Ryan., 1991 ; Ryan et of .. 1990 ; 1986] . The rate of this
transfer processis much faster than that ofbuman CETP [Singh et al.• 1992] . PreliminaIy
cxpc:rimeotal evidence suggests that part of LTP has a functional similarity to human MTP.
It has been suggested that one of the three subunits of LIP CapoLTP-m . S5 kDa] might
function lilceprotein disulfide isomerase involved in the processof protein [subuni t] folding
and tmfolding [Brei.ter et al ., 1991J. If this is true , it would explain why LTP is so efficient
in loading hydrophobic compounds into a tightl y pack ed LOL particl e. Unlike CETP . LTP
was effective in transferrin g drug mo lecules . The advantage ofsuch transfe r is that the dru g
will be transported to the core of the LOL.
In the present study I have examinedthe capac ity of LDL particles to accep t cytotoxic
mo lecules as well as the substratespecificity of LTP-mcdiatcd transfer. The resul ts provide
evidence that the drug incorporation into LOL can be s ignifi can tly increasedand reveal a
potentially useful and improved method whereby lDL-drug conjugates can be produced from
LD L in vur o.
142
T ab le 4.1 HPLC aD_lyrica l profiles of CI
Values are the me an WIthCV less than10""' .
Profile cr-
Mobile phase 22% TIIF in acetonitrile
UV detection (wave length. nm] 254
Retention time. (minutes} 8.65
Detection limit,. (~glmL] 0.25
Linearrange , [j.1g1mLJ 1.0 to 50
% Recovery from LOL samples >95%
.
Tab le 4.1 l ater- a ad iDtraday variations or CI
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Spiked antOl.Dlt
[pglmL)
25 so 100
Inler-day va riation [iadividual va la n, pea k area! 1
Day I 23.65,24.15 49.15, 48.62 92.42, 97. 85
Day 2 28.75. 25.05 47.25, 4825 93.65, 98.75
Day 5 23.55,24.75 49.95, 5125 102.26, 99.95
Day 7 25.10, 25.46 48.75,SLl2 98.0,9925
Day 15 26.25 , 25.4 7 49.58, 52.26 97.75,9825
Mean [SO] [a -101 25.20[1.5] 49.60 [154] 97 .8 [2.87]
'YoCV[n" IO] 5.95 3.10 2.93
Two-way ANOVA
p value 0.60S 0.074 0.244
lalra-(by vari.tioa (peak areas)
Allsamplcs 23.10,24.52.25.2 7 4653 , 4752, 49.84 92.53.97.50, 103
Friday 23.51,25.42, 26.25 48.5,50.10. 52.24 96.10,95.52, 105
Mean [SO ) [0-6] 24.85 [1.2) 449.10 [2.0) 97.7 [5.25J
%CV [n-4] 4.85 4.07 5.37
pvalue 0.49 0.19 0.797
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Fipre 4.2. RadioiodiDatioD or CI. CI was radioiodinated by an isotope exchan ge
reactio n wi th Na'l'f: in a melt of pivaIic acid according to the procedure of
Weichert et al.• [1985]. Tbereaction was complete in an hour at 1550C with
no decomposition of Cl. The radiochemical yield was more than 95% with
a specific acti vity of over 2000 cpml.,ag CI.
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Figure 4.3. HPLC chromato grams of CI in chl oroform .
Figures 4.2a, Standard CI in chloroform;
Figure 4.2b. CI in LDL extracted in chloroform (recovery of CI is more than
95%].
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Peak area - -0.151 + 0.51' • Ceeceetranee, R2 =0.999
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Filure 4.3. Calibratioll tul"'Vt of peak area vtnus tonCf:utra.tioo of spiked It.ad.reI
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Figure 4.5. The erred or incubation time 00 LTP-mediatcd lipoprotein sa mp le
turbidity . HDLp [250 IJ.gof protein] and LDL [50 ~g protein] were
incu bated in the presence: of 2 Ili LIP for indicated times at 37°C.
Followin g incubation, sampl e absorbance at 40 S nm.was determin ed on a
microtiter plate read er. The results shown are the mean ::t::SD of three
determinations.
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Figure 4.6. The etrtct orL TP con«ntratioD ODlipoprotein SIImple absorban ce at 405
DID. HDLp [250 JI&protein] andLOL [SOJ1g protein} were incubatedwith
givenamount ofLTPfor60 minIt 3?OC. FolJowineincubation the40S·nm
absorbance of each sample wasdetermined. The resultsshown arc the
mean%SD ofthrcc determinations .
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Figure 4.7. SDS-PAGE o'nativeLDLaad LDL-drvg ronju gates. A 5%gcl wasnm
according to the method of Lammelli [1970). Lane l. Control LDL during
Incubati on, and Lane 2. LDL-Dox conjugates. Twenty 1J8of LDL protein
were run in the gel for each sample . In all eases, the LDL-Dox or LDL-CI
coojuga1e produced only one band indicating DO degradation of LDL during
loading [data not shown ).
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Figure 4.8. EledroDmicrographs of LDL preparations. Panel A. Native LOt; B.
LOt-Do" (prepared by the direct addition method] ; C. LDL-Do"; and D.
LDL-CI [C and D was prepared by the contact method with Tween 20]. The
LOt preparations were applied to carbonformvar membranes and ne gatively
stained with 2% phospbotungstate solution. They were examined on a
Philips EM 30 1 instrument at a magnification of7S,OOOX.
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F igure 4.9 . Pa rticle size m euurem ellt of LDL sa m ples by EM. The LDL preparation
were app lied to carbonformvar mem branes and negatively stained with 2%
phosphotun gstate solution. They were examined on a Philips EM 301
insuument a1 a magnification of7S.000x. The diameter of 100 particles were
calculatedand the results are expressed as themean ofdiameter ±SO .
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FipR 4.10. Loa diDgeflicieDcyof LTP iD ro nta ct mdbods. A. Dry film method: Drugs
(Dox. 01" CI) wac dried down on a test tube from. a chlorofonn so lution [dIy
film] and LDL was added in the presence or absence of LTP. B. Organic
solvent aided method: the dry film of the drug was so lubulized in few drops
ofetbanol and incubated with LDL in the presenceor absence of LTP. C.
Detergent aided method: the dry film. ofthe drug was suspend ed with Tween
20 [> 3% of the total volume] and incubated with LDL in the presence and
absenceofLTP . In all cases . incubatio n followed in the dark: at )7<>Cfor 12
hours und er gen tle shaking . The results are mean ±SO of at least three
determinations . The asterisks indicate statistically signifi can t differen ce
(sin gle . p<O.OS. dou ble. p<O.OOI) compared to contro l witho ut LTP .
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Figure 4.11. LodiDl efficleacy ef LTP in the dind additi on meth od. Drug [Dox.HCI
in normal saline ] were dmctI. y added to LOL samples in the presence or
abscDocof LTP. 1Dcubation foUowed at3rc for 12 boW'Sin the dark. under
gentle shaking. The amount of drug incorporated into LOL in the presence
and absence LTP was calculated and shown as mean ±SD of three
determinations .
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Figure 4.12. Loading efficiency of LTP and CETP in incorporating drugs in LDL.
Drug incorporation in LDL using LTP was described in Figures 4.7 and 4.86.
Drug incorporation using CElP was performed according to Blomhoffet al.,
{1984}. Fifty ug drugs (Dox or CI] were dried down from their chloroform
solutions with Nz"The resultant residue was dissolved in 50 J1l. of acetone
and 500 JJL of LPDP was added. After evaporation of acetone with N2• 300
~ ofPBS was added. For DoxHCl, 50 Ilg drugs were directly added to 500
ilL of LPDP followed by the addition of300 IJL of PBS . The LPDP-drug
preparation was then incubated with 500 IJ-gofLDL at 37°C for 4 hours in
the dark..The amountofdrog incorporated into LOL in the presence ofLTP
or CETP was calculated and shown as the mean ±SD of three determinations.
The double asterisks indicate statistically significant difference (p>O.5)
compared to control withoutLTP.
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Figure 4.12. UV·visible scans of Dox aDd LDL-DoI coajugates. Dox HC I was
dissolved in PBS or free Dox was dissolved in chIorofonn. DoxH CI and
Dox were SC8IUled after subtracting scans of PBS and chlorofo rm (contr ols].
respectively . LDL-Dox conjugates was scanned after subtracting LDL scan
taken as controL Panel A, LDL-Dox conjugates wi th (1) or without (2) LIF;
panel B. additionally Dox.HCl in PBS solution at different concentrations (3
and 4); and panel C, free Dox in CHell (5,6,7) and Dox .HC I in PBS (8.9 in
addition to 3,4). Not e that a shoulder around 540 WD when Dox is in CHC13>
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CHAPTER ~:
IN VITRO DELIVERY OF CYTOTOXIC DR UGS INTO TUMOR CELLS VIA
THE LDL RECEPTOR PA11IWAY
5.1. Introduction
The phy sico-c bemlcal cbaracterization of LDlAirug conjugates was described in
Chapters 2 and 3. I have demo nstrated that LDL-conjugates are biochemi cally and
biophysically similar to native LDL. In thischapter, I discuss the biological charact erization
of both free and LDL -Dox co njugates in a human cervical canc er ce ll line, HeLa.
The main path wa y of cellular recogni tion and uptake of LD L is mediated by the LDL
recepto r, which is predo minantly presen t on tumorceUs. This cellular uptake mechani sm can
be up- and do wn-regulated in response to cellular cho lestero l supply anddemand [Soutar and
Knight, 1990]. Ifthe LDL is modified. its uptake by receptor mediated processes will be less
than expect ed in tumo r cells . It must be remembered that LDL can be modifi ed by
manipul ations, such as minimal oxidation (Berlin er el oJ., 1990; 1986], sto rage. and
vortexing [Lougheed et ai ., 199 1], making it possibl e that some experiments wi th purifi ed
LDL may inadvertently invo lve a degreeof modifieation. This minute modifi cation of LDL
may not be detec table by the pbysic:ocbemical techniq ues. However, such modificati ons can
easil y be dis tinguished by ce lls in culture [Figure 1.4]. Biological eval uation of the LDL-
drug conjugates in an appropriate tumor model may further identify whether or not any
chan ges hav e occurred during the loading experiments . In my studies, the uptak e of the
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LDL-drug conjugates were evaluated by their cytot oxic effect on HeLa cells . HeLa cells
were chosen beca use they have previously been shown to specifically bind LDL by a
receptor -mediatedpa1hway[Lestavel-Delattreeto/.• 1992;lohnson et a/.• 1983]. [{LDLis
modified during the loading experiment, a decrease in uptake via LOL receptors by the cell
will be observed. I also proposed to compare the cytotoxicity of free drugs or LDL-drug
conjugates in HeLa cell s as a measure of their potencyr Ce jl cytotoxicity determination using
MIT is an acceptable method and widely used in cancer research. lbis assay is based on the
metabolic reduction of a soluble tetrazolium salt, MIT. by the mitochondrial enzyme activity
ofviab le tumor cells into an inso luble colored formazan product. Thi s prod uct is measured
spectrophotometricall y after disso lution in DMSO [Ford et a1., 1989 ; Alley et al. , 1988;
Carmi chael et al•. 1987] . The colorimetric assay has the advantages of bein g safer . less
costly and sim pler than the radiom etric assays.
I hypothesize that Dox will be selectively transported by the carrier . LDL, into the
ce ll muc h faster than the free drug, whi ch does not have any carri er . Free drugs will be
transferred inside the cell only by diffusion. If this is true , the cytotoxicity ofthc LDL-dtug
conjugate will be more pronounced compared to the free drug and will be proportional to the
efficiency of the carri er in transferring the dru g insid e the cell . The cellular uptake ofLDL
by the recep tor mediated processes are subjec t to up- and. downregulation, as desc ribed in
Chapter I, section 1.5.3. lithe cytotoxicity of the LDL-drug conjugate can also be similarly
modulated in cells, this \WI strengthen the hypothesi s that LDL carri ed the molecules inside
the cells . To prove my hypo thesis, thischapter describes cell cyto toxicity studies ofDox in
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HeLa ce lls using MTf. Additionally, the carrier efficiency of LDL to deliver Dox and in to
the cells was compared with carrier-free or existing formulations offree Dox:.
5.2. Materials and meth ods
5.2.1. Mat eri als
HumanLDL, LPDP.and Doxwere described in Chap ters 3 and 4. MIT [M2128]
and DMSO were purchasedfrom Sigma [81. Louis. MOl. Filters [0.2 um] were from
Millipore. MIT was dissolved in PBS at a concentration 0[0.5 mglmL, sterile filtered and
sto red in a dark enviro nment at 4°C for up to a maximum of 1 week . Drug or LDL-drug
conjugate dilutions were prepared in the cell culture medium [range, 0.00 1- 40 ug/ml.] .
5.2.2. Preparation of LDL-Drug conju gat es
Dox-LDL drug conjugates were prepared using the direct addition method as
mentioned in Chapters 3 and 4. The LDL conjugates were fully characterized using
biochemical and biophysical techniques as detailed in those chapters.
5.2.3. Cell cul ture
HeLa cells, were gifts from Professor Alan Pater [Facul ty of Medicine . Memorial
University ofNewfoundland, St. John's, Canada}. Cells were grown in Dulbecco's modified
Eagle 's medium [DMEM] supplemented with 2 mM Lcglutamine, 0.1 mM nonessenti al
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amino acids. 0.08 % (wlw], 2 % sodium bicarbonate., 10% heat inactivated fetal calf serum
[FCS ] [GIBCO] plus 0.2 mg/mL streptomycin and200 nJ/mL peni cillin G. Cells were
maintained at 37"C and gassed with 4% [vlv] CO2 in air. Thedoub ling time was 27 ± 1.5
hours [mean :t: SEM] . For all experiments. exponentially growing cells were used.
5.2.4. Dete rmination of t)'tocoIkity
Cyto toxicity of free drug or LDlAirug form ulations was conducted by the meth od of
Ford et aJ.• [1989] and Carmic hae l et af ., (1987) with minor modifications.
l. Under stcri lc conditions, 100 I-l1. cf'the cell suspensi on (Sx 10' cells] harvested from
log -phas e growth were seeded into 96 flat well botto med plates. Three types of
media were emp loyed, standard media as listed above, media containing LP DP
insteadof FCS and the FCS supp lemented media with IS Jlg!mL ofan extra LO L-
2. The p lates were incubated for 24 bows as above.
3. Medi um was removed from the cells and test dilutions were added in l00...r. fresh
medium . Under sterile conditions, medium was aspirated by a microti.tre pipette
from the wells and doubling dilutio ns ofDox or LDL-Dox co nj ugalcs were added in
a volume of 100 J.1L CO each well. The test was performed in quadruplicate for each
dilution. with appro priate con tro l we lls that received 100 IJ.Lmedium or LO L only.
The pla tes were incubated for 48 hours [step 2].
4. The medium was aspirated as discussed above and each well washed twice with
sterile PBS [200 !-LL] at RT. One hundred lolL of medium was then added to eachwell
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and a 24 hour recovery period followed.
5. Following removal of the medium by aspiration under sterile conditions after
reco very , MIT solution [100 J.tL 1was added to each we ll. A 4 hour incubation
period in the humi dified incuba tor at 37 °C followed.
6. After incubation, medium was aspirated from each well, DMSO [100 1J.l!we1l] was
added. the plates gently shaken andthe absorbance ofthe well measure d at 570 and
630 om using aBiotekEL310 EIA plate reader. Absorbance at 630 om was used as
the referenc e wavelength for detecting artifacts in the plastic plates and was
subtrac ted from the S70-nm values. The mean absorbance for these wells was
subtracted from the absorbance values in the other wells. Tests using LDL and LPD P
were conducted in the same manner .
8. Results from the plate reader were expressed as follows :
% Cell survival aJ each dilution = Mean absorbance at each dilution x 100
Mean control absorbance
9. A dose response curve of %cell survival [ordinate] against drug concentration
[abscissa] was constructed. The ICsovalue was calcula ted from the plot.
5.2.5. Statis tical a nalysis
For statistical evaluation of the data, one way ANOVA for multiple gro ups and the
t-tesr for two groups was performed to compare between/amo ng groups with the calculation
ofp values. All values are expressed in mean ±SEM .
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5.3. Results
5.3.1. Ph ysico-chemical ch aracterization of LDL-drug co njugates
I have characterized the LDL-Dox conjugates as mentioned in Chapters 3 and 4. The
drug loading capacity of the conjugates were complimentary to my previous results as
mentioned in Figure 2.1 1 and Tab le 5.1. Similar results were obtained when the samples
were analyzed by 80S-PAGE [as shown in Figure 3.4], EM [as shown in Figures 3.3 and
3.4), and DSC [as shown in Figure 4.7] and Table 5.1.
5.3.2. Cytotoxicity ofLDL-drug conj ugat es
Th e cytotoxici ty ef'Dox, and LDL -Dox conjugates. was studied in tenus ofo/oeeU
survival in HeLa cells. The dose response curves are plotted in Figure 5.1. Figure 5.1 shows
the cytotoxicity of different fonnulations of Dox on Hela cells. Free Dox in its existing
formulations was the least effective compare d to LDL-Do x formulations. The cytotoxic
parameter, ICsovalue, for Dox was found to be 1 J,lglmL which is at least 6-fold higher than
any LDL formulations. I~ values for different formulatlcns were found to be 0.055 , 0.142,
and 0.173 J.lglmL in down- , normal, and up-regulated cells [fable 5.2J [one way ANOVA
p value<a.OS]. There was a statistically significant difference in up- and down-regulated
cell s [paired t-test p values for up- and down regulated cells compared to normal cells
were<a.S]. Theoretically, cellular uptake of LDL should be down-regulated by fasting cell s
overnight. Cell s were incubated in LPDP instead ofFCS to upregulate LDL receptor activity
l7l
in cells. After fasting , when LDL was supplied in the form ofLDL-drug conjugates, cellular
uptake ofLDL-drug conjugates were increased relative to normal ce lls . The comparative
cellular uptake ofLDL-drug conjugate s could be inferred using th e cytotoxicity pro files of
the different formulations. If the cellular uptake of the cytotoxic drug is increased, a
correspondingly increased cytotoxic effect should be observed. Indeed, the ICsovalue ofDox
in up-regu1atedcells were 2.58 -fold bigherthan normal ce lls (p<O.05] . Likewise, the cellular
uptake ofLDL coul d be down-regulated by incu bating ce lls in the presence of excess LOL.
A higher ICsovalue for LDL-drug conj ugates in down -regul ated cells is expected compared
to the normal ce lls. A sligh tly higher but statistically significant [t-test p<O.05] I~ value
[0.173 l!g/mL ] in up-regulated cells was observed co mpared to normal cells [0.142 ~g1mLl
for Dox [p<O.05]. This implies that upregulation of the cell is a more effective way in
increas ing LDL receptor activity. Forthe LDL-Dox formulation, the highest cytotoxic effect
was observed in up-regulated cells [lew = 0.055 ).lglmL] which is almost 20-fo ld more
cyto toxic than free Dox [ lese= 1.0 J.l.g/mL] (p<O.OOI]. Free Dox had no signifi can t effect
in up- or down regula ted cells when compared. to norm al ce lls (p> 0.05] [data not shown].
The native LDL in the same LDL protein concentration range had no effect on ce ll growth.
Thedifference in cytotoxic effects is more pronounced among the LDL form ulations at lower
concentrations [Figure 5.1 ].
It can thus be note d that the cytotoxic activity of the LDL conjugates is 6-fold highe r
than that of freedru g depending on the cellular concentrations ofLDL rec eptors. Th e leso
of Dox fell 18-fo ld when transpo rted within LDL , illustrating the ability of the LDL to
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potentiate the action of Creedrug.
5.4. Discussion
Theresults presented in this study support the findings that HeLa cells internalized
LOL drug preparations by receptor-mediated processes (Lestavel-Delattre et al.• 1992;
Johnson et al., 1983]. If the drug is tightly bound to LOr.. then excess native LOL should
compete with the conjugate for binding to the LDL receptor and, hence, reduce uptake and
toxicity ofthe conjugate. The LOL receptor mediated uptake was confirmed by the up- and
downregulation effects caused by a large excess ofLDL or LPDP in the media in addition
to normal constituents. I have demonstrated that this receptor mediated process could be
used to dclivercytotoxic agents to cells. This method is especially important for drugs which
need to be transported inside the cells to exert their cytotoxic effects. Dox, is unique in
inducing cytotoxicity even without entering inside the cells [Tritton and Yee, 1983]. lf the
drug does not enter the cell, cytotoxicity to cells is negligible. Free Dox is effective in
inducing cytotoxicity in cells without actually entering the cells . However, I inferred from
my data that Dox action inside cells, perhaps by DNA intercalating, inducing of
topoisomerase ITmediated DNA cleavage, inhibiting of background DNA cleavage, seems
to be more effective than its action at the cell surface [Bodley et al .; 1989]. This view is in
agreement with previous findings related to the site of action of Do x [Bodley et aI., 1989].
I propose that LDL can be used to deliver drugs more effectively into the cell .
The LDL receptor-mediated endocytosis of cytotoxic LDL-drug might provide
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distinct advantag es over the trapping of antiDeopl asti c: drugs in artifi cial carriers. The main
reason for this statcmeo1 is that utificial c:aniers are subj ected to dc:struc:tionby blood borne
co mpo nents. primarily by lipoproteins (Rohrer eroJ., 1990] and to fast clearance from the
circul ation by the RES [Suits et aI... 1989]. Sin ce the loading of tbe particles with drug
molecules does DOt infl uence the receptor recognition of tbc protein co mpone:ot af W £..this
preparation is expected to follow the in vivo fate of native LDL particles in animal or human
studies. This is very important. as the use of LO L as a drug carrier depends on the
preservation ofpartidc characteristics such as receptor recognition and RES avoidance. If
the physical properties o f the core lipids of LDL is disturbed during dru g loadin g, e.g., a
change in fluidity of core , a premature drug leakag e into the systemic circulation may occur
and much of the drog will be released before the LDL-drug conj ugates reach the target site.
In the case ofLDLs, the fluidity oftbe core is therefore important as it infl uence the drug
release ltincti.cs and~by detc:nnines iftbe carrier can be used for any drug targc tiDgor if
only the dep leted carri er will reac h the target tissue [Weslcsen et aJ...1995] . The present
study indicates tha t in favon.blc eases, such as loading with the anticancer dru g. the
characteristics aCthe LO L stIuCtW'e and its dynamic properties are preserved in addition the
inco rpo rati on of signifi cant and effective amounts of dru g. Thi s present stud y also
de mo nstrates that cyto toxic drug s can be modified. inco rporated into LO L and selectively
deli vered to cells by LO L receptors in vitro.
It is essential to realize that the effective use ofLDL as a targeting vehicle in medical
practice will require the use of a drug substance with high cytot oxic activity. Unde r normal
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i n vi\Io conditions. the LOL receptor can be down-regul.ated by the native LOL in theblood
stream [Goldstcin et al .. 1977]. lDL4ugconjugatcS arc diluted by the native LOr.. which
will compete for the binding sites on the receptor . This problem might, in part, be dealt with
by downregulation of receptors in patients as discussed in Chapter I. I demonstrated that
downre gulation of LO L receptors does not significantly effe ct cytotoxicity of LDL-drug
co njugates. This has been demonstrated in hwnan studies by Filipoeska et al ., [1992] .
However , in light of these coDSiderations. it is obvious that the l o-fold increase in cytotoxic
activity obtainedby the new formulations presented in thisstudy . is a significant progress in
the field of drug delivery targeting using LOL or lipid emulsions.
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Table 5.1. Physico-chemical chancteristics ofLDf...Dox cODjugates used in HeL a
«u.
Features ofLDL.drug conjugates Mean value ±SEM
Dru g loadin g capac ity 47.06 ± 3.10
[Jlg ofdruglmg ofLDL protein]
Ratio of choleste rol to protein 1.7 :1:: 0.20
Apo B integrity from 80S-PAGE [no. of bands observed} Single
Particle size from EM, [nm] 22.12 ± 0.12
Transiti on enthal py [KJlkg of protein] calculated from DSC 1.474 ± 0.1I
thermograms]
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T ab le 5.2. l e w· values for cytotoxicity or HeL. cells tnated with fr ee DOI or L DL-
DoI. con ju gat es
Formulations ICsob. (lJ.g/mL] in HeLa cells
Normal I Up-regulated I Down-regulated
Free Dox 1.00:1::0.2 I 0.85 :1:0.13 I 1.12 :1:: 0.121
LDL·Dox conjugates 0.142 :1:0.01 I 0.055 :1::0.01 I 0.173 ±0.04
• Concentration required to reduce cell survival of He La cells to SO%.
b 5 X 10 4 cells were plated in 96 wells sterile microtitre plates and after 24 hour cultures
were exposed to varying concentrations of drug formulations for 48 hows. Plate s were then
rinsed with PBS and 200 ilL fresh growth medium was added. Afte r 24 hour cell
cytotoxicity was determined with MIT. I~ value s were calculated from three separate
experiments. each performed in quadru plicate.
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F igure 5.1. Cytotoxie effect urthe Dos: and LDL-Dox conjugates on Dormal, up- and
down-regulated B eLa cells . Cells (5 X 10' ] were incu bated at 37°C with
the Dox or LDL-Dox conjugates in doubling dilutions. The cells were
sampl ed aft er 24 hour incu bation and followed by washing twice with PBS
and cytoto xicity wascounted using the MIT assay as mentioned in Materials
and methods. The cytotoxicity of'Dox in normal, up- and down-regulated
cells were compara ble and only the cytotoxicity Of OoXOD normal cells are
shown in the figure for clarity . Each point is the mean ± SEM of four
detenninations in two independent experiments .
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CHAPTER 6:
IN VITRO EVALUATION OF MODIFIED LDL.DRUG CONJUGATES ON
MACROPHAGES
6.1. Introduction
Macropbages [M~I are bone marrow-derived mononuclear cells wi th established
roles in host protection against facultative and obligate bacterial path ogens (Edwards et aI.,
1986; Adams and Hamilton. 1984], virus es [Kofi' et al., 1985; Ishihara et al.• 1985J,
protozoan parasites [Wirth and Kierszenbaum, 1988], and neoplastic cells [Shaw et al. , 1988;
Adams and Hamilton. 1985,]. They belong to the mononuclear phag ocyti c system [MPS},
which includes the Kupffercclls in the liver, alveolar. sp lenic, lymph node, and bone marrow
McP, tissue bistiocytes, and circulatory blood mon ocytes . However. M¢l are not
constitutively compe tent to destroy pathoge nic organisms or neoplastic cells . They take up
ljpoprote ia-bound cholesterol either by phagocytosis ofwbole cells or membrane fragments
or via receptor-mediated endocyto sis of plasma lipoproteins. Although LDL receptors are
present on a variety of cell types, normal tissue M<pexpres s few receptors for native LOL
[Goldstein et aI.• 1980] and takeup native LDL very slowly in vitro (Brown and Gol dstein,
1983; Goldstein et ai., 1979). In contrast, LDL that has been reacted with acetic anh ydride
in vitro to form AcL DL is taken up rapidly by a scavenger-receptor medi ated endocytotic
pathway inM~ [Shaw et al., 1988; Pitas et aI., 1985; Brown and Goldstein., 1983; Johnson
et aI., 1983; Goldstein et al.; 1980; 1979 ;). This pathway is functional in M~, blood
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monocytes, sinusoidal endothelial cells. and to a lesser extent.microvascular endothelial
cells [Pitas et al .• 1985; Via eroJ.. 1985; Voyta et oJ.. 1984; Brown and Goldstein, 1983;
Nagelketkc et aI.. 1983] . The i" viw>functio n of the AcLDL pathway has been suggested
to be the scavenger system for LOLs thai: are modified by oxidation products of arachidonic
acid [Brown andGoldstein. 1983; Goldsteinel oJ. 19791andIorto play a role in M4>-induccd
inflammati on [Brown and Goldstein. 19 83]
As indicated earlier the scavenger recept or existson a restricted nwn ber ofcell types,
thereby offering a distinct targeting advantage over the LOt receptor syst em [Matsum oto et
aJ., 1990; Shaw et ai., 1987]. Thi s receptor is a 260 kDa, tryp sin-sensitive glyco protein
[Shaw et al.; 1987]. These receptors bind negatively charged lipoproteins and parti cipate in
the removal of altered lipoproteins (AcLDL] from the circulation [Basu et al., 1976]. LDt
will DOt bind the scavenger receptor and docs not interfere wi th AcLDL uptake by Mil>[Shaw
et oJ.. 1988; 1987 ; Brown and Goldstein,. 1983]. AcLDL bas been proposed as a carrier 10
deliver drugs specifically to M$ [Shaw eta!.. 1987]. Liposomcs have also been proposed
as a carrier for delivering drugs [such as immunomodulators] in M4' diseases (Schwendc:Der
eral .. 1984; Rahman et m.. 1982]. Drug delivery through liposomes to M¢l doesDOt have
any targeting advantages [poste et aJ.. 1982]. Liposomesintcraet with a variety ofeeU types
and are therefore nonspecific for M4'. Furthermore . they are often unabl e to pass through the
vasc ular endotheli um . Hence they bypass resident tissues or tumor associated M¢I. As a
drug carrier. AcLDL prese nts some ad vantages in compariso n with lipo somc s: [I] AcLDL
measures 21 om and is smaller than the majori ty ofliposomes. and therefore may provide
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better infiltration into the different tissues than liposomes; [ii ] AcLDL binds only with cells
presenting the scavenger receptor and does not bind with other cells as do liposomes. This
increases the specificity oftbe target and may decrease the toxicity of the drugs [Hossaini et
al., I994J . Furthermore, it is now possible to incorporat e a number oflipophilic drugs into
LDLorAcLDL [Hossaini et al, 1994; Shaw et al. 1987, 1988 ; Yanovich er cf. , 1984].
Histocytic malignancies are aggressive neoplastic diseases which affect the cells of
the MPS and are usually fatal if untreated. Dox is commonly used in the treatment of
histiocytic malignancies [Buzdar et aI.• 1985J. I have demonstrated that Dox can be loaded
in LDL and the LDL-Dox conjugates were Zo-fold more effective than free Dox in killing
HeLa cells . Since the scavenger receptor system is known to be pres ent primaril y on the
cells of the M4J. it may be possib le to achieve selective delivery of antitumor agents to the
neop lastic ce lls in histiocytic malignancies through these receptors. Recently, it hasbeen
demonstrated that the scavenger receptor-mediated delivery ofDNM elicits selective toxicity
towards murine neoplastic cells of macrophage lineage whereas receptor negative cells
remain unaffected. both-in vuro and in vivo [Basuet a1., 1994; Mukhopadhyay et a1., 1993;
1992].
It is important to establish the efficacy of AcLDL-drug co njugates in an appropriate
model system as a prelude to determining the feasibility of extending this approach to human
malignancies or infections of macrophage origin . In this study,l propose to deliver OOK
using AcLDL as the carrier. The efficacy ofAcLDL-drug conjugates in terms oftargeti.ng
potential will examined in a well characterized mouse macrophage cell line, 1774.Al. In
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additi on, normal LDL-drug conjugates will be used to compare the selectivity of modified
LDL over normal LDL-dru g conjugales.
6.1. MaterUib .ad meth ods
6~1. M.tcrUb
Dox, LOL, LDL -Dox.. MIT, and. DMSO have been described in the previous
chapters.
6.2.2 . Acetylation of LDL
The LOL was acetylated with the repeated additio n of acetic anh ydride as described
by Dasu e/al . [1976] and dialyzed for 36bours at40C againstPBS. Turbidity oftbesolution
was removed by centrifugation (1000x g. 10 minutes ]. Sterile filtratio n using the Millipore
membrane filter [0.20 !Jm pore size ] was doneto make the final preparati on. AcLDL was
stored at 2_8°C for no more than two weeks before use .
6.2.3. PRp....tion of AcDlrdrug conjugates
The drug loadin g procedure was essential ly the same as descri bed previously in
Chapter 2. Dox was incubated by the direct addition method. AcLDL-drug conjugates were
characterized by 80S-PAGE , EM, and DSC as described in Chapter 3.
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6.204. CeUculture
Mouse M4I ce lls, m 4.A l. were grown in DMEM supplemented with 2 mM L-
glutamine, 0.1 mM nonessential amino acids, 0.0 8% (wIw) sodium bicarbo nate, 10% beat
inactivated FCS plus 0.2 mglmL strepto mycin and 200 nJ/mL penicillin G. Cells were
maintainedat 37'"C and gassedwith 4% [vlv] COl in air. For all experiments, exponen tially
growin g cells were used . Ce lls were seed ed in 96 well micro titre pla tes at a density of5 x
10' ceUslweU. Forty eight boun afterseeding, the growth medium was replacedby medium.
containing a 10% hwnan LPDP or LOL [IS JIgprot einlmL] . Th ese cells were cultured for
a further 24 hours and used for cytotoxic stud ies. Henceforth, 1774 .Al cells cultured with
LPDP or LDL will be referred to as up. or down-regulated J714.A l cells. respectively.
Nanna! cells were grown in standard medium. as mentioned earlier.
6.2.5. Dctermioati oa of cytotoxicity
The procedure was essential ly the same as descnbcd in Chapter5, section52.4, with
minor modifi cations. Briefl y, cells harv ested from log-phase gro wth were seededinto 96-
well flar-bonocsed plates at 5 x 10' cells/well. Free drug, LD L-dru g. and AcLDL.<frug
formulations were then added to the plates at doubling dilutions. After 48 hours exposure
to the drug s, the cells were washed twice and fresh media was added. Ce lls were incuba ted
until the control cells reachedconfluence. At this point 100 J1LMIT so lution [0.5 mglmL }
was added to eacb well and the cells were incubate d in the dark for 4 hours at 37°C. Aft cr
incubation, DMSO (l OOIJ.Uwe ll] was added,. the plates gently shak:.cnand thc absorban ce of
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the well measured at 570 and 630 am using an ELISA plate read er. Cytoto xicity was
measured as described in Chapter 5 [section 2.4].
6.3. R esults
6.3.1. Effi ciency of drug incorp orated in to AeL DL
The MW ofDox is 543 dalton [Da]. LDL mo lecules contain onl y one apo B protein
[Kostner and Laggner , 1989] and its MW is 543 kDa. I calculated that one AcLDL particle
incorporated 44 ::l:: 10 molecules ofDox [n~5 assays].
6.3.2. Characte riza tion o f AcLDL-d rug conjuga tes
T o study the sto ichio metry of the incorporation procedure. I added varying amounts
of the drug to fixed amounts ofAcLDL . Results were similar to that observed for LDL-drug
co njugates . As the amount ofdrug was increased, the drug to AcLDL prot ein ratio of the
complex increased until a plateau at approximately 44 molecules per AcLDL particle fur Dox
was approached [Figure 6.1]. HPLC analysis revealed that Dox constituted more than 95%
of the incorporated drug [Dox] which indicated stability of the Dox during processing and
within LOL. This indicates that Dox is as stable in AcLDL as it is in native LOL. The
electrophoretic mobili ty of AcLDL-drug conjugates was similar to AcLDL on denaturing
15% pol yacry lamide electrophoresis gel. indicating that both particles had an identical size .
No apo B fragmentation in the gel was visualized [Figure 62]. This sugg ests that the loadin g
I8S
procedure did oot change the native integrity of the apo B protein. Particle size
measurements by EM revealed thatthe conjugates preparedby the CIDTtD1 method bad almost
the same size as tbcnative LDL [Figure 6.3J. AcLDL-Dox was found to be 23 ± 1.2 om.in
diameter. Figure 6.4 sbows electron micrographs of Dative WI., AcLDL, and AcWL-Dox
conjugateSpreparedby the indicated methods. All AcLDL or AcLDL-drug conjugates show
similar morphologies to native LDL. Theseresults indicate that there is no differeoce in
physicochemical behavior ofdrug loaded LOL or AcLDL using my expe rimental protocols.
6.3.3 . Cytotoxicity of AcLDL-drug eonj uga tes
The biological activity of AcLDL-dru g co njugates was studied in vitro in JTI4 .Al
M$ . The selectivity of AcLDL-drug conjugates was compared to free dnIgs and normal
LDL-drug conjugates. The dose response curves plotted in Figure 6.5 shows that
cytotoxicity ofOox., LDL-Dox.,and AcL DL-Dox conjugates in normal cells . AcLDL-Dox
conjugates dearly show a much higher activity than the other formulations [fabl e 6.1]. Ie.
values obtained for AcLDL-Oox., LDL-Dox, and free Dox formulations were compared
[Tabl e 6. 1]. AclDL-Dox conjugates sbowed at least 3· 5 times more cytotoxicity than native
LOL-Dox conjugates (p<O.OOI] which was again 7 times lower for cytotoxicity compared
to freeDox [p<tH>O I]. The IC)Ooftbe Dox fell from 0.04 to O.026 11g/rnL [> 15 fold ] when
transported within AcLD L and to 0.008 4 [4.7 fold] when transported in native LDL.
The native AcL DL, which was in the same AcLDL protein concentration range, had
no effect on the ce ll growth. The cytotoxic efficacy is more pronounced at low concentrations
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for AcLDL-Dox conjugates.
6.3.4. Uptake of A£LDL-drug conjugates by u p--and down-regulated «Us
The scavenger receptor mediated uptake was studied by examining the up- and the
downregulation cells on the cellular uptake of LOL formulations. M$ predominantly
express the scavenger receptor which cannot be modulated like the LDL receptor by the use
ofLDL or LPDP in the media as mentioned in Chapter 5. Since the expression of the LDL
recepto r is minimal, a significant increase in cytotoxic effects for LDL-drug conjugates by
modulating cells via up- or downregulation of receptor would not be expected. Indeed, cells
did not show any change in cytotoxicity in the different media for free drugs and AcLDL
formulations (Table 6.1]. When the cells were down -regulated no statistically significant
difference between the efficacy ofDox or AcLDL-drug conjugates were observed [p>O.OS].
For the LDL-drug formulation a higher cytotoxicity was observed when cells were up-
regulat ed using LPDP in the growth medium . However , only minimal modulation [1.728
fold] in the ICsovalues was observed. This suggests that 1774.Al cells express a limited
number of the LDL receptors but express predominantly scavenger receptors. The WL-drug
conjugates were more effective thanthe free drug s, indicating that the LDL receptor pathwa y
is more efficient than the free drug formulations. As expected, a low uptake of the LDL
preparations was observed for the down-regulated cell s compared to the up-regulated cells .
187
6.4 . DiscuSlIIion
Much work has been done on the various modifications that can affect LDL , and on
their consequences for its recognition, uptake and degradation by Mcfl, endothelial cell s and
smooth muscl e cells. The se modifications are thought to be primaril y oxidative in origin
[Witzman and Steinberg, 1991]. and to be mediated by endothelial and smo oth muscle: cells
either via lipoxygenase [parthasarathy er al. , 1989] or iron-catalyzed peroxidation [Heinecke
et ai. , 1984]. The modifi cations include acylation oflysin e e-amino groups [Steinbrecher,
1987], increased levels oflysolecithin [parthasarathy et aI., 1985], increase in thiobarbuturic
acid-relative substances [Bonnefont er al .; 19891. aggregation of the lipoprotein particl es
{Hoffet aI., 1992] and cross-linking or fragmentation of the apo B polypeptide [Fong et al .,
1987] .
ModifiedAcLDL is taken up by cells mainly by two mechanisms: [1] The sca venger
receptors present on M41 and endothelial cells, which recognize AcLDL that has bad a certain
proportion a f it e-aminc group s modified to increase its net negative charge (Zhang et al .,
1993J; tw o variants have bee n cloned and sequenced [Kodam a et al., 1992, Rohrer et al.,
1990] ; and [2} the ape a -media ted macrophage AcLDL phag ocytosis mechanism [Suits et
al., 1989], which is thought to take up AcLDL that bas been less severel y modified and is
more likely to aggregate . The two mechanisms do Dot appear to downregulate and M~ can
thereby become overloaded with lipid and cholesterol [both esterified and free], eventuall y
becoming foam cells.
It must be remembered that LDL can be modified by manipulations, such as minimal
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oxidation [Berlineret oJ•• 1990; 1986], storage andvortexing [Khoo et al .. 198B], making
it possible that some experiments with purified lipoprotein may involve a degree of
modification. Conjugates and complexes of various drugs with LOL [Halbert et oJ.. 1985,
Lundberg. 1987] have been posndatcd as delivery vehicles to tumors but the relative lack of
success bas been accounted for in the case of complexes by the lack of stability and. in the
case ofconjugates, by the switch in affinity towards M4l' [Schultis et al., 1991].
The current study indicates that AcLD~g conj ugates are effective in deliverin g
lipo phil ic cyt otoxic drugs to Mil>. Although Mcflpossess receptors for the native LOL, the
uptak e and degradation of AcLDL occ urs at rates approximately 20- fold greater thanL OL
(Brown andGo ldstein, 1983; Gol dstein et al.• 1979) . How ever . in my studies, the AcLDL
pa thway was found to be less effec tive which was 3.2-fo ld higher than the native LOL
pathway in case ofDox conjugates, This may be due to the difference in cell line or the dru g
candidates. It was demoostrated that drug loading into the AcL DL panicl es does not alter
its specificity or binding for M41[Shaw et al.. 1988J. My demonstration that the cytotoxicity
of the AcLDL-dtug conjugates was not completely inhibited by native LDL suggests that the
intetaet:ion of AcLDL occurs by means of the scavenger receptor. Cytotoxicity studies
performed with m4.A1 cell s demonstrate the ability to induce cytotoxicity by the AcLDL
in vitro. Delivery ofthc dru gs using native LDL also led to enhanced cytotoxicity. However,
the nonspec ific uptake of drugs , in the case of the free dru g formulations, was foun d to be
least effective com pare d to nati ve or modified LD L fonnulations.
M$ exist non naUy in various stages of fun ction al activation as heteroge nous
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populations within the body [Fogelman et aJ.. 1990; 1980; Johnson et al.. 1982; Sorg , 1982 ;
Miller and Morahan, 1982] . Although the specific delivery of cytotoxic agents to
oonactivazedM$ bas obvious tberapeuticpossib ilities.,delivery to fuoctiODalJ.y activated M$
in vivo may alsobe useful in light offindings that y~interferonand mmamyl dipeptide can
act synergistically in activating the tumoricidal properties of mouse M41 [Saiki and
Fidlcr .19 85].
It is not clear bow AcL DL-drug co njugat es wil l function in 1100 in the reducing the
tumor mass and preventing metastasis. However, AcLDL drug conjugates have:been found
to be more effective in mice on some oncogenic viruses compared to, freedrugs. lipophil ic
deri vatives or liposomal preparations (Dietrichet al ., 1986; Ikeda et aI., 1985; Ishihara et af .•
1985; Koffet al ., 1985 ; Canonico et a/., 1984; Mashihi el al., 1984; Kotani et aI., 1983].
TheAcLDL conjugate is completely soluble in aqueous solutions and represents an
optically c lear, yeUow, apoproteiIH:oated oaooemulsion. Thesmall size and watc:r so lubility
of the packaged lipophili c drug particle conjugates will provide distinct advantages when
tested in vivo . Scver:aJ.lines of ;n vitro evidence suggest that the: coqjugates remain. tightl y
associated, a criterion absol utely essential for use of the LDL-drug conjugates in vivo.
During cytotoxic assays. the efficacy ofAcLDlAirug conjugates was maintained even in the
presence ofa large excess of LDL. Exchange ofdrog from AcLDL-drug conj ugates to LDL
or leakage ofdru g fro m AcLDL to the medi um. shoul d have lowered the cyto toxicity of the
Ac LDlAhug conju gates . In my studies no such depression ofcyto toxi c effect was ob served.
Moreover . I have dem onstrated with LDL-drug conjugates in Chapters 2 and 3 that leakage
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or exchange ofdrug from LDL-drug conjugates was nomimal,
I have shown that the AcLDL allows specific targeting to M~. However, the AcLDL
is removed from the circulation by the sinusoidal endothelial ce lls ofthe liver, sp leen. bone
marrow, adrenal glands and ovary. The other endothelial cells [of arteries, veins , or
capillaries of the heart, testes, kidney , brain, adipose tissue . and duodenum] did Dot
endocytose AcLDL {Soutar and Knight, 1990]. The specific uptake of AcLDL by sinusoidal
endothelia co uld reflect the requirement for cholesterol: in the ovary and adrenal glands for
hormone produ ction, in the spleen and bone marrow for blood ce ll membrane, and in the
liver for bile production [Soutar and Knight, 1990J. One has to assume that, in vivo,
administIation ofbile acids could decrease the requirement ofcho lesterol and the refore the
clearance of AcLDL by the liver endothelial cells . However, this limitation for targeting
drugs to M4tcan bean advantage if the drug is released from endothe lial cells to the live r,
spleen and bone marrow cells tha t contain putative target M4>for mY. In addition, since it
was recently shown that human live r endothelial cells are potential target cells for mvand
can play a role in the pathophysiology of AID S (Sun et al ., 1992], one can propose to use
AcLDL for anti-IDV drug targeting to these cells . Mifl are described as susceptible targets,
and persistent reservoirs for IDV, and key imm uno modulatory elements that contro l the
extent of AIDS [Zhang et a/., 1993J. On the other hand.it has been described tha t efficient
viral replicatio n in Mcfldepe nds on both cell activation and differentiation [Kodama et ai .;
1990], and this is known to increase the number ofscave nger receptors for AcLDL at the cell
surface [Rohrer et aI., 1990, Suits et a/., 1989] . Consequently, the use of the AcL DL
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receptor-mediated endocytosis for anti-ffiV drug wgeting appearsanractive . Finally, Ifthe
increase of AcLDL eodocytosis in some CD4 monocytcs reflects functional abnormalities
of M41in later stages of tbc disease, It may be propi tious to use AcLD L to cany drugs to
these cells to resto re at' stim ulate their functi ons [Juompan et al .; 1995).
AcWL particl es appear to bave potential for de livery ofcytotoxic agents. A distinct
targeting advantage can be gained with the AcLDL receptor as it is not subject to feedback
inhibition andresides on a restricted number of cell types, primarily M<fl. monocyte s, and
endothelial cells . Enhanced site delivery to M¢t would beexpec ted to increase the efficacy
of the compound in question whi le simultane ously lowering its toxicity or und es ired side
effec ts generated from interactions with non-M¢t. The AclDL parti cles themselves are
nonimmunogenic, do not alter the physicochemical stabili ty of the incorporated drug[ s1, and
are capab le of associating with a significant quantity of drug.. The combination ofspecificity
o n the part of both the dru g and its carri er provides a useful approach for the therapeutic
manage ment ofdisease states .
In summary, this stud y hasdemonstrated that ActOr.. exhibi ts sui tab le physi cal
propeni es can be used to iDcrease the deli very of Dox to M¢t or macrophage tum ors
expressing AcLDL recepto rs, with cytotoxic consequences. More importantly , such
inc reases result in enhanced therapeutic indices o f tbe drug s compared to that achievable
with the corresponding free drug . The AcL OL based formulations are expected 10 be more
tolerable beca use of its simi larity in physico-cl\emi cal characteristics to na tive LOL
[Filipowska et at. 1992]. Thus , the com bination of increased drug delivery for WL and
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increased tolerated dru g doses for AcL DL based formulations shoul d result in higher
therapeutic benefits in cancer and/ or AIDS treatment, respec tivel y.
It is reasonable to suggest that signifi can t targeting of AcL DL-Dox. by means of
scavenger receptors. to M¢l and to a lesser extent arterial endothelial cells [Voyta et aI..
1984 ; Fogelman et aI.. 1980; Brown and Goldstein. 1979 ] might beanti cipa ted. However,
th e desired drug efficacy associated with tumo ricidal activation by AcL DlAIrug conju gates
should be highly confined to Mill cell types, as these cell types express predominantly
scavenger receptors. Consequently, the combination ofspc:cificity on the part ofboth the
drug and its carrier for • particulartissue oc cell type may provide a useful general approach
for drug targeting and the therapeuti c management of disease states.
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Table 6.1. Ie,.- values for cytotoUcity l.a J 774.Al cclb treated with di.fl'erut
formulati ons
Compound ICso· in J774.Al cells
Normal Up- Down -
regulated regulated
Frec:Dox 0.04 0.036 0.044
LDL-Dox conjugates 0.008 0.009 0.005
AcLDL-Dox conjugates 0.003 0.0026 0.0032
• Concentration required to reduce cell survival of m4.AI cells to 50% .
·5 X 10' cells were plated in 96 wells sterilemicrotiter plates and after 24 hour cultures were
exposed to varying concentrations of each drug for 1 hour. Plates were then rinsedwith PBS
and 200J,ll. fresh growth medium was added. Cell cytotoxicity after 24 hour incubati on was
determined wi th MIT. 1<;0 values were calculated from two separate experiments. each
performed in duplicate. Values arc the mean of four determinations in three independent
experiments with a CV less than 20%. Note that the values in DOIID.a1. up- and down -
regulated cells for Free Dox and AcLD L-Do x conjugates are statistically insignificant
(p>O.5).
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Figure 6.1. Stoichiometry of AcLDL-Do:r. w aj ucatc:s. Tbe AcLDL-Oox conjugates
were prepared using the direct addition method. A constant amount of
AcLDL protein (300 ~g) was iDc:ubated with a variabl e amount of Dox as
indicated . Val ues are expressed as the mean *SE M (N=S) .
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Figure 6.2. El«trophoretic mobility of AcLDL usin g SDS-P AGE. Lanes 1 and 8:
broad range MW markers; Lanes 2 and 3: native LOL; Lanes 4 and 5:
AcLDL ; and Lanes 6 and 7: AcLDL·Dox conjugates.
196
-3
MWX10
12345678
~02~-'''''---'''''''-~,~= .-67--_ -
45~- •
-
21.5~. •
•
14.4-.
6.5~~
'-- ...J
197
Figun 6.3. Electron micrograph of Ac:LDL preparations. The AcLDL preparations
were applied to carbon formvar membranes and negatively stainedwith 2%
pbosphotungstate solution. They were examined on a Philips 300 instrument
at a magnification of 75,OOOX. Panel A, AcLDL; panel B. AcLDL-Dox
conjugates [the direct addition method] ; panel C, AcLDL processed with
Tween 20 (control) and panel D. AcLDL-Dox conjuga tes prepared by the
contact method with Tween 20. The bar represents 100 run.
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Partide,tze.am
FiguR 6.4. Particle size or AcLDL prep.ratioD. measured by EM. Results are the
mean :l::SD of at least 100 particles' diameters (see Figure 6.3 for
explanation ].
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Figure 4i.5. DO!le-respoIUe curves or J 774.A1 M41 control cells after 48-bour
treatmen t with 00:1:. LDL--Dox conjugates in Dormal and up-regulated
cells . The efficacy of down-regulated cells were statistically nonsignificant
compared to normal cells [p>O.OS], AcLDL-Do x conjuga tes in normal cells.
Dox and AcLDL-Dox had statistically nonsignificant effect on nonnal, up-
or down-regulated cells [p>O.05]. % Cytotoxicity was calculated from the
MIT assay, as described in section 6.2.5. The data are presented as % of
corresponding control cell survival from three independent experime nts
[mean at each point ±SEM].
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CHAPTER 7:
DR UG INTERFERENCE IN THE PRO TEIN ASSA Y METIlOD USING DCA I
7.1. Introduction
1bis chapterdescri bes the interference of Dox in the BCA protein assay meth od.
During my drug incorporation studi es, I demonstrated the importance of protein quantitatiOD
to determine the loading efficien cy of a drug into LDL. Any nonprotein molecule. if it
interferes with the protein assay , may give an inaccurate protein conce ntra tion depending on
the degree of interference in the SCA method. This issue is the prime focus point of this
study.
Common methods for the assay of proteins in biol ogical fluids include the Biuret
[Gomall et al .. 1949], Lowry(Pctcnon, 1979 ; 19n ;Lowry et ol.. 19511. Coomassie Brilliant
Blue G-2S0 protein dyc-binding assay [Bmdford] [Scdmak and Grossberg, 1977; Pierce and
Sooter, 1977; Bradford, 1976;], and the BCA assay [Wiechclmao et oJ., 1988; Smith et al .,
1985] . All oftbcsc methods have their advantages and disadvantages (LIeu and Rebel. 1991 ;
Baker, 1991; Vico et a/., 1989; Brown et aJ.. 1989; Hill and Straka. 1988; Kessler and
Fanestil, 1986; Kirchbaum, 1986; Compton and Jones . 1985; Lea et al .• 1984]. Among
them. th e Lowry method bas been used widel y for protein quan titation in bio logical samples .
However. complications are encountered due to reagent instability and because many
lA version of this c hapter is in pre ss : Abdul Kader and Hu
Li u, Cl i n ica l Ch e mist ry , (:1.9 97 )
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substances commonly used during protein purification interfere with the Lowry assay
[peterson. 1979]. Thus, alterna tive protein assays have been developed which simplify
protein quantitatioo and eliminate many of the problems associated with the Lowry method.
One alternative procedure:develo ped by Smith et a/ .. [1985] is based on the reduction ofCtt""
to Cu'" by protein.. The Cu" then comp lexes wi th bicincbo ninic acid [RCA ] [p ierce BCA
protein reagent ]. which absorbs light maximally at 540 - 600 m:n.. Thisassay is similar to the
Lo wry method in that both rely on the biuret reacti on for generatio n of a co lore d complex
betweenpeptide bondsandcuprous ions when prot ein is placed in an allcaline environm ent
co ntaining Ctr+ [Bensado Wland Weinstein, 1976; Weic hselbaum, 1946]. Howev er, whereas
the Lowry method empl oys Folin-C iocalte u reagen t to enhance the color response of the
Bi uret reaction. the DCA assay utilizes the sodiwn salt of BCA. a highly specific
chromopbore foc Cu' , Thehigh specificity and stability of the bicinchoninate chromopbore
has permitted the devel opment of a simplified. one step protein determination with
exceptional tolerance to oonionic detergents and simple buffer salts [Kansbal and Barnes.
1986] . Neverthe less, hydrogen peroxides [Baker , 199 1J, sucrose and detergents (Minamide
and Bamburg, 1990; Hill and Straka, 1988], biogenic amines [Tracy and Jean, 1991 ],
cho loropromazine., penicillins. vitamin C. paracetamole [Marshall and Williams. 1992;
1991) . or any othe r compound that can reduce Dr' to Cu", will produce the characteristic
purpl e color associated with the binding of Cu" wi th BCA . It would not be surpri sing if
anthracyclines, which are easil y oxidized in alkaline media in the presence of metal ions,
would produce the necessary reduction of etr" for the formation of a Cu"-B CA compl ex.
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In the Bradford method, the Coomassie blue dye binds primarily to basic and aromatic amino
acid residues. especi.aJ.ly arginine; and formsa co lor complex. In Ibis method. Ieterfeeeeces
may be caused by drug-protein andfor drug-dye interactions. Since the mechanism ofcolor
formation is differen t in the DCA and the Bradford method, both methods wen: considered
for interfereocc: studies. The observed interferences are particularly troublesome when
attem pting to compare protein levels at: various stages dwing protein quantitatiOD in protein-
drug conjugat es in dru g loadin g studi es (Iwanik el al .• 1984 ; Yanovich et al ., 19 84}.
di stribution studi es [Wasan and Molton, 1996; Cusac k et aI., 1993], in enzyme acti vity
measurements [Mangiapane, 1990], and in cell culture studi es to quan tify cell prot ein [Bose
et aI., 1995; Goldschmi dt and Kime lberg, 1989; Tuszynski and Mwphy, 199OJ.
Theprimary objective of this work was to determine wbether an anthracycline, for
example, Dox, interferes wi th the mea:sumnc:nt ofprotein cooccntrations using the DCA and
Bradford assay . To answer this question I also examined the sensitivity and specificity of
BCAforDox..
7.2. rttateriab and methods
7.2.1 DCA &55&Y
The DCA reagent [No. 23225J. BSA [No. 23209] were purchased from Pierce
[Rockford, ILl and us ed acco rding to the instructions supplied with the reagents . Samples
of Dcx in 0.9 % NaC I or BSA in water were added in a vol ume of 20 ~L to a micro titer
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p1ale. BCA reagent {200 J,lL]was thcu.added. Color was then allowed to develop for either
2 hoursat RT, 30 min at ) , "C. or IS minat6O"C. The miaotiter plate was then read in an
ELISA plate reader [Model EL 310, Biotek, Vermo nt, USA].
7.1.1. Bradford m ethod
Protein determinations Vo"CI'Cperformed as described by Bradfo rd [1976], using the
dye reagen t purchased from Bio-Rad [Ontari o, Canada ] and BSA standards. Standard
procedure for mlceotiter plates was followed as outlined in the Bio-Rad Protein Assay
catalogue.
7.2.3. Statistic. lnalysis
Statistical analysis was performed using least squares linear regression. the student' s
t test, and ANQVA. Comparison among groups was done by one way AN OYA and the post
test Bonferroni method. The Bonferroni p value was used to make all multiple paired
comparisons. Diffcn:oc:es wereconsidered significant ifp was<JJ.05 . All data are cxpn::sscd
as mean ±. SE (Standard Error ].
7.3. Resul ts
Dox showed B significant interferen ce in the BCA assay . whether assayed in the
prese nce or absen ce of BSA protein standard [Figure 7.1]. The interference was found to be
linear with an immedi ate appearance o f typical assay color without turbidity [even after
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further dil utions). The interf~ was linear over the standard protein range. The reaction
of Dox with the DCA reagent at RT for 2 bow's [Figure 7.2) suggests that a wide range of
anthracyclines will react with the DCA reagent to produce the characteristic purple color
[Tab le 7.1]. This is based on the assumption that the structure of tbe different anthracyclines
are similar and. as such, they should rcaet with BCA reagcnt in a similar fashion [fable 8.1].
When compared wi th BSA protein, the sensi tivity cftbe method towards Dox was found to
behigher [33 fold] than for the standard BSA protein. Sensitivity of Dox was found to be
0.0 16 nmolelmL or 180 nglmL [0-4 , A,lO=O.009. p<O.OScom pared to blank]. compared to
BSA sens itivity [6 ~glmL] . The sensi tivity was further confirmed at picomoleslmL range
by plotting a calibrati on curve between 16.53 picomoleslmL and 1.653 nanomo leslmL Dox .
The calibnrtion curve (y -.2.0 e .] + 2.0Sn e -4 x, R2 - 0.994] was found to be linear [0 - 4,
two-tail ed t statistic, p<O.Ol. indicating that the slope was very significantly different than
zero][curvenot shownJ. Tberc:appeared to be a linear increase in absorbance between 0 .017
and 1.700 nmolesImL Dox suggesting thai:the BCA method could be used to quantitate Dox
cccceetratices that an: in the 16nM to 1.600~ range [Figw'e 8.3]. However, Dox did DOl
interfere wi th the Bradford method to q uantitate protein [Figure 8.2].
Th e development of color associated wi th the reaction of prote in with the DCA
reage nt is slow at RT and enhanced by increasing the temperature and incubation time
[Gomal l et ai., 1949]. Color development with different concentrati ons of protein for :2
hours at RT [21°C) is equivalent to that developed over 30 min at 37°C and less than that
produced after 15 min at 60°C (Smith et al.• 1985). Color developm ent with Dox under
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different incuba tion conditions bas beenfound comparab le [p>O.05. in all cases when
comparison was made by a Bonfcrrooi test among different groups [Figure 83 ]. Color
changes produced by the ICM:tion ofprotcin with the BCA reagents continues to develop. at
a slow rare,over the next 20 how'S1Nben left at RT [Figure 8.4). I therefore wanted to know
wbethc:ror not thereis any variation in color.formationwith Dox in the assay protocol UDder
different conditions. At RT, the co lor development produced by Dox changes rap idly over
the first 1.5 hours [Figure 8.4]. Th ere is only a 10-12 % further enhancem ent of'cclor ove r
the next 20 hours . The color devel opment after 2 hours at RT is simi lar [p> 0.05J to that
deve loped over 30 min at )70C] [Figure 8.3J. BSA. at a concentration 0£0.01 mglmL did
not interfere wi th the color developed by Dox [Bonferroni p> 0.05] compared to the color
formation of Oox wi th the BCA reagent [Figure 85]. However, at 0.10 mglmL and higher,
BSA concentrations significantly (Bonfcmmi pQJ.05] interfere with the co lor developed. by
Do x (Figure S.5l- Also . Dox co ncen trati ons of 1.6n to 33 .430 nmol eslmL with different
protein concentrations have produced color intensiti es that are significandy [Bonferroni
p<O.OI with 1.672 nmol esImL aDd p<O.OOI with the other Dox concentrations when
compared to BSAJ higher than those due to the protein alone [Figure 8.6]. These results
indicate that anthracyclines will signifi cantly alter color development produced by proteins
at anthracycline concentrations that exceed 1.6 nmoVmg protein. These studies also
demonstrate the feasibility of using the BCA reagent to quan titate Dox at concentrations that
are in the 1-1000 nM range.
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7.4. Discuu ioa
Clinically, it is essential to mollitor the nutritional status of a patient under
chemotherapy by measuring the total protein concentration of the plasma [Mayhew and
Thom, 1995] . Assessment of chemotherapy-assoc iated nephrotoxicity in pati ents with
cancc:rcan be madeby measuring blood and urine protein [Skinner eraJ.. 1991]. The most
commonly used dosage schedule for Dox is 6.0 to 7.5x1O-:g/m l as a single IV injecti on
administered at 21-day intervals. When calculated for an healthy individual. the plasma
concentrati on ofDoxor its metabolites is expected to be more than 0.02 gIL [Lentner. 1984].
Therefore. plasma and urinary anthracycline concentrations ofanthnu:yclines including both
the parent and the metabolites are expected to bein a range where Dox would affect protein
assay by the BCA method . If the BCA method is used in determinati on of the protein o f
these biological samples. an increase in protein concentration would be observed. Thi s
res ults may have significant impact on patient ' s therapy and prognosis . AnthIacy clines
[Dox, daunomycin, and annam ycin aDdtheir analogs] have been used in drug loading into
lipopro teins. in particular , LD L and HDL [Shaw et aI . 1987; lwanik. el aJ, 1984; Yano vicb
et oJ.. 1984J, and tbeir distri bution in plasma proteins hasbeen stud ied [Wasanand Morto n.
1996] . To quanti tate the dru g associ ated with lipoprotein. it is essen tial to determin e the
pro tein coeceatraticas of the lipoprotein(s] as well. lD all cases , the anthracycline
concentration bas been found higher than 0.22 nmo les and as high as 50 nmo lesimL .
Therefore, the concentration of Dox and the ratio of Dox to prote in is high enough [for
examp le , 0.24-1.6 J.1g of druglmg of protein, 26] to interfere in the color development of
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pro tein in the BCA method. Also , protein concenD'ation is being used as a bench marie to
quan titate eeus in cell culture studies [Mangiapane. 1990; Goldschmidt and Kimelberg ,
1989; Yaoovi ch et aJ.. 1984J. The Doxcoooentration in cell culture studies was found to be
bigber [7 to 133.9 nmoles ofDo xlmg of ceUprotein, rruszynsk;i and Mwph y, 1990] which
will interfere with the BCA protein analysis . Anthracyclincs have potential adverse reactio ns
and in recent years a eumber of enzyme activity studies have beencarried out to discernthe
mechanism. of various adverse e ffects (for exampl e, the role of an enzyme. glutathione
pero xidase. in oxidation of cardiac muscle and in daunorubicin c:ardiotoxicityj [Cusack et
a1. 1993. Mangiapane. 1990]. In these studies. protein determinations have to be done to
express enzyme acti vity, for example, glutathione peroxidase activity expressed as nmol
NADPH oxidizcdfminlmg protein, [Cusac k et al . 1993J. Recently, in a daunonabicin-
induced apoptosis study, cells were treated wi th IJ!M daunorubicin to observe morpholo gical
alt eration ofcbromatin durin g apop tos is (Bose et oJ. 1995]. In all of lhc above situations,
anthracyclines have the potential to interfere with the BCA protein assay resulting in
inaccurate protein detmnination.
This inaccurale protein determination may signifi cantly influence the results obtained
from different studies related to b iochemical phannacology of anthracyclin es. The resul ts
from my studies indicate a significan t increase in the co lor developm ent of the BCA reagent
with Dox in the RCA method. However, Dox did not interfere wi th the Bradfo rd assay .
Thes e res ults also suggest that different anthracyclines or their metabolites beca use of their
similarstruetural moieties (Table 8.1] may interfere in a similar fasbi on in the BCA and not
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in the Bradford method. Anthracyclines. which are widel y used in antineoplastic therapy
[Arcamooe, 1981J, would interfere with the BCA protein assay resulting in inaccurate or
high protein conce ntrations. To overco me these interferences with the BCA protein assay
method. the Bradford method would bean acceptable alternative .
«:¢l0 OH R,,r """" I I H " OH
OC H30 QH H R,
Anthracyclinone aglycone Daunosamine sugar (0)
2ll
Table 8.1. Dox. its princip al metab olites, and dauDorubicin
Comp ound R, R, R, R,
Do. D COCH zOH H OH
Doxo l D COCHOHCHzOH H OH
DO:lol aglycon OH CHOHCHlOH
7-0B Dos: ag lycon OH COCH1 O H
7. DeoxyDoJ:agly con H COCH 1OH
DauDoru bicin D COCH] H OH
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Fipre 7.1. Dox int erfereD ce ill the DCA protein assay. Aliquots of20 pI. of samp le
containing 1.67. 5.02, 836, 10.04, 13.38, and 16.n nmoIcslmLo feachoftbe
following were assayed: Dox [closed diamond}. BSA protein standard [open
square] , and BSA standard containing Oox [BSA: Dox ... I : I) [open
diamo nd). The data are expressed as the mean :SEM of quadruplicate
detenninations .
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Figure 7.2. Stao dard ulibratioD c:u~e 0(00:1 with SCA reageDt [OpeD d iam ond)
and Coo mass ie blue [closed diam ond ). Concentratio ns range between
16.72S nM [picomo leslmL] to 1.67256 ~[nmolesImL] _ Tbe data poims are
the mean ± SE ofquadrup licate determinations,
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Figure 7..3. Sen sitivity or Dos: to color development with BCA re agen t. Dox was
reacted wi th 200 IJ1. of the BCA reagent at concentrations between 1.67 and
16.72 nmoVmL for either 2 hour at RT [closed square], 30 min at 37°C
[closed diamond] or 60°C for 15 min [open square]. Data points represe nt
the mean of quadriplicate detenninati ons ± SE.
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Figure 7.4. Rate of in~rrase iD color a bseebeaee produc:ftl by DoL The J\s,g
produced by incubation of 200 ul, BCA reagent at RT and concentrations
from 1.672{open squareJ. 8.363 [closed~].1 6.726 [opencin:lel. 4L814
[open diamood] to 83.63 [closeddiamood] nmollmL was measuredafter 15.
30, SO,70, 90, 110, 133. 149, 184. 360. 1320 min. All data points represent
the mean oftriplicatc determinations ± SE.
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Figu re 7.5. Co lor d n elopm ellt prod uced by Dox in tbe preee eee of BSA. The color
prod uced by 0 [open square] . 0.01 [closed diamond] and 0.10 [closed squar e]
m gfmL e SA protein reacting wi th 200IJ.LDCA reagent in the presence of
1.6n to 16.72 nmo lclO. l mL Dox after 2 bouriDcubation at RT. The data
are the mean ± SE ofquadruplicate detcnninations.
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Figure 7.6. Color dnelopmcat prod uced by USA in tbe prestDce aDd the absence of
DoL The BCA reagent was added to various concentrations ofBSA protein
[0.01 to 0 .10 mglmL] and the color was developed over a 2 hour period at
RT. the data pointsrepresenttbe mcan ±SEofquadruplieatc dctenninations.
Color deve lopment was with various ooncentrati ons ofBSA in the presence
or o [open square], 1.672 [closed diamond} . 8363 [open circ le], 16.73 (open
diamo nd] , and 33.43 [do sed circle] pmo leslmL ofDox.
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CHAPTER 8:
GENERAL DISCUSS ION AND FUTURE DIRECTIONS
The study ofthis thesis has prod uced some new perspectives en drug targeting using
the endogenous LDL. A substantial amo unt ofdru g has been incorporated into the native or
the modified LDL (AcLDL) and ill vitro drug targeting to both the tumor cells and the Mcfl
has been achieved. The following is a sum.maryoCsom e key points obtained over the course:
oftbe study and recommendations for future experiments.
8.1. Pbyl lco-c:bem ia l princip ia a O"ectiD g d ru C loadirlg into LDL
Physical factors such as incubation time, temperature, stoichiometry of LDL-drug
conjuga tes, and a variety of formulation additives, such as solvents, surface increasing agent,
and wetting agents . were studied (Chapter 2). Additionally, different formulations of the
drug, such as, solution,. suspension,.or liposomal preparation were studied and found to have
significant effects in drug loadin g. All these factors have been found respo nsible for dru g
loading into LDL particles. I conclude that optimization of the process parameters is
imperative to maximize drug loading into LDL particl es .
8.2. Physiro-c:bemic al cb....ctcrizatiOD of LDL-dru g oonjugllltes
The use ofLDL as a dru g targeting vecto r require s a highly efficacious dru g, abl e to
incorporate into the particle maximally without modifying its struc tural integrity or receptor
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binding properties. The use of biochcmi ca1 and biophysical techniques provides val uab le
information regarding the physi cochemical characteristics ofLDL-drug conjugates. I have
incorporated substantial amounts of cytotoxic compotmds into LDL or AeLDL particl es and
showe d that the use of 80 S-PAGE. EM, and DSC to characterize LDL-drug co nj ugates
provides useful informa tion (Chapters 2.3. and 6] . Addi tionall y, particle size meas urem ent
coul d bedone using the quasielastic (Vitols et oJ.. 1990] , laser scattering technique [Samadi -
baboli ttl al .. 199OJ, photon correlation spectroscopy [McNeil-Watson and Parker, (99 1).
or synchrotron radiation solution X-ray scattering [Weste:sen, 1995]. The site of the
incorporated drugs in LDL was examined by UV-visibJe spectroscopy (Chapter 4].
Additionally, the incorporation sites can be examined by NMR. spectroscopy [Westesen er
01., 1995], or fluorescence quenchin g experim ents (Sauterea u et ai., 1995). The use oCCD
spectroscopy [Provencher and Gloclmer, 1981] and/or ' H NMR spectroscpoy [Ala-Korpela
et al ., 1995] can beapp lied to examine the apo B integrity after drug loading and may be
useful to further examine the conformation of the protein. Especially important. are
fluorescence quenching experim ents in which a fluorescen t drug is used to identify the
location of incorporated drug molecules in LDL, because , if the drug is primarily located in
the core, it will DOt exchange or leak from the LDL i1lvivo.
8.3 . LTP as an co bancing agent 10 inco rp orate d rug s ta te LDL partida
In my studies. LTP was found to be effective in enhancing drug loading fro m 2- to
S-fold [Chapter 4]. This increase in drug loading is signifi can t as the native integri ty a f the
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LOL particle remained unchanged. However. more studies~ nccdcd to expl oit better drug
candi dates for LOL or to design betterdrug donors suc h as microemulsi on or liposom es for
Lll'.
8.4. Multip le drug res ista nce [MDRJ studies
MDR can beovercome by delivering dru g usin g LOL. Shaw et 01. (1987) sbowed
that LDL-drug conjugateS suppressed P-gp activity related to drug resistance. However, no
in vtvo studies have been performed. Recentl y. MetheTall er01.. ( 1996) showed that MDR
activity is required for the esterification of LDL-derived cholestero l. I speculate that LDL-
drug conjugates will deliver substantial amount of cholesterol to MDR cells and will
suppress the activity ofP-gp. In a preliminary stud y. I have seen that LOL preparations have
the potential to overcom e p.gp mediated drug res istance in a CEM:VL B·lOOO MDR hum an
leukemic cells (Bradley et al., 1989; Kader and Liu, unp ublished data) . If this can be shown
in vivo , it would be an efficient method to overcome MDR in cancer chem otherapy.
8.5. Modifica tio n of LD L 10 targd specific ceU Iypes
LO L can bemodified to selectively target specific type: of cells, For instance, I have
shown in Chapter 6 that acetylation of LDL lead to de liver cytotoxic drugs primarily to M41.
Recentl y, LDL was modified by lacto sylation and the modified LOL was rapi dly and
specifically internalized by the galactose-specific receptors on Kupffer ce lls [B ijster bosc h
and Van Berkel, 1990; Bijsterboscb.et al.. 1989J. Later.lactosylatedLDLbasbeeo.proposed
227
as a potential canierfocthetargetedddiveryofdrugs 10 Kupffercells [Bijstc:rboseh and Van
Berk el , 1990; Bijsterboscb. et oJ.. 1989J. These modified parti cles thc:msclves are
nonimmunogenic. do not alter the partitioned dru g' s bioactivity, and are capab le of
assoc iating significant quantitities ofcompounds. I speculate that, in the future. LO L can be
suitably modified to deliver therapeuti c agents specifically to certain cell types depending on
th e type of modifi cation of the LOL.
8.6. I" vivo stud ies
Tbeultima!c goal oftbe LDL·mediated dru g targeting is to elicit a selective in vivo
effect. I bave demonstrated that the LDL-drug conjugates did not sho w any significant
chan ges in In vitro cbaractcrization compared to native L OL. However , it sho uld be tested
in vivo whethe r the LDL-drog conjugate has maintained its recognition properti es . Important
param eters for in vivo validation of thc LDL-dru g co njugate are plasma half- life and tissue
distributio n studies. whi ch can be perfo rmed in rats or mice, arc therefore (V ersl uis et aL,
1996 ; De Smidt and Van Berkel, 1990 ). An addi tional method for detennining if the LD L-
dru g conjugate is intemalizcd via the LOL -receptor pathway in l'iw.t can be provided by
selective upregulation of rat liver parenchymal LOL receptors [Harkes et al ... 1983] .
Pretreatment orms with high dosesof ethiny lestrad.iol establishes a 17-fold upre gula tion of
paren chymal LOL receptors. Compared wi th contro l rats. the liver uptak e of the
reconstituted LDL in the ethinylestradiol-treated rats should be greatly increased if the
particl e is internalized by the LOL-re ceptor pathway.
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8.7. lI u maD trials
Further experiments are req uired in vivo, probably in nud e mice with human tumor
xenografts. to determine theaffini ty of LDL-druQ: complexes for tumor and nonnal tiesces,
to examine the comparative pharmacokinetics of the LDL-drug conj ugates relative to free
drug and to exp lore the possibility of a differential therapeutic effect, A small scal e clinical
trial of LDL -vin cristine conjugates in hum ans bas been repo rted [Filipowska, 1992].
However, thus far. there have been no reports of pharmaco kinetic data in humans. Such
studi es are critical. since a prerequisite for successfuldrug targeting is that the LDL-drug
conjugate is recognized as self; otherwise. the LDL-drug conjugate would becleared rapidly
from the blood stream.
8.8. Distributi ODstu d ies
Compared to albumin and el l aci d glycoprotein, lipoproteins have recei ved less
attention as potential carrier proteins of drugs in plasma. However, basic drugs such as
quinidine and tetracycline [piafsky, 1980J. pclyemmatic hydrocarbons such as 2,3,7,8-
tetraehl orobcnzo..p-d.ioxin and beozo [a]pyrene (Shu and Bymun,.1983J. and probuco l [Urien
eta!.. 1984] have beenrcported to bind to lipoproteins. In addi tion, the lipoproteins are best
kno wn as the carriers afCE [Brown and Goldstein. 1986). ForDox, I speculate thai bigh
binding of the drug with albumin may be the mechanism for its fatal cardi oto xicity . In vitro,
a redistri buti on to lipop roteins was achie ved using differen t concentra tions of the oleic acid
[Chapter 2, section 3.9J. I speculate that a similar redistribution of Dox from plasma
229
albumin to lipoproteins. if it occurs in vivo. may help to decrease or eliminate fatal
card.iotoxici ty .
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